cytarabine has been researched along with Recrudescence in 918 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 111 (12.09) | 18.7374 |
| 1990's | 221 (24.07) | 18.2507 |
| 2000's | 263 (28.65) | 29.6817 |
| 2010's | 266 (28.98) | 24.3611 |
| 2020's | 57 (6.21) | 2.80 |
| Authors | Studies |
|---|---|
| Hirschberg, CB | 1 |
| Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S | 1 |
| Böll, B; Borchmann, P; Borchmann, S; Bröckelmann, PJ; Eichenauer, DA; Engert, A; Fuchs, M; Gillessen, S; Haverkamp, H; Heger, JM; Hüttmann, A; Kobe, C; Müller, H; Plütschow, A; Sasse, S; Schmitz, C; Topp, MS; Viardot, A; von Tresckow, B; Vucinic, V | 1 |
| Becker, PS; Cassaday, RD; Cherian, S; Estey, EH; Garcia, KA; Halpern, AB; Keel, SB; Martino, CH; Oehler, VG; Orozco, JJ; Percival, MM; Shustov, AR; Stevenson, PA; Walter, RB | 1 |
| Akahoshi, Y; Gomyo, A; Kako, S; Kameda, K; Kanda, Y; Kawamura, M; Kawamura, S; Kimura, SI; Kusuda, M; Matsumi, S; Misaki, Y; Nakamura, Y; Nakasone, H; Okada, Y; Sato, M; Takeshita, J; Tamaki, M; Tanihara, A; Wada, H; Yoshimura, K; Yoshino, N | 1 |
| Bagnoli, JW; Enard, W; Hellmann, I; Herold, T; Jayavelu, AK; Jeremias, I; Jurinovic, V; Mann, M; Richter, D; Valtierra-Gutiérrez, IA; Vick, B; Zeller, C | 1 |
| Arrigo, G; Audisio, E; Cerrano, M; D'Ardìa, S; Frairia, C; Freilone, R; Giai, V; Secreto, C; Urbino, I | 1 |
| Fang, YJ; Huang, J; Li, HM; Sun, XY; Wang, YP; Xue, Y | 1 |
| DU, Y; Li, H; Li, JX; Lu, WJ; Qi, SS; Tao, F; Xiong, H; Yang, L; Zhang, LN | 1 |
| Ahn, MJ; Bae, SH; Bang, SM; Cho, EK; Choi, JH; Chong, SY; Hyun, MS; Jo, DY; Kim, B; Kim, BS; Kim, CS; Kim, DY; Kim, H; Kim, HJ; Kim, HS; Kim, I; Kim, SH; Kwon, H; Lee, JH; Lee, KH; Lee, MH; Lee, WS; Min, YJ; Moon, HN; Mun, YC; Nam, SH; Oh, D; Park, JH; Park, KT; Park, SY; Park, YH; Ryoo, HM; Seo, JJ; Seong, CM; Yoon, HJ; Yoon, SS; Zang, DY | 1 |
| Beck, J; Fuellen, G; Gladbach, YS; Hamed, M; Junghanss, C; Murua Escobar, H; Roolf, C; Schütz, E; Sklarz, LM | 1 |
| Anzai, N; Arai, Y; Atsuta, Y; Fukuda, T; Hiramoto, N; Kanda, J; Kawamura, K; Kimura, T; Konuma, T; Mizuno, S; Murata, M; Nakamae, H; Onizuka, M; Ota, S; Ozawa, Y; Sawa, M; Shimomura, Y; Takahashi, S; Takami, A; Tanaka, M; Yanada, M | 1 |
| Balsat, M; Barraco, F; Ducastelle-Leprêtre, S; Fossard, G; Ghesquières, H; Gilis, L; Hayette, S; Heiblig, M; Huet, S; Labussière-Wallet, H; Larcher, MV; Loron, S; Meur, GL; Michallet, M; Plesa, A; Renault, M; Sujobert, P; Thérèse, RM; Thomas, X; Tigaud, I | 1 |
| Chiba, S; Hattori, K; Kato, T; Kurita, N; Maruyama, Y; Nanmoku, T; Nishikii, H; Obara, N; Sakamoto, T; Sakata-Yanagimoto, M; Suehara, Y; Tsuboi, Y; Yokoyama, Y; Yoshida, C | 1 |
| Bo, J; Dou, L; Gao, C; Gao, X; Li, H; Liu, D; Lu, N; Wang, L; Wei, Y; Wu, Y; Zhang, R; Zhu, C | 1 |
| Albano, F; Attolico, I; Carluccio, P; Contento, C; Delia, M; Di Gennaro, D; Gagliardi, VP; Musto, P | 1 |
| Fang, JP; Huang, K; Li, Y; Liao, XY; Qiu, KY; Xu, HG; Zhou, DH | 1 |
| Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ | 1 |
| Cheng, J; Li, L; Lu, J; Wang, S; Yang, J; Zhang, S; Zhao, L; Zhou, L | 1 |
| Darwish, C; Farina, K; Tremblay, D | 1 |
| Cagnin, S; Peroni, E; Randi, ML; Rosato, A | 1 |
| Biemond, BJ; de Jong, G; Hazenberg, MD; Janssen, JJWM; Meijer, E; Nur, E; Ossenkoppele, GJ; Visser, O; Zeerleder, SS | 1 |
| Dührsen, U; Flasshove, M; Hanoun, M; Noppeney, R; Schmitz, C; Westhus, J | 1 |
| Beutel, G; Dammann, E; Eder, M; Eggers, H; Ehrlich, S; Gabdoulline, R; Ganser, A; Göhring, G; Hambach, L; Heuser, M; Klement, P; Koenecke, C; Markel, D; Neziri, B; Rehberg, A; Reuter, M; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Wichmann, M | 1 |
| Chen, G; Gong, D; Huang, S; Jing, Y; Li, Y; Lv, N; Wang, L; Wang, N; Xiong, Q; Xu, Q; Yu, L; Zhou, W | 1 |
| Au-Yeung, R; Kwong, YL; Sim, JPY | 1 |
| Amrein, PC; Attar, E; Ballen, KK; Behnan, T; Bergeron, MK; Bertoli, C; Blonquist, TM; Brunner, AM; Burke, M; Chen, YB; Connolly, C; Duong, VH; Emadi, A; Fathi, AT; Foster, JE; Graubert, TA; Hasserjian, RP; Hobbs, G; Hock, H; Lescinskas, C; Lesho, P; Macrae, M; Mann, ML; McAfee, SL; McGregor, K; Moran, JA; Narayan, R; Neuberg, DS; Preffer, FI; Rae, J; Ramos, AY; Som, TT; Story, JL; Vartanian, MK; Wey, MC | 1 |
| Jin, J; Li, J; Yu, W; Zhang, X | 1 |
| Ojha, S; Ooi, MG | 1 |
| Arora, R; Hildebrandt, GC; Munker, R; Qasrawi, A; Ramlal, R | 1 |
| Cai, H; Cao, X; Chen, M; Duan, M; Feng, J; Li, J; Wang, W; Yang, C; Zhang, L; Zhang, W; Zhang, Y; Zhou, D; Zhu, T; Zhuang, J | 1 |
| Brossart, P; Glasmacher, A; Hahn-Ast, C; Mayer, K; Schmidt-Wolf, IGH; Schwab, K; von Lilienfeld-Toal, M | 1 |
| Gong, L; Huang, X; Jia, J; Jiang, H; Jiang, Q; Lai, Y; Liu, K; Liu, X; Lu, R; Lu, S; Ruan, G; Shi, H; Wang, J; Wang, Y; Wu, Y; Xu, L; Yan, C; Zhang, X; Zhao, X | 1 |
| Abbenante, MC; Arpinati, M; Baccarani, M; Baldazzi, C; Bertamini, L; Bochicchio, MT; Bonifazi, F; Caso, L; Cavo, M; Cristiano, G; Curti, A; de Polo, S; Fontana, MC; Marconi, G; Martinelli, G; Nanni, J; Olivi, M; Ottaviani, E; Paolini, S; Papayannidis, C; Parisi, S; Ragaini, S; Sartor, C; Sessa, M; Talami, A; Testoni, N | 1 |
| Carraway, HE; Chandhok, NS; Griffiths, EA; Prebet, T | 1 |
| Arnan, M; Bargay, J; Coll, R; Cruz, D; Díaz-Santa, J; Escoda, L; Esteve, J; Gallardo, D; Garcia, A; Garrido, A; Heras, I; Lloveras, N; Moret, C; Osca, G; Pratcorona, M; Quiñones, T; Rodríguez-Romanos, R; Salamero, O; Sampol, A; Sierra, J; Tormo, M; Vives, S | 1 |
| Arens, AIJ; Brice, P; Burggraaff, CN; De Jong, D; Diepstra, A; Driessen, J; Gastinne, T; Hagenbeek, A; Hutchings, M; Kersten, MJ; Liu, R; Lopez-Yurda, M; Lugtenburg, PJ; Morschhauser, F; Nijland, M; Plattel, WJ; Tonino, SH; Valkema, R; van Tinteren, H; Zijlstra, JM | 1 |
| Chan, SY; Dang, CC; Guan, YK; Lau, NS | 1 |
| Agrawal, V; Arain, S; Cahill, K; Calip, GS; Christian, S; Esen, A; Griffin, S; Khan, I; Konig, H; Odenike, O; Patel, P; Quigley, JG; Shergill, A; Stock, W; Sweiss, K | 1 |
| Baumann, T; Caballero, AC; Canet, M; Escoda, L; García, O; Iserte, L; López-Guillermo, A; Magnano, L; Mercadal, S; Muntañola, A; Salar, A; Sánchez-González, B; Sancho, JM; Soler, A; Sorigué, M; Villalobos, MT | 1 |
| Amberg, S; Bokemeyer, C; Christine Wilke, A; Chromik, J; Deppermann, U; Fiedler, W; Ganser, A; Heuser, M; Janning, M; Kebenko, M; Kranich, AL; Modemann, F; Schlipfenbacher, V; Serve, H; Theile, S; Thol, F | 1 |
| Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X | 1 |
| Bonaldi, L; Branca, A; Gurrieri, C; Manni, S; Martines, A; Piazza, F; Pizzi, M; Riva, M; Scapinello, G; Semenzato, G; Trentin, L; Visentin, A | 1 |
| Bakhshi, S; Chopra, A; Ganguly, S; Garg, A; Vishnubhatla, S | 1 |
| Abdul-Hamil, NA; Cherchione, C; Martinelli, G; Nagarajan, C; Wong, GC | 1 |
| Cangini, D; Cerchione, C; Ghelli Luserna Di Rorà, A; Giannini, MB; Gottardi, M; Martinelli, G; Padella, A; Simonetti, G; Sperotto, A | 1 |
| Bar-Natan, M; Lancman, G; Mascarenhas, J | 1 |
| He, J; Wang, L; Yan, X | 1 |
| Abraham, M; Aharon, A; Al-Rawi, AN; Altman, JK; Andreeff, M; Bohana-Kashtan, O; Borthakur, G; Bueso-Ramos, C; Cortes, JE; DiPersio, JF; Foley-Comer, A; Foran, J; Glicko-Kabir, I; Kadosh, SE; Lustig, TM; Nagler, A; Oberkovitz, G; Ofran, Y; Peled, A; Pemmaraju, N; Pereg, Y; Rowe, JM; Samara, E; Shaw, S; Shimoni, A; Showel, MM; Sorani, E; Tallman, MS; Uy, GL; Vainstein-Haras, A | 1 |
| Leach, M; McKay, P; Oun, H; Wilson, M | 1 |
| Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K | 1 |
| Alencar, AJ; Moskowitz, CH | 1 |
| Díaz-Fernández, S; Fernández-Miranda, JJ; López-Muñoz, F | 1 |
| Arasaretnam, A; Bishton, M; Bolam, S; Creasey, T; Crosbie, N; Dawi, S; Dutton, D; Eyre, TA; Follows, G; Goradia, H; Harrison, S; Johnston, R; Kirkwood, AA; Lambert, J; Lewis, D; McCulloch, R; McKay, P; McMillan, A; Miles, O; Osborne, W; Patmore, R; Phillips, N; Robinson, A; Rule, S; Wilson, MR | 1 |
| Alder, DS; Beatrice, L; Beckmann, K; Geigy, C; Günther, C; Steffen, F | 1 |
| Ambrusko, S; Andolina, JR; Barth, M; Boulware, R; Comito, M; Fraint, E; Fries, C; Monteleone, P; Vargas, A | 1 |
| Alonzo, TA; Aplenc, R; Brodersen, LE; Gamis, AS; Gerbing, RB; Guest, E; Hirsch, B; Kolb, EA; Loken, MR; Meshinchi, S; Pollard, JA; Raimondi, SC | 1 |
| Hosono, N; Ida, N; Kuze, A; Negoro, E; Yamauchi, T | 1 |
| Aotsuka, N; Doki, N; Fujisawa, S; Fujiwara, SI; Gotoh, M; Ishizaki, T; Kanamori, H; Kanda, J; Kanda, Y; Kimura, SI; Miyazaki, T; Mori, T; Najima, Y; Okamoto, S; Onizuka, M; Saito, T; Sakaida, E; Shono, K; Tachibana, T; Takahashi, S; Tanaka, M; Watanabe, R | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Arai, Y; Atsuta, Y; Fukuda, T; Hoshino, T; Kawakita, T; Kondo, T; Mizuno, I; Mizuta, S; Mori, T; Ohashi, K; Onizuka, M; Ozawa, Y; Shigematsu, A; Tanaka, J; Ueda, Y; Yoshida, S | 1 |
| Chen, P; Dong, X; Gu, L; Li, D; Shao, J; Xu, L; Yang, Y; Zhao, H | 1 |
| Amengual, JE; Barta, SK; Bast, MA; Behdad, A; Blum, KA; Calzada, O; Cassaday, RD; Chavez, JC; Cohen, JB; Costa, C; Falkiewicz, MK; Feldman, T; Fenske, TS; Gerson, JN; Hernandez-Ilizaliturri, F; Hill, BT; Howlett, C; Kaplan, JB; Landsburg, DJ; Lansigan, F; Li, S; Lue, JK; Maly, J; Mato, AR; Medeiros, LJ; Nathan, S; Olszewski, AJ; Peace, DJ; Persky, DO; Petrich, AM; Reddy, NM; Rivera, X; Singavi, A; Torka, P; Vose, JM | 1 |
| Becker, PS; Buckley, SA; Chen, TL; Estey, EH; Halpern, AB; Hendrie, PC; Huebner, EM; Orlowski, KF; Othus, M; Percival, MM; Pogosova-Agadjanyan, EL; Scott, BL; Stirewalt, DL; Walter, RB | 1 |
| Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L | 1 |
| Aqel, N; Ayto, R; Camilleri, M; Griffin, JC; Siow, W | 1 |
| Cao, XX; Li, J; Niu, N; Sun, J; Zhou, DB | 1 |
| Albano, F; Carluccio, P; Casieri, P; Delia, M; Mestice, A; Pasciolla, C; Pastore, D; Ricco, A; Rossi, AR; Specchia, G | 1 |
| Murphy, T; Yee, KWL | 1 |
| Berdel, WE; Bormann, E; Braess, J; Büchner, T; Flasshove, M; Görlich, D; Haferlach, C; Hecht, A; Hiddemann, W; Hofmann, WK; Horst, HA; Kreuzer, KA; Krug, U; Lengfelder, E; Lindemann, HW; Nowak, D; Sauerland, C; Schiel, X; Schliemann, C; Schneider, S; Schnittger, S; Spiekermann, K; Wörmann, B | 1 |
| Auvrignon, A; Baruchel, A; Bertrand, Y; Felix, A; Fenneteau, O; Gandemer, V; Leblanc, T; Leverger, G; Michel, G; Nelkem, B; Paillard, C; Petit, A; Ragu, C; Rohrlich, PS; Schmitt, C; Sirvent, A | 1 |
| Baldus, CD; Bamopoulos, SA; Berdel, WE; Blum, H; Bohlander, SK; Bräundl, K; Görlich, D; Graf, A; Greif, PA; Hartmann, L; Hellmann, I; Herold, T; Hiddemann, W; Jurinovic, V; Kerbs, P; Konstandin, NP; Krebs, S; Ksienzyk, B; Mattes, R; Metzeler, KH; Neumann, M; Pastore, F; Schneider, S; Schumacher, D; Spiekermann, K; Stief, SM; Vosberg, S; Wolf, S; Wörmann, BJ; Zellmeier, E | 1 |
| Duan, M; Liang, G; Xu, X; Zhang, L | 1 |
| Benavente, C; Bergua, J; Boluda, B; Cordón, L; Díaz-Beyá, M; Esteve, J; Garrido, A; Jiménez-Ubieto, A; Martínez, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Pérez-Simón, JA; Prieto-Delgado, J; Rodríguez-Veiga, R; Salamero, O; Sanz, MA; Sempere, A; Serrano, J; Vidriales, B; Vives, S | 1 |
| Advani, AS; Appelbaum, FR; Erba, HP; Li, H; Liedtke, M; List, AF; Medeiros, BC; Michaelis, LC; O'Dwyer, K; Othus, M | 1 |
| Borschel, L; Bourquin, JP; Creutzig, U; Dworzak, M; Klingebiel, T; Klusmann, JH; Lehrnbecher, T; Rasche, M; Reinhardt, D; Zimmermann, M | 1 |
| Bellò, M; Benevolo, G; Bisi, G; Boccomini, C; Botto, B; Castellino, A; Chiappella, A; Ciochetto, C; Freilone, R; Nicolosi, M; Orsucci, L; Passera, R; Pecoraro, C; Pregno, P; Vitolo, U | 1 |
| Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Sanz, MÁ | 1 |
| Andreeff, M; Bueso-Ramos, C; Cortes, JE; Coyle, M; Daver, N; DiNardo, CD; Futreal, PA; Garcia-Manero, G; Gumbs, C; Issa, GC; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, HM; Konopleva, M; Little, L; Morita, K; Patel, KP; Pemmaraju, N; Ravandi, F; Sasaki, K; Song, X; Takahashi, K; Thornton, R; Tippen, S; Wang, F; Wang, S; Yan, Y; Zhang, J | 1 |
| Appel, B; Bush, R; Constine, LS; Cox, J; Dharmarajan, KV; Fernandez, K; FitzGerald, TJ; Friedman, DL; Kessel, SK; Laurie, F; Parzuchowski, A; Pei, Q; Punnett, A; Schwartz, CL; Terezakis, SA; Wolden, SL | 1 |
| Hanmantgad, M; Liu, B; Liu, D; Narurkar, R; Song, Y; Zafar, W | 1 |
| Acton, G; Carella, AM; Cortes, JE; Craig, AR; Craig, MD; Egyed, M; Fox, JA; Horst, HA; Jabbour, E; Kantarjian, HM; Klimek, VM; Krug, U; Lancet, JE; Pigneux, A; Ravandi, F; Récher, C; Ritchie, EK; Sayar, H; Schiller, GJ; Smith, JA; Strickland, SA; Stuart, RK; Vey, N; Ward, R | 1 |
| Bhatnagar, N; Greenough, A; James, B; Norton, A; O'Marcaigh, AS; Roberts, I; Tunstall, O; Vyas, P; Watts, T; Wright, M | 1 |
| Cortes, JE; Rytting, ME; Short, NJ | 1 |
| Hu, DZ; Li, YY; Tian, C | 1 |
| Abou Mourad, Y; Clissa, C; Connors, JM; Gerrie, AS; Guiducci, B; Isidori, A; Loscocco, F; Nantel, SH; Power, M; Sanford, D; Savage, KJ; Scott, DW; Sehn, LH; Song, K; Sutherland, H; Toze, C; Tsang, ES; Villa, D; Visani, G | 1 |
| Dührsen, U; Hanoun, M; Noppeney, R; Westhus, J | 1 |
| Harada, K; Ikegawa, S; Kobayashi, T; Ohashi, K; Sasaki, S; Sekiya, N | 1 |
| Deng, T; Jiang, L; Wang, D; Xiao, Y | 1 |
| Bahashwan, S; Bay, JO; Berger, MG; Douge, A; Guièze, R; Hermet, E; Lemal, R; Moluçon-Chabrot, C; Ravinet, A; Tchirkov, A; Tournilhac, O; Veronese, L; Veyrat-Masson, R | 1 |
| Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y | 1 |
| Hagenbeek, A; Hutchings, M; Kersten, MJ; Liu, R; Lugtenburg, P; Mooij, H; Nijland, M; Spiering, M; Tonino, S; van Imhoff, G; van Tinteren, H; Zijlstra, J | 1 |
| Ashaye, AO; Cappelleri, JC; Fahrbach, K; Khankhel, Z; Lang, K; Mamolo, C; Mokgokong, R; Orme, ME; Xu, Y | 1 |
| Lv, T; Tian, X; Wang, L; Xu, J; Yuan, G | 1 |
| Abdalla, K; Abrar, MB; AlAzmi, AA; Elimam, N; Jastaniah, W; Mustafa, O | 1 |
| Chen, J; Ngo, D; Rosenthal, J | 1 |
| Arai, Y; Hatsumi, N; Honda, S; Ishida, F; Kano, Y; Komatsu, N; Machida, S; Miyawaki, S; Morii, T; Naoe, T; Nishii, K; Ogura, M; Ohnishi, K; Takeshita, A; Usui, N; Yamauchi, T | 1 |
| Farooq, A; Farooq, MU; Khan, DH; Mir, MA; Mushtaq, F | 1 |
| Kajimura, Y; Matsuguma, M; Nakamura, Y; Tanaka, M; Tanaka, Y; Tanizawa, Y; Tokunaga, Y; Yamamoto, K; Yujiri, T | 1 |
| Geldenhuys, WJ; Gibson, LF; Martin, KH; Nair, RR; Piktel, D | 1 |
| Kantarjian, HM | 1 |
| Aladjidi, N; Auperin, A; Couec, ML; Gandemer, V; Haouy, S; Jourdain, A; Lambliotte, A; Landman-Parker, J; Leblanc, T; Michon, J; Minard-Colin, V; Patte, C; Plat, G; Rigaud, C | 1 |
| Alary, AS; Bouscary, D; Deau, B; Fontenay, M; Hermine, O; Kosmider, O; Mondesir, J; Sibon, D; Suarez, F; Tamburini, J; Willems, L | 1 |
| Ballerini, F; Cagnetta, A; Cea, M; Clavio, M; Colombo, N; Gobbi, M; Guolo, F; Lemoli, RM; Marcolin, R; Miglino, M; Minetto, P; Todiere, A | 1 |
| Anyang, BN; Baer, MR; Beumer, JH; Carrier, F; Espinoza-Delgado, I; Fang, HB; Gojo, I; Lapidus, R; Ross, DD; Sadowska, M; Srivastava, RK; Tan, M | 1 |
| Di Bona, E; Finotto, S; Laveder, F; Paolini, R; Pomponi, F; Rodeghiero, F; Ruggeri, M; Sartori, R; Trentin, L; Visco, C | 1 |
| Advani, AS; Charman, A; Cortes, J; Feldman, E; Kantarjian, H; Rizzieri, D; Spruyt, R; Toal, M; Yee, K | 1 |
| Garosi, L; Lowrie, M; Smith, PM | 1 |
| Ambinder, R; Ayala, E; Burns, LJ; Carter, S; Fenske, T; Fisher, R; Horowitz, M; Mineshi, S; Moskowitz, CH; Press, OW; Stadtmauer, EA; Tomblyn, M; Vose, JM | 1 |
| Chan, TS; Chim, CS; Gill, H; Hwang, YY; Kwong, YL; Leung, AY; Lie, AK; Tse, E | 1 |
| Chen, X; Gao, L; Kong, P; Li, Y; Liu, Y; Su, Y; Wang, C; Wang, Q; Wang, S; Wen, Q; Yuan, Z; Zeng, Y; Zhang, C; Zhang, X; Zhang, Y | 1 |
| Adès, L; Cassinat, B; Chevret, S; Chomienne, C; de Botton, S; Deconinck, E; Degos, L; Dombret, H; Fenaux, P; Ferrant, A; Guerci-Bresler, A; Huguet, F; Lambert, JF; Lamy, T; Lioure, B; Pigneux, A; Quesnel, B; Raffoux, E; Thomas, X; Vekhoff, A; Vey, N | 1 |
| Jin, J; Mai, W; Mao, L; Meng, H; Qian, J; Qian, W; Tong, H; Tong, Y; Yu, W | 1 |
| Cui, HX; Tang, XW; Wu, DP; Xue, MX; Xue, SL; Zhang, YM; Zou, JY | 1 |
| Christos, P; Feldman, E; Gergis, U; Mark, T; Mayer, S; McKenna, M; Pearse, R; Ritchie, E; Roboz, G; Scandura, J; Shore, T; van Besien, K; Wissa, U | 1 |
| Czuczman, MS; Edvardsen, K; Fayad, L; Fecteau, D; Fennessy, M; Henkel, K; Jewell, RC; Joyce, R; Kharfan-Dabaja, MA; Liao, Q; Lisby, S; Lossos, IS; Matasar, MJ; Moskowitz, CH; Rodriguez, MA; Shea, TC; Singh, RP; Spitzer, G | 1 |
| Eckert, C; Henze, G; v Stackelberg, A | 1 |
| Castaigne, S; Celli-Lebras, K; Chevret, S; Dombret, H; Fenaux, P; Gachard, N; Gardin, C; Malfuson, JV; Merabet, F; Micol, JB; Pautas, C; Preudhomme, C; Quesnel, B; Sarkozy, C; Terré, C; Thomas, X; Turlure, P | 1 |
| Aoki, T; Harada, Y; Kasai, M; Matsubara, E; Morishita, T; Nakamura, S; Ogura, M; Suzuki, T; Tsuzuki, T; Uchida, T | 1 |
| Badoux, X; Jones, JA; Kantarjian, H; Keating, MJ; Kipps, TJ; O'Brien, S; Plunkett, W; Tsimberidou, AM; Wen, S; Wierda, WG | 1 |
| Escherich, G; Hagel, C; Hartz, B; Löbel, U | 1 |
| Colafati, GS; Corsetti, T; DE Ioris, MA; Del Bufalo, F; Iacono, A; Mastronuzzi, A; Secco, DE; Serra, A | 1 |
| Adès, L; Ame, S; Beyne-Rauzy, O; Braun, T; Charbonnier, A; Delaunay, J; Dreyfus, F; Fenaux, P; Prebet, T; Raffoux, E; Stammatoullas, A; Vey, N; Wattel, E | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 1 |
| Arellano, M; Bumpers, K; Flowers, CR; Heffner, LT; Hutcherson, D; Kaufman, J; King, N; Langston, A; Lechowicz, MJ; Lonial, S; Nooka, A; Shenoy, PJ; Sinha, R; Waller, EK | 1 |
| Beelen, D; Berdel, WE; Braess, J; Büchner, T; Fiegl, M; Grüneisen, A; Heinecke, A; Hentrich, M; Hiddemann, W; Kern, W; Reichle, A; Rieger, C; Sauerland, C; Schiel, X; Schöndube, D; Serve, H; Spiekermann, K; Staib, P; Unterhalt, M; Wörmann, B | 1 |
| Ravandi, F | 1 |
| Coccia, PF; Coulter, DW; Gordon, BG; Grovas, AC; Harper, JL; Patel, SA; Sanger, WG; Warkentin, PI; Wisecarver, JL | 1 |
| Bergua, JM; Chevassut, T; Duarte, R; Gianella-Borradori, A; Hals, PA; Jacobsen, TF; Johansen, M; Knapper, S; Rasch, W; Salamero, O; Smith, M | 1 |
| Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM | 1 |
| Ahlberg, L; Amini, RM; Åström, M; Bernell, P; Hägglund, H; Hallböök, H; Hulegårdh, E; Karlsson, K; Kozlowski, P; Markuszewska-Kuczymska, A; Smedmyr, B; Tomaszewska-Toporska, B | 1 |
| Kim, I; Kwon, JH; Lee, JS; Lee, YG; Park, S; Yoon, SS | 1 |
| Abboud, CN; Cashen, A; Dipersio, JF; Fiala, M; McBride, A; Ramsingh, G; Stockerl-Goldstein, K; Uy, G; Vij, R; Westervelt, P | 1 |
| Monteith, G; Parsons-Doherty, M; Poirier, VJ | 1 |
| Miyawaki, S | 1 |
| Chihara, D; Chou, T; Hasegawa, Y; Henzan, H; Izutsu, K; Kaneko, H; Kato, K; Kondo, E; Mizuta, S; Sakai, R; Sakamaki, H; Sugahara, H; Suzuki, R; Suzumiya, J; Yokoyama, K | 1 |
| Bae, SH; Jo, JC; Joo, YD; Kim, DY; Kim, H; Lee, JH; Lee, KH; Lee, WS; Park, JH; Ryoo, HM | 1 |
| Advani, AS; Appelbaum, FR; Becker, M; Coutre, S; Elkins, S; McDonough, S; Mims, M; O'Donnell, M; Othus, M; Radich, J; Wood, B | 1 |
| Jin, Z; Lin, G; Liu, L; Ma, A; Si, Y; Sun, Y; Wang, L; Wu, D; Zhang, X; Zhang, Y; Zhao, G | 1 |
| Andreola, G; Babic, A; Frungillo, N; Gardellini, A; Laszlo, D; Martinelli, G; Montoro, J; Negri, M | 1 |
| Daw, S; Hayward, J; Hewitt, M; Kirkwood, A; McCarthy, K; Morland, B; Shankar, A | 1 |
| Altman, JK; Arellano, M; Foss, Ø; Gianella-Borradori, A; Giles, FJ; Gobbi, M; Hills, R; Jacobsen, TF; Montesinos, P; O'Connell, C; Pigneux, A; Roboz, GJ; Rosenblat, T; Solomon, SR; Vetrhusand, S; Vey, N | 1 |
| Adachi, S; Hamamoto, K; Hanada, R; Hayashi, Y; Horibe, K; Imaizumi, M; Kobayashi, R; Kudo, K; Miyamura, T; Morimoto, A; Moritake, H; Nakayama, H; Shimada, A; Tabuchi, K; Taga, T; Tawa, A; Tomizawa, D; Tsuchida, M; Tsukimoto, I; Yabe, H | 1 |
| Caballero, D; Corradini, P; Dreger, P; Dreyling, M; Geisler, C; Ghielmini, M; Hermine, O; Kimby, E; Le Gouill, S; Robinson, S; Rule, S; Vitolo, U | 1 |
| Advani, AS; Appelbaum, FR; Copelan, E; List, AF; McDonough, S; Mulford, DA; Othus, M; Sekeres, MA; Willman, C | 1 |
| Benton, CB; Borthakur, G; Dara, S; Franklin, AR; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Kwari, M; O'Brien, S; Pierce, SR; Ravandi, F; Rytting, M; Thomas, DA; Yang, H | 1 |
| Burbury, K; Carney, DA; Cheah, CY; Dickinson, M; Fedele, PL; George, A; Gilbertson, M; Harrison, SJ; Herbert, KE; Januszewicz, EH; Kennedy, GA; O'Rourke, K; Opat, SS; Prince, HM; Ritchie, DS; Seymour, JF; Tam, CS; Tan, SY; Westerman, DA; Wolf, M | 1 |
| Kato, S; Konuma, T; Oiwa-Monna, M; Takahashi, S; Tojo, A | 1 |
| Bodaghi, B; Chapiro, E; Charlotte, F; LeHoang, P; Maloum, K; Nguyen-Khac, F; Thepot, S; Touitou, V | 1 |
| Ahn, JS; Chung, JS; Jo, DY; Joo, YD; Jung, SH; Kim, DY; Kim, I; Lee, JJ; Lee, KH; Moon, JH; Park, S; Shin, HJ; Sohn, SK; Song, IC; Yang, DH | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Apel, A; Avigdor, A; Koren-Michowitz, M; Maayan, H; Nagler, A; Shem-Tov, N; Shimoni, A; Volchek, Y; Yerushalmi, R | 1 |
| Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY | 2 |
| Amadori, S; Arcese, W; Buccisano, F; Cerretti, R; De Angelis, G; Del Principe, MI; Di Veroli, A; Ditto, C; Irno-Consalvo, M; Lo-Coco, F; Maurillo, L; Nasso, D; Panetta, P; Piciocchi, A; Refrigeri, M; Sarlo, C; Sconocchia, G; Venditti, A | 1 |
| Chen, F; Han, X; Huang, H; Ni, B; Wan, H; Xiao, F; Xu, L; Zhong, H; Zhong, J; Zhong, L; Zhu, J | 1 |
| Capasso, M; Ciprandi, G; Della Volpe, A; Malafronte, L; Mansi, N; Varricchio, A; Varricchio, AM | 1 |
| Gao, Z; Gong, R; Ma, L; Tian, W; Wang, T; Zhu, Q | 1 |
| Hasegawa, K; Hirayama, Y; Ishihara, T; Kanagawa, M; Koyama, J; Suzuki, T; Terui, T | 1 |
| Banat, A; Basara, N; Derigs, G; Flohr, T; Frickhofen, N; Gramatzki, M; Hess, G; Kirschey, S; Kolbe, K; Link, H; Meyer, RG; Peter, N; Schmitz, N; Schulz, A; Theobald, M; Weidmann, E; Wolf, HH | 1 |
| Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A | 1 |
| Chen, J; He, H; Li, X; Liu, Z; Qian, C; Xu, X; Yin, J; Zhai, M; Zhang, Y; Zhou, H | 1 |
| Bar-Natan, M; Douer, D; Herscovici, C; Itchaki, G; Raanani, P; Ram, R; Shpilberg, O; Tallman, MS; Wolach, O; Yeshurun, M | 1 |
| Eray, M; Haapasaari, KM; Haapasalo, H; Harjama, L; Jantunen, E; Karjalainen-Lindsberg, ML; Kuittinen, O; Kuitunen, H; Lehtinen, T; Leppä, S; Mannisto, S; Nousiainen, T; Soini, Y; Turpeenniemi-Hujanen, T; Vasala, K; Vornanen, M | 1 |
| Esiashvili, N; Flowers, CR; Jegadeesh, N; Khan, MK; Liu, Y; Okwan-Duodu, D; Rajpara, R; Shi, Z | 1 |
| Baetz, T; Chen, BE; Cheung, MC; Couban, S; Crump, M; Desjardins, P; Hassan, S; Hay, AE; Imrie, KR; Kouroukis, CT; Kukreti, V; Le, A; MacDonald, D; Meyer, RM; Mittmann, N; Risebrough, N; Shepherd, L; Song, Y; Sussman, J; Szwajcer, D | 1 |
| Fan, X; Hu, J; Tang, W; Wang, L | 1 |
| Kakiuchi, S; Kawamoto, S; Matsuoka, H; Minami, H; Yakushijin, K; Yamamoto, K | 1 |
| Cao, XM; Chen, YX; Gu, LF; He, AL; Lei, B; Liu, J; Ma, XR; Wang, FX; Wang, J; Wang, JL; Xu, Y; Yang, Y; Zhang, PY; Zhang, WG; Zhao, WH | 1 |
| Cao, Z; Gong, BF; Gong, XY; Gu, RX; Li, W; Li, Y; Lin, D; Liu, BC; Liu, KQ; Liu, YT; Mi, YC; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, GJ; Zhao, XL; Zhou, CL | 1 |
| Hotinski, AK; Lewis, ID; Ross, DM | 1 |
| Ding, C; Jiao, W; Li, X; Liu, L; Qu, Q; Wu, D; Zhang, Y | 1 |
| Caimi, PF; Campagnaro, EL; Cooper, BW; Creger, RJ; de Lima, M; Fox, R; Fu, P; Gerson, SL; Lazarus, HM; Reese-Koc, J; Silva Rondon, CH; William, BM | 1 |
| Alamoudi, S; Anglin, P; Baetz, T; Chen, BE; Cheung, M; Couban, S; Crump, M; Djurfeldt, MS; Hay, AE; Ismail, WS; Kouroukis, CT; Kuruvilla, J; Luminari, S; MacDonald, DA; Meyer, RM; Olney, HJ; Seftel, M; Shepherd, L; Turner, AR | 1 |
| Feng, G; Huang, XL; Wan, H; Wang, F; Wang, XJ | 1 |
| Ahmed, T; Berenzon, D; Dralle, S; Ellis, LR; Holwerda, S; Isom, S; Klepin, HD; Lyerly, S; Manuel, M; Pardee, TS; Powell, BL | 1 |
| Brunet, S; Castro, N; Chillón, MC; Díez-Campelo, M; González, M; Herrera, P; López, J; Mateo, M; Mateos, MV; Montesinos, P; Ocio, EM; Olave, MT; Oriol, A; Pérez-Simón, JA; Prieto-Conde, MI; San Miguel, JF; Sanz, MÁ; Vidriales, MB | 1 |
| Alebouyeh, M; Faranoush, M; Hedayati Asl, AA; Mehrvar, A; Niktoreh Mofrad, N; Reinhardt, D; Tashvighi, M | 1 |
| Arico, M; Armari Alla, C; Bardet, O; Barkaoui, M; Bernard, F; Clausen, N; Donadieu, J; Gandemer, V; Henter, JI; Jeziorski, E; Lambilliote, A; Mura, R; Piguet, C; Van Den Bos, C; van Noesel, M; Weitzman, S | 1 |
| Bae, SH; Chi, HS; Eom, HS; Hyun, MS; Jang, DY; Joo, YD; Jung, CW; Kim, DY; Kim, H; Kim, HJ; Kim, I; Kim, MK; Lee, GW; Lee, JH; Lee, KH; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Park, S; Ryoo, HM; Shin, HJ; Sohn, SK; Won, JH; Yang, DH; Yun, SC | 1 |
| Abhyankar, S; Aljitawi, O; Bivona, C; Bray, WM; Ganguly, S; Grauer, D; Henry, D; Lin, TL; McGuirk, J; Rockey, M; Singh, A | 1 |
| Baty, J; Chang, GS; Christopher, M; Demeter, RT; DiPersio, JF; Duncavage, EJ; Fronick, C; Fulton, R; Graubert, TA; Griffith, M; Griffith, OL; Heath, SE; Helton, NM; Hundal, J; Ketkar-Kulkarni, S; Klco, JM; Kulkarni, S; Lamprecht, TL; Larson, DE; Ley, TJ; Link, DC; Magrini, V; Mardis, ER; Miller, CA; O'Laughlin, M; Ozenberger, BA; Payton, JE; Petti, A; Radich, JP; Shen, D; Spencer, DH; Walter, MJ; Wartman, LD; Welch, JS; Westervelt, P; Wilson, RK | 1 |
| Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Altuntaş, F; Civriz Bozdağ, S; Durgun, G; Esbah, O; Kaya, A; Kayıkçı, Ö; Kocubaba, Ş; Şirinoğlu Demiriz, I; Tekgündüz, E; Tetik, A | 1 |
| Li, X; Liu, L; Qu, Q; Wu, D; Zhang, Y | 1 |
| Gillem, J; Giuffrida, M; Krick, E | 1 |
| Akhtar, S; Edesa, W; Elhassan, TAM; Maghfoor, I; Rauf, MS; Zahir, MN | 1 |
| Aulitzky, W; Baldus, CD; Berdel, WE; Bornhäuser, M; Brandts, CH; Burchert, A; Dürk, H; Ehninger, G; Einsele, H; Frickhofen, N; Geer, T; Giagounidis, A; Görner, M; Hänel, M; Hase, J; Heits, F; Herbst, R; Hüttmann, A; Illmer, T; Junghanß, C; Kaiser, U; Kiani, A; Klut, IM; Krämer, A; Kramer, M; Krause, SW; Krug, U; Kullmer, J; Kunzmann, V; Link, H; Mackensen, A; Müller-Tidow, C; Neubauer, A; Noppeney, R; Parmentier, S; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Serve, H; Thiede, C; von Bonin, M | 1 |
| Alram, M; Borchmann, P; Doehner, H; Engert, A; Fischer, T; Metzner, B; Müller, H; Niederwieser, DW; Raemaekers, JM; Sasse, S; Schäfer-Eckart, K; Schmalz, O; Schmitz, N; Smardová, L; Tresckow, BV | 1 |
| Dai, M; Fan, Z; Huang, F; Jiang, Q; Li, Y; Lin, D; Liu, Q; Nie, D; Sun, J; Xiao, Y; Xuan, L; Zhang, Y | 1 |
| Buckley, SA; Estey, EH; Godwin, CD; Othus, M; Powell, MA; Walter, RB | 1 |
| Bhatnagar, B; Blum, W; Canning, R; Devine, SM; Garzon, R; Geyer, S; Klisovic, R; Marcucci, G; Vasu, S; Walker, AR; Walsh, K; Wang, H; Wu, YZ | 1 |
| Bag, HG; Berber, I; Erkurt, MA; Kaya, E; Koroglu, M; Kuku, I; Nizam, I; Ozgul, M | 1 |
| Ben-Neriah, S; Connors, JM; Ennishi, D; Farinha, P; Gascoyne, RD; Johnson, NA; Kansara, R; Kridel, R; Mottok, A; Savage, KJ; Scott, DW; Sehn, LH; Slack, GW; Steidl, C; Tan, KL; Villa, D | 1 |
| Chen, CC; Teng, CL; Yeh, SP | 1 |
| Ding, J; Jing, Y; Wang, HX; Wang, LJ; Yang, H; Yu, L; Zhu, CY | 1 |
| Ashizawa, M; Fujiwara, S; Hatano, K; Ito, S; Kanda, Y; Kawasaki, Y; Mashima, K; Minakata, D; Muroi, K; Nakano, H; Oh, I; Ohmine, K; Okazuka, K; Sato, K; Sugimoto, M; Suzuki, T; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Bojic, M; Greinix, H; Hermann, A; Jäger, U; Kalhs, P; Lamm, W; Leiner, M; Mitterbauer, M; Rabitsch, W; Schörgenhofer, C; Schulenburg, A; Sillaber, C; Skrabs, K; Sperr, WR; Wohlfarth, P | 1 |
| Ding, K; Geng, L; Liu, H; Qiang, P; Song, K; Sun, Z; Tang, B; Tong, J; Wang, X; Yao, W; Zhang, L; Zhang, X; Zheng, C; Zhu, X | 1 |
| Fan, C; Huang, J; Jin, J; Mai, W; Mao, L; Meng, H; Qian, W; Suo, S; Tong, H; Yu, W | 1 |
| Gurion, R; Hamlin, P; Horwitz, S; Lunning, M; Mehta, N; Migliacci, JC; Moskowitz, A; Moskowitz, C; Zelenetz, A | 1 |
| Hazeki, D; Imamura, M; Kawakami, K; Kawano, Y; Nakagawa, S; Okamoto, Y; Shinkoda, Y | 1 |
| Gui, R; Li, M; Li, Z; Song, Y; Wei, X; Zhang, Y; Zhao, H; Zhou, J; Zu, Y | 1 |
| Fang, B; Huang, H; Lin, Q; Liu, L; Liu, Y; Song, Y; Yu, F; Zhang, Q | 1 |
| DU, QF; Huang, YX; Liu, XS; Long, H; Wu, BY; Xu, JH; Zhu, JY | 1 |
| Briones, J; Cantalapiedra, A; Díaz-López, A; Domingo-Domenech, E; Espeso, M; García, JF; García-Sanz, R; Jiménez, MJ; López, FJ; Martínez, C; Pérez-Ceballos, E; Rodriguez, MJ; Rodriguez-Calvillo, M; Sampol, A; Sureda, A; Terol, MJ | 1 |
| Chen, D; Du, XH; Jin, J; Liu, XH; Lu, Y; Ma, JX; Pei, RZ; Si, T; Ye, PP; Zhang, PS | 1 |
| Christofides, A; Isidori, A; Visani, G | 1 |
| Chang, CL; Chi, HS; Cho, YU; Jang, S; Jo, SY; Kim, HH; Kim, IS; Lee, EY; Park, CJ; Park, SH; Yi, J | 1 |
| Carrión Campo, R; Martínez Rubio, M; Moya Moya, MA; Rico Sergado, L; Saldaña Garrido, JD | 1 |
| Duan, MH; Feng, J; Han, X; Li, J; Tian, LP; Yang, C; Zhang, L; Zhang, M; Zhang, W; Zhang, Y; Zhou, DB | 1 |
| Bang, SM; Kim, I; Koh, Y; Lee, JO; Park, H; Park, S; Yoon, SS; Youk, J | 1 |
| Baritussio, A; Bucciarelli-Ducci, C; Gately, A; Marks, DI; Pawade, J | 1 |
| Ali, S; Burnett, AK; Burns, S; Cahalin, P; Clark, RE; Dennis, M; Freeman, S; Hills, RK; Kell, J; Milligan, D; Nielsen, OJ; Pocock, C; Russell, NH | 1 |
| Arai, Y; Atsuta, Y; Ichinohe, T; Ishikawa, J; Kanamori, H; Kobayashi, T; Kondo, T; Kouzai, Y; Mizuta, S; Onishi, Y; Sawa, M; Shigematsu, A; Takahashi, S; Takanashi, M; Tanaka, J; Uchida, N; Yokota, A | 1 |
| Chen, P; Chen, X; Chen, Z; Hu, J; Hua, X; Le, S; Li, J; Lin, Q; Liu, T; Luo, X; Ren, J; Yang, T; Yuan, X; Zhang, L; Zheng, H; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Fridle, C; Manz, MG; Medinger, M; Pabst, T; Passweg, J; Seipel, K; Wilk, MC | 1 |
| Gaynes, JS; Gordon, PM; Gossai, NP; Jonart, LM; Naumann, JA; Zamora, EA | 1 |
| Adachi, S; Goto, H; Hasegawa, D; Hayashi, Y; Horibe, K; Iwamoto, S; Miyamura, T; Mizutani, S; Moritake, H; Nakayama, H; Saito, A; Shiba, N; Shimada, A; Taga, T; Tanaka, S; Terui, K; Tomizawa, D | 1 |
| Hayakawa, M; Ichihashi, T; Iida, H; Iino, M; Kiyoi, H; Naoe, T; Narimatsu, H; Sawamoto, A; Sugiura, I; Suzuki, R; Takeo, T; Tsuzuki, M; Yanada, M; Yokozawa, T | 1 |
| Abboud, C; Becker, M; Friedberg, J; Ifthikharuddin, J; Komrokji, RS; Liesveld, JL; Messina, P; Mulford, D; Oliva, J; Phillips, G; Walker, AR | 1 |
| Attarian, H; Ghadiany, M; Hajifathali, A; Khosravi, A; Molanaee, S | 1 |
| Ansell, SM; Costa, LJ; Inwards, DJ; Johnston, PB; Litzow, MR; Micallef, IN; Porrata, LF | 1 |
| Au, WY; Fong, BM; Kwong, YL; Tam, S | 1 |
| Camera, A; Cantore, N; Ferrara, F; Grimaldi, F; Guerriero, A; Luciano, L; Mastrullo, L; Mele, G; Mettivier, V; Miraglia, E; Palmieri, S; Rinaldi, CR; Rotoli, B | 1 |
| Ferreri, AJ; Foppoli, M; Mazzucchelli, L; Ponti, G; Ponzoni, M; Zucca, E | 1 |
| Basso, G; Biondi, A; Fabbri, G; Locatelli, F; Paganin, M; Polato, K; Rizzari, C; Zecca, M | 1 |
| Itoyama, S; Kishi, H; Mikata, I; Momose, S; Mori, M; Tamaru, J; Toyozumi, Y | 1 |
| Baruchel, A; Bertrand, Y; Boutard, P; Brethon, B; Bruno, B; Chevret, S; Dalle, JH; de Lumley, L; Jérome, C; Leblanc, T; Nelken, B; Oudot, C; Yakouben, K | 1 |
| Buffardi, S; Di Cesare-Merlone, A; Locatelli, F; Mangione, A; Marra, N; Menna, G; Misuraca, A; Parasole, R; Petruzziello, F; Poggi, V | 1 |
| Avet-Loiseau, H; Chevallier, P; Delaunay, J; Dmytruk, N; Garand, R; Girault, S; Guillaume, T; Harousseau, JL; Hunault, M; Ifrah, N; Milpied, N; Mohty, M; Pigneux, A; Turlure, P | 1 |
| Cabanillas, F; Fayad, L; Hagemeister, F; Kantarjian, H; Kwak, LW; McLaughlin, P; Rodriguez, MA; Romaguera, J; Wang, M; Zhou, Y | 1 |
| Berlanga, JJ; Besalduch, J; Brunet, S; Bueno, J; Esteve, J; Gallardo, D; Guardia, R; Heras, I; Hoyos, M; Llorente, A; Nomdedeu, J; Pérez-García, A; Ribera, JM; Sierra, J; Tormo, M | 1 |
| Apollonsky, N; Lipton, JM | 1 |
| Bergamaschi, G; Corazza, GR; Girino, M; Gobbi, PG; Lambelet, P; Perfetti, V; Valentino, F | 1 |
| Hagiwara, S; Kawabata, KC; Miwa, A; Oka, S; Tachikawa, N; Takenouchi, A; Tanimura, A; Tanuma, J | 1 |
| Huh, J; Kim, BS; Kim, K; Kim, SJ; Kim, WS; Ko, YH; Suh, C | 1 |
| Brown, AW; McGregor, BA; Osswald, MB; Savona, MR | 1 |
| Abe, D; Adachi, S; Asai, K; Daifu, T; Izawa, K; Kato, I; Matubara, H; Nakahata, T; Tokumasu, M; Umeda, K; Uryu, K; Watanabe, K | 1 |
| Ayuk, F; Bacher, U; Brümmendorf, TH; Fiedler, W; Hochhaus, A; Iwanski, GB; Klyuchnikov, E; Kröger, N; Ocheni, S; Schafhausen, P; Schnittger, S; Zabelina, T; Zander, AR | 1 |
| Bulusu, R; Camilleri, D; Follows, G; Marcus, R; Raj, S; Stafford, G; Todd, T; Williams, M | 1 |
| Bruns, I; Czibere, A; Fenk, R; Gräf, T; Haas, R; Kobbe, G; Schroeder, T; Zohren, F | 1 |
| Fujii, N; Harada, M; Ikeda, K; Maeda, Y; Matsuo, K; Matsuoka, K; Nishimori, H; Shinagawa, K; Takenaka, K; Tanimoto, M | 1 |
| Abebe, L; Einzig, A; Lee, SH; Paietta, E; Wiernik, PH | 1 |
| Ahn, JS; Chae, YS; Cho, YY; Choi, YJ; Chung, JS; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Lee, SR; Shin, HJ; Sohn, SK; Yang, DH | 1 |
| Hong, M; Li, JY; Lu, H; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, SJ; Zhu, BG | 1 |
| Chen, YM; Dou, HJ; Hu, JP; Tang, Y; Yao, YY; Zhu, Q; Zou, LF | 1 |
| Cai, Y; Lin, L; Ling, JY; Sun, XF; Tong, GL; Xia, Y; Zhen, ZJ | 1 |
| Du, X; Huang, ZL; Li, QH; Lin, W; Lu, ZS; Weng, JY; Wu, SJ; Zhong, LY | 1 |
| Altman, JK; Andreeff, M; Borthakur, G; Brandwein, J; Carter, BZ; Estey, EH; Hedley, DW; Jacob, C; Jolivet, J; Karp, JE; Kassis, J; LaCasse, E; Mak, DH; Morris, SJ; Schiller, GJ; Schimmer, AD; Tallman, MS; Xu, W | 1 |
| Albitar, M; Boskovic, D; Brandwein, J; Cahill, A; DeAngelo, D; Giles, F; Kell, J; O'Brien, S; Pigneux, A; Robak, T; Seiter, K; Staib, P; Stock, W; Stuart, R; Tallman, M; Thomas, X; Vey, N | 1 |
| Bennett, JM; Cripe, LD; Dewald, GW; Gore, SD; Lazarus, HM; Lee, SJ; Litzow, MR; Othus, M; Paietta, EM; Rowe, JM; Tallman, MS | 1 |
| Armistead, PM; Champlin, R; de Lima, M; Estey, E; Giralt, S; Kantarjian, H; Pierce, S; Qiao, W; Ravandi, F; Thall, PF; Wang, X | 1 |
| Qin, TJ; Wang, JY; Xiao, ZJ; Xu, ZF; Zhou, CL | 1 |
| Avery, S; McLean, C; Opat, S; Patil, S; Ritchie, D; Schwarer, A; Spencer, A; Wei, A | 1 |
| Einsele, H; Grigoleit, GU; Kapp, M; Mielke, S; Stuhler, G; Tan, SM; Topp, MS; Unzicker, C | 1 |
| Bosch, F; Carreras, E; Esteve, J; Fernández de Larrea, C; Fernández-Avilés, F; Gaya, A; López-Guillermo, A; Lozano, M; Martínez, C; Montserrat, E; Nomdedeu, B; Rovira, M | 1 |
| Kurokawa, M; Nagai, S; Nannya, Y; Takahashi, T | 1 |
| Hirayama, Y; Ishitani, K; Iyama, S; Kato, J; Kobune, M; Kohda, K; Koike, K; Kuroda, H; Neda, H; Sato, T; Takimoto, R; Terui, T | 1 |
| Abdulghaffar, EE; Abou El Asrar, M; Adly, AA; El-Bostany, EA; El-Ghouroury, EA; Tantawy, AA | 1 |
| Asou, N; Emi, N; Honda, S; Kishimoto, Y; Matsuda, S; Mitani, K; Miyawaki, S; Miyazaki, Y; Ogawa, Y; Ohno, R; Ohtake, S; Sakamaki, H; Takahashi, M; Yagasaki, F | 1 |
| Chen, H; Deisseroth, A; Farrell, A; He, K; Justice, R; Kane, R; Pazdur, R; Sridhara, R | 1 |
| Barosi, G; Fanti, S; Gianni, AM; Martelli, M; Petrini, M; Tura, S; Vitolo, U; Zinzani, PL | 1 |
| Filanovsky, K; Shtalrid, M; Shvidel, L | 1 |
| Aureli, V; Balduino, G; Caniglia, M; Cometa, AM; Isacchi, G; Landi, F; Miele, MJ; Pinto, RM; Rana, I; Scerpa, MC; Zinno, F | 1 |
| Boesen, AM; Browett, P; Cunningham, D; Grigg, A; Hancock, B; Holte, H; Hoskin, P; Jack, A; Linch, DC; Maclennan, K; Qian, W; Smith, P; Trneny, M; Yung, L | 1 |
| Asai, T; Hangaishi, A; Imai, T; Kurokawa, M; Nannya, Y; Takahashi, T; Ueda, K; Yamamoto, G | 1 |
| Bourquin, JP; Creutzig, U; Dworzak, M; Henze, G; Kremens, B; Lakomek, M; Reinhardt, D; Stary, J; Urban, C; Zimmermann, M | 1 |
| Adachi, S; Asami, K; Endo, M; Goto, H; Hanada, R; Hara, J; Hori, T; Horibe, K; Horikoshi, Y; Hosoya, R; Ikuta, K; Kikuta, A; Kobayashi, R; Koike, K; Mugishima, H; Nagatoshi, Y; Nishimura, S; Ohara, A; Ohta, S; Sugita, K; Tsukimoto, I; Tsurusawa, M; Watanabe, A | 1 |
| Ebell, W; Escherich, G; Fengler, R; Henze, G; Karachunsky, A; Kaspers, G; Klingebiel, T; Mann, G; Niggli, F; Ratei, R; Schrappe, M; Tallen, G; von Stackelberg, A | 1 |
| Advani, AS; Bates, J; Copelan, EA; Cotta, CV; Egorin, MJ; Howard, M; Hsi, E; Jin, T; Kalaycio, M; Lim, K; Maciejewski, J; Noon, E; Price, C; Rush, ML; Salvado, A; Saunthararajah, Y; Sekeres, MA; Sobecks, R; Tiu, R; Tripp, B | 1 |
| Blinder, R; Chang, P; Galinsky, I; Ho, VT; Housman, E; Kesari, S; Lane, SW; Mullally, A; Stone, RM | 1 |
| Bosi, A; Chiappella, A; Chitarrelli, I; Fabbri, A; Lauria, F; Levis, A; Puccini, B; Rigacci, L; Vitolo, U | 1 |
| Abidi, M; Abrams, J; Atallah, E; Ayash, L; Bentley, G; Ratanatharathorn, V; Uberti, J | 1 |
| Rheingold, SR; Seif, AE; Sutter, JA | 1 |
| Apperley, JF; Auner, HW; Contento, A; Ellis, S; Giles, C; Kanfer, EJ; MacDonald, DH; Naresh, K; Pavlů, J; Rahemtulla, A; Szydlo, RM | 1 |
| Bosly, A; Brière, J; Gisselbrecht, C; Glass, B; Hagberg, H; Ketterer, N; Linch, DC; Ma, D; Moskowitz, CH; Mounier, N; Schmitz, N; Shpilberg, O; Singh Gill, D; Trneny, M | 1 |
| Brice, P; Briere, J; Faure, P; Franchi, P; Gisselbrecht, C; Lignon, J; Madelaine, I; Mounier, N; Sibon, D; Thieblemont, C | 1 |
| Huh, J; Kim, BS; Kim, K; Kim, SJ; Kim, WS; Ko, YH; Park, K; Park, Y; Suh, C | 1 |
| Hamamoto, K; Hanada, R; Horibe, K; Imaizumi, M; Kigasawa, H; Kobayashi, R; Kudo, K; Morimoto, A; Nakayama, H; Tabuchi, K; Tawa, A; Tsuchida, M; Tsuchiya, S; Tsukimoto, I; Yabe, H | 1 |
| Dong, HQ; Ji, BX; Liu, CY; Liu, YO; Su, L; Sun, WL; Wan, SG; Xu, J; Zhang, P | 1 |
| Akcan, M; Hazar, V; Karasu, GT; Küpesiz, A; Uygun, V; Yesilipek, A | 1 |
| Andreeff, M; Borthakur, G; Byrd, AL; Carter, BZ; Estey, E; Kantarjian, H; Konopleva, M; Mak, DH; Morris, SJ | 1 |
| Arnoulet, C; Blaise, D; Charbonnier, A; D'incan, E; Devillier, R; Esterni, B; Etienne, A; Prebet, T; Romeo, E; Vey, N | 1 |
| Reilly, AF; Rheingold, SR; Seif, AE | 1 |
| Berthou, C; Eveillard, JR; Guillerm, G; Ianotto, JC; Tempescul, A | 1 |
| Advani, AS; Appelbaum, FR; Coutre, SE; Gundacker, HM; Lai, R; Lancet, JE; Mims, MP; Radich, JP; Sala-Torra, O; Slovak, ML; Stiff, PJ; Stuart, RK | 1 |
| Chen, S; Li, W; Qiu, H; Sun, A; Wang, Y; Wu, D | 1 |
| Ancliff, P; Darbyshire, P; Goulden, N; Green, N; Hancock, J; Leighton, C; Love, S; Masurekar, A; Moorman, AV; Morgan, M; Parker, C; Révész, T; Saha, V; Sutton, R; Waters, R | 1 |
| Durrbach, A; Fermé, C; Hanna, C; Matta, C; Moise, L; Pilorge, S; Ribrag, V | 1 |
| Cao, XM; Chen, YX; Gu, LF; He, AL; Liu, J; Ma, XR; Wang, FX; Zhang, WG | 1 |
| Lo-Coco, F; Sanz, MA | 1 |
| Damm, F; Ganser, A; Göhring, G; Görlich, K; Heil, G; Heuser, M; Krauter, J; Schäfer, I; Schlegelberger, B; Thol, F; Wagner, K | 1 |
| Agura, E; Berryman, RB; Cooper, B; Fay, J; Holmes, H; Li, S; Maisel, C; Saracino, G; Tadic-Ovcina, M; Vance, E | 1 |
| Allen, SL; Asatiani, E; Feldman, EJ; Kolitz, JE; Lancet, JE; List, AF; Louie, AC; Mayer, LD; Ritchie, EK; Roboz, GJ; Swenson, C | 1 |
| Glass, B; Griesinger, F; Hasenkamp, J; Hohloch, K; Lakhani, VJ; Meller, J; Riggert, J; Sahlmann, CO; Trümper, L; Wulf, G | 1 |
| Kwong, YL; Lee, HK; Leung, AY; Liu, HS; Sim, J; Tse, E; Yip, SF | 1 |
| Chi, HS; Jang, S; Lee, JH; Park, BG; Park, CJ; Seo, EJ | 1 |
| Choi, CW; Choi, YJ; Jung, KY; Kim, BS; Kim, SJ; Lee, SR; Park, KH; Park, SJ; Park, Y; Sung, HJ | 1 |
| Appelbaum, FR; Becker, P; Estey, E; Hendrie, P; Knoebel, RW; McQuary, A; Petersdorf, S | 1 |
| Bautista, F; Del Mar Andres, M; Fernandez-Navarro, JM; Moreno, L; Tasso, M; Verdeguer, A | 1 |
| Baer, MR; Ball, ED; Borthakur, G; Cortes, J; Dipersio, J; Fernandez, HF; Goodman, M; Kantarjian, H; Kolitz, JE; Wetzler, M | 1 |
| Battiwalla, M; Ford, LA; Hahn, TE; McCarthy, PL; Tan, W; Wallace, PK; Wang, ES; Wetzler, M; Wilding, GE; Zeidan, A | 1 |
| Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA | 1 |
| Adjei, AA; Ames, MM; Chen, Y; Erlichman, C; Flatten, KS; Greer, J; Hogan, W; Ivy, SP; Karnitz, LM; Karp, JE; Kaufmann, SH; Litzow, MR; Loegering, DA; Maurer, MJ; Mesa, RA; Peterson, KL; Reid, JM; Schneider, PA; Smith, BD; Steensma, DP | 1 |
| Abril, C; Al-Kali, A; Brandt, M; Cortes, J; Faderl, S; Jones, D; Kantarjian, H; Pierce, S; Ravandi, F | 1 |
| Caballero, MD; Capria, S; Cuberli, F; Falcioni, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Giardini, C; Gobbi, M; Isidori, A; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Sarina, B; Specchia, G; Stefani, PM; Visani, G | 1 |
| Appelbaum, FR; Becker, PS; Estey, EH; Faderl, S; Harrington, E; Hendrie, PC; Kantarjian, HM; Pagel, JM; Petersdorf, SH; Pierce, S; Shan, J; Shustov, AR; Stirewalt, DL; Storer, B | 1 |
| Shigematsu, A | 1 |
| Artz, A; Campbell, NP; Daugherty, C; Gajria, D; Godley, LA; Green, M; Gurbuxani, S; Huo, D; Hyjek, E; Larson, RA; Larson, SM; Odenike, O; Sipkins, D; Stock, W; Thirman, M; Van Besien, K; Weiner, H; Zhang, Y | 1 |
| Boudova, L; Briere, J; Bron, D; Chevalier, C; Cogliatti, S; Cuccuini, W; Gaulard, P; Gisselbrecht, C; Hirchaud, E; Houlgatte, R; Jack, A; Mounier, N; Rosenwald, A; Schmitz, N; Soulier, J; Sundstrom, C; Thieblemont, C; Trougouboff, P; Voelker, HU; Ysebaert, L | 1 |
| Bourquin, JP; Corbacioglu, S; Creutzig, U; Dworzak, MN; Reinhardt, D; Sander, A; Schrauder, A; Stary, J; Teigler-Schlegel, A; von Neuhoff, C; Zimmermann, M | 1 |
| Au, WY; Kumana, CR; Kwong, YL; Lau, JS; Lee, HK; Lin, SY; Liu, H; Yeung, DY | 1 |
| Eyre, T; Grech, H; King, AJ; Rangarajan, D; Sampson, R | 1 |
| Altman, J; Carlson-Leuer, K; Coyle, K; Frankfurt, O; Mehta, J; Newman, D; Rademaker, AW; Tallman, MS; Trifilio, SM | 1 |
| Holodny, A; Omuro, A; Palomba, ML; Pentsova, E; Rosenblum, M | 1 |
| Avigdor, A; Avivi, I; Levi, I; Nagler, A; Or, R; Patachenko, P; Rowe, JM; Shimoni, A; Yeshurun, M; Zwas, T | 1 |
| Albert, DH; Carlson, DM; Dudley, M; Enschede, S; Glaser, K; Hogge, D; Koh, LP; Li, X; McKeegan, E; Pradhan, R; Stock, W; Wang, ES; Yee, K | 1 |
| Chiba, S; Enami, T; Hasegawa, Y; Nanmoku, T; Obara, N; Okoshi, Y; Suzukawa, K; Yokoyama, Y | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ | 1 |
| Arai, H; Handa, T; Iso, H; Maki, K; Mitani, K; Nakamura, Y; Sasaki, K; Tadokoro, J; Takahashi, W; Tokita, K; Tsurumi, S | 1 |
| Ardeshna, K; Kayani, I; Linch, DC; Lowry, L; Moore, S; Peggs, K; Qian, W; Thomson, K | 1 |
| Dehghani, M; Haghighinejad, H; Mohamadian, M; Nourani, H; Ramzi, M; Vojdani, R; Zakerinia, M | 1 |
| Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L | 1 |
| Botteri, E; Calabrese, L; Cocorocchio, E; Martinelli, G; Peccatori, F; Piperno, G; Preda, L; Travaini, L; Vanazzi, A | 1 |
| Huang, TS; Lin, HW; Shih, SR; Yao, M | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Plunkett, W; Ravandi, F | 1 |
| Arnoulet, C; Autret, A; Blaise, D; Charbonnier, A; D'incan, E; Etienne, A; Fürst, S; Jean, E; Prébet, T; Rey, J; Vey, N | 1 |
| Avigan, D; Collins, R; Craig, M; Faderl, S; Ganguly, S; Goldberg, S; Greiner, J; Hari, P; Huebner, D; Jagasia, M; Kantarjian, HM; Kovacsovics, T; Maris, M; Ravandi, F; Recher, C; Rizzieri, D; Schiller, G; Seiter, K; Stuart, R; Vasconcelles, M; Vey, N; Wang, ES; Wetzler, M | 1 |
| Andersen, NS; Bentzen, H; Brown, P; Delabie, J; Ehinger, M; Elonen, E; Eriksson, M; Geisler, CH; Jerkeman, M; Karjalainen-Lindsberg, ML; Kimby, E; Kolstad, A; Kuittinen, O; Laurell, A; Lauritzsen, GF; Nilsson-Ehle, H; Nordström, M; Pedersen, LB; Ralfkiaer, E; Räty, R; Sundström, C | 1 |
| Bartolesi, AM; Fanci, R; Pecile, P; Pini, G | 1 |
| Gassner, EM; Pircher, A; Steurer, M; Wolf, D | 1 |
| Avery, S; Campbell, P; Coutsouvelis, J; Fong, CY; Grigoriadis, G; Hocking, J; Muirhead, J; Patil, S; Paul, E; Schwarer, A; Spencer, A; Walker, P; Wei, A | 1 |
| de Revel, T; Eddou, H; Foissaud, V; Konopacki, J; Malfuson, JV; Thepenier, C | 1 |
| Asou, N; Horikawa, K; Iwanaga, M; Kimura, Y; Kishimoto, Y; Kiyoi, H; Matsuda, M; Monma, F; Nakaseko, C; Naoe, T; Ohtake, S; Okada, M; Ono, T; Shinagawa, K; Takahashi, M; Takeshita, A; Tsuzuki, M; Yamauchi, T | 1 |
| Adde, M; Adeodou, O; Aken'Ova, Y; Brown, BJ; Durosinmi, M; Githang'a, J; Hurwitz, N; Kaijage, J; Leoncini, L; Magrath, I; Naresh, K; Ngoma, T; Rajab, J; Raphael, M; Rohatiner, A; Scanlan, P; Venzon, D | 1 |
| Chang, CS; Cho, SF; Liu, TC | 1 |
| Chang, CK; He, Q; Li, X; Song, LX; Wu, LY; Xu, L; Zhang, QX; Zhang, Y | 1 |
| al-Farsi, K; Crump, M; Keating, A; Kuruvilla, J; Puig, N; Seshadri, T; Wang, L | 1 |
| Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M | 1 |
| Guo, M; Hu, KX; Qiao, JH; Sun, QY; Wang, YR; Yu, CL | 1 |
| Al-Ahmari, A; Al-Musa, A; Al-Seraihy, A; Ayas, M; Belgaumi, AF; Bukhari, A; El-Solh, H; Siddiqui, KS | 1 |
| Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Enke, C; Hankins, J; Loberiza, FR; Vose, JM; Weisenburger, DD | 1 |
| Gotoh, M; Ito, Y; Mihara, M; Miyawaki, S; Naoe, T; Ohnishi, K; Ohtake, S; Ohyashiki, K; Takada, S; Wakita, A | 1 |
| Granell, M; Mozos, A; Pajares, V; Puzo, C; Szafranska, J; Torrego, A | 1 |
| Brychtova, Y; Chovancova, J; Doubek, M; Francova, HS; Horky, O; Krejci, M; Mayer, J; Navratil, M; Pospisilova, S; Stehlikova, O; Tichy, B; Tomiska, M | 1 |
| Anchukova, LV; Bondarenko, SN; Gavrilova, LV; Ialykomov, IV; Kaplanov, KD; Kaporskaia, TS; Kliasova, GA; Kokhno, AV; Kondakova, EV; Konstantinova, TS; Kravchenko, SK; Kulikov, SM; Kuz'mina, LA; Lapin, VA; Moskov, VI; Parovichnikova, EN; Pristupa, AS; Ryzhko, VV; Samoĭlova, OS; Savchenko, VG; Shaforostova, II; Sokolov, AN; Troitskaia, VV; Volodicheva, EM; Zagoskina, TP | 1 |
| Ando, S; Hashino, S; Higashiyama, A; Imamura, M; Kahata, K; Okada, K; Onozawa, M; Takahata, M; Tanaka, J | 1 |
| Camara-Clayette, V; Hermine, O; Ribrag, V | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C | 1 |
| Angelucci, E; Biagiotti, C; Borin, L; Bosi, A; Caracciolo, F; Cutini, I; Fanci, R; Gianfaldoni, G; Longo, G; Mannelli, F; Pogliani, EM; Romani, C; Scappini, B; Simonetti, F; Susini, MC | 1 |
| Ahn, HS; Kang, HJ; Kim, H; Lee, JW; Park, JD; Park, KD; Shin, HY; Yoon, JH | 1 |
| Bacher, U; Bokemeyer, C; Fiedler, W; Haalck, T; Janjetovic, S; Janning, M | 1 |
| Fukayama, M; Kurokawa, M; Nakamura, F; Takazawa, Y; Uni, M; Yoshimi, A | 1 |
| Gisselbrecht, C | 1 |
| Béné, MC; Bories, P; Bouscary, D; Cahn, JY; Chapuis, N; Chevallier, P; Delepine, R; Demur, C; Dreyfus, F; Ifrah, N; Lacombe, C; Lamy, T; Leguay, T; Mayeux, P; Merlat, A; Park, S; Prebet, T; Recher, C; Saint Marcoux, F; Tamburini, J; Vey, N; Witz, F | 1 |
| Goulden, N; Hancock, J; Hough, R; Mitchell, C; Richards, S; Rowntree, C; Vora, A; Wade, R | 1 |
| Andre, V; Andreeff, M; Brandt, JT; Callies, S; Erba, HP; Juckett, M; Kadam, S; Lahn, M; Sayar, H; Schmidt, S; Van Bockstaele, D | 1 |
| Barraco, D; Candoni, A; Fanin, R; Pirracchio, A; Simeone, E | 1 |
| Gibson, AD | 1 |
| Elonen, E; Franssila, K; Itälä, M; Jantunen, E; Kuittinen, O; Lehtinen, T; Oinonen, R; Wiklund, T | 1 |
| Cortes, J; Davis, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; O'Brien, S; Thomas, D | 1 |
| Sekeres, MA; Stone, R | 1 |
| Arcese, W; Aricò, M; Barisone, E; Basso, G; Biondi, A; Casale, F; Comis, M; Conter, V; Del Giudice, I; Dini, G; Giona, F; Ladogana, S; Lippi, A; Locatelli, F; Mandelli, F; Masera, G; Messina, C; Micalizzi, C; Micozzi, A; Moleti, ML; Mura, R; Pinta, MF; Rondelli, R; Santoro, N; Testi, AM; Valsecchi, MG | 1 |
| Amir, G; Cohen, Y; Da'as, N; Gillis, S; Polliack, A; Rund, D | 1 |
| Engert, A; Glossmann, JP; Josting, A; Paulus, U; Pfistner, B | 1 |
| Altés, A; Escoda, L; Guardia, R; López-Guillermo, A; Martino, R; Montserrat, E; Perea, G; Ribera, JM; Salar, A; Sierra, J | 1 |
| Diehl, V; Dörken, B; Engert, A; Hossfeld, DK; Josting, A; Kirchner, HH; Mapara, M; Reiser, M; Rudolph, C; Sieber, M | 1 |
| Choi, CW; Kim, BS; Kim, JS; Kim, YH; Paek, CW; Seo, JH; Shin, SW | 1 |
| Creutzig, U; Hählen, K; Harbott, J; Huismans, DR; Kaspers, GJ; Pieters, R; Slater, RM; Veerman, AJ; Zimmermann, M; Zwaan, CM | 1 |
| Castel, V; Dini, G; Fagioli, F; Ferrant, A; Frassoni, F; Labopin, M; Locatelli, F; Meloni, G; Messina, C; Ortega, J; Pession, A; Shaw, PJ; Sociè, G; Yaniv, I | 1 |
| Arthur, DC; Bloomfield, CD; Byrd, JC; Carroll, AJ; Davey, FR; Dodge, RK; Edwards, CG; Feldman, EJ; Koduru, PR; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Patil, SR; Pettenati, MJ; Rao, KW; Schiffer, CA; Stone, RM; Watson, MS | 1 |
| Barge, RM; Honders, MW; Veuger, MJ; Willemze, R | 1 |
| Hynan, L; Kamen, BA; Mantadakis, E; Smith, AK; Winick, NJ | 1 |
| Bacigalupo, A; Ferrua, MT; Gallamini, A; Ghirardo, D; Lo Nigro, C; Mattei, D; Mordini, N; Osenda, M; Viscoli, C | 1 |
| Breitenbuecher, F; Fischer, T; Gamm, H; Gschaidmeier, H; Hess, G; Huber, C; Kindler, T; Kirkpatrick, CJ; Marx, A | 1 |
| Alvarado, Y; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, A | 1 |
| Alonzo, TA; Arceci, RJ; Bernstein, ID; Gerbing, RB; Lange, BJ; Loken, MR; Sievers, EL; Smith, FO; Woods, WG | 1 |
| Go, RS; Johnston, KL | 1 |
| Corbacioglu, S; Eber, S; Gungor, T; Hummerjohann, J; Niggli, F | 1 |
| Baer, MR; Barcos, M; Blumenson, L; Ferrone, S; Ford, LA; McElwain, BK; Mortazavi, A; Slack, JL; Stewart, CC; Wetzler, M | 1 |
| Buquicchio, C; Carluccio, P; Greco, G; Liso, A; Liso, V; Mestice, A; Pastore, D; Rizzi, R; Specchia, G | 1 |
| Bunin, N; Cotte, J; Gregson, B; Grupp, S; June, CH; Laport, GG; Levine, BL; Liebowitz, DN; Luger, SM; Porter, DL; Rivers, P; Schuster, SJ; Stadtmauer, EA; Strobl, FJ; Vonderheide, RH; Zheng, Z | 1 |
| Heinonen, K; Jantunen, E; Mahlamäki, E; Nousiainen, T | 1 |
| Beyan, C; Cetin, T; Kaptan, K; Nevruz, O | 1 |
| Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, A; Verstovsek, S | 1 |
| Huang, XJ; Lu, DP; Lu, J | 1 |
| Dmoszyńska, A; Grosicki, S; Hellmann, A; Hołowiecki, J; Jedrzejczak, W; Kowal, M; Kuliczkowski, K; Kyrcz-Krzemień, S; Lech-Marańda, E; Maj, S; Robak, T; Skotnicki, A; Wierzbowska, A; Wrzesień-Kuś, A | 1 |
| Boogaerts, M; Daenen, S; de Greef, G; Ferrant, A; Fey, M; Gmür, J; Gratwohl, A; Huijgens, P; Kovacsovics, T; Löwenberg, B; Schouten, H; Sonneveld, P; Theobald, M; van Putten, W; Verdonck, L | 1 |
| Cerny, T; Gähler, A; Hess, U; Hitz, F | 1 |
| Cortes, JE; Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, S; Thomas, DA; Tsimberidou, AM; Verstovsek, S | 1 |
| Au, WY; Chan, EC; Kwong, YL; Leung, AY; Liang, R; Lie, AK; Ooi, GC; Siu, LL | 1 |
| Blazek, B; Cerná, Z; Dembická, D; Gajdos, P; Hak, J; Hrstková, H; Hrusák, O; Jabali, Y; Kopecná, L; Mihál, V; Mydlil, J; Pospísilová, D; Procházková, D; Ptoszková, H; Slavík, Z; Starý, J; Timr, P; Trka, J; Vávra, V; Zahálka, F | 1 |
| Aulitzky, W; Berger, U; Berndt, A; Deininger, MW; Fischer, T; Freund, M; Fruehauf, S; Gattermann, N; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; Hossfeld, DK; König, H; Krause, SW; Kreil, S; Lahaye, T; le Coutre, P; Merx, K; Müller, MC; Nerl, C; Neubauer, A; Ottmann, OG; Paschka, P; Sayer, HG; Schneller, F; Waller, C | 1 |
| Benchekroun, S; Harif, M; Qachouh, M; Quessar, A | 1 |
| Kim, DH; Kim, JG; Lee, KB; Lee, KS; Lee, NY; Sohn, SK; Suh, JS | 1 |
| Baccarani, M; Malagola, M; Martinelli, G; Piccaluga, PP; Ronconi, S; Rondoni, M; Visani, G | 1 |
| Huang, F; Liu, QF; Liu, XL; Meng, FY; Sun, J; Xu, B; Yang, LJ; Zhang, Y; Zheng, WY | 1 |
| Kondo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suemori, S; Suetsugu, Y; Sugihara, T; Tsujioka, T; Wada, H; Yamamori, S | 1 |
| Ahn, HS; Choi, HS; Han, KS; Kang, HJ; Shin, HY | 1 |
| Araki, H; Hoshino, N; Katayama, N; Lorenzo V, F; Miyashita, H; Nishii, K; Ohishi, K; Sakakura, M; Shiku, H; Sugimoto, Y; Usui, E | 1 |
| Almqvist, A; Anttila, P; Elonen, E; Jantunen, E; Koistinen, P; Koivunen, E; Koponen, A; Mikkola, M; Nousiainen, T; Oksanen, K; Pelliniemi, TT; Pulli, T; Remes, K; Ruutu, T; Sarkkinen, R; Silvennoinen, R; Timonen, T; Vanhatalo, S | 1 |
| Arthur, DC; Bloomfield, CD; Byrd, JC; Carroll, AJ; Davey, FR; Edwards, CG; Koduru, PR; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Ruppert, AS; Stamberg, J | 1 |
| Aoyama, Y; Hasegawa, T; Hino, M; Mugitani, A; Nakamae, H; Nakao, Y; Ohta, K; Ohta, T; Yamamura, R; Yamane, T | 1 |
| Hoang-Xuan, K; Levy, V; Soussain, C | 1 |
| Boiron, JM; Buzyn, A; Delannoy, A; Fegueux, N; Fière, D; Gardin, C; Georges, M; Hacini, M; Huguet, F; Kuentz, M; Lhéritier, V; Micléa, JM; Reman, O; Stamatoullas, A; Thomas, X; Vernant, JP | 1 |
| Altundag, K; Altundag, O; Celik, I; Kars, A; Turker, A | 1 |
| Bujassoum, S; Lipton, JH; Rifkind, J | 1 |
| Beran, M; Cortes, JE; Estey, E; Giles, FJ; Kantarjian, HM; O'Brien, SM | 1 |
| Pui, CH; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Santana, VM; Srivastava, DK | 1 |
| Chen, H; Gocke, CD; Gojo, I; Greer, J; Guo, C; Karp, JE; Morris, L; Pili, R; Qian, D; Tidwell, M; Zwiebel, J | 1 |
| Kawano, Y; Nagatoshi, Y; Nagayama, J; Okamura, J | 1 |
| Aschan, J; Dugas, M; Hahn, J; Hegenbart, U; Holler, E; Kolb, HJ; Ledderose, G; Niederwieser, D; Ringdén, O; Schleuning, M; Schmid, C | 1 |
| Baccarani, M; Gaitani, S; Malagola, M; Martinelli, G; Piccaluga, PP; Rondoni, M; Visani, G | 1 |
| Borthakur, G; Cortes, JE | 1 |
| Balleari, E; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Venturino, C | 1 |
| Coutinho, F; Del Giglio, A; Manhani, AR; Velasquez, WS | 1 |
| Berlier, P; Berthier, JC; Bertrand, Y; Bleyzac, N; Bruno, B; Contamin, B; Dai, QY; David, M; Galambrun, C; Homole, E; Manel, AM; Massenavette, B; Pages, MP; Philippe, N; Souillet, AL; Souillet, G | 1 |
| Aloulou, S; Cainap, C; Carde, P; Chalhoub, B; Fermé, C; Jabbour, E; Ribrag, V; Suzan, F; Toumi, N | 1 |
| Anghilieri, M; Cairoli, R; Marbello, L; Minola, E; Morra, E; Nosari, A; Ricci, F | 1 |
| Avramis, V; Douglas, JG; Felgenhauer, J; Geyer, JR; Hawkins, DS; Holcenberg, J; Loken, MR; Meshinchi, S; Park, JR; Thomson, B | 1 |
| Acquatella, G; Carneiro, M; García, R; Gómez, R; Hernández, M; Insausti, CL; Nouel, A; Santos, S | 1 |
| Camps, A; de la Rubia, J; Jarque, I; Jiménez, C; Lorente, P; Lorenzo, I; Martín, G; Martínez, J; Moscardó, F; Sanz, G; Sanz, MA | 1 |
| Beran, M; Bonate, P; Cortes, J; Du, M; Estey, E; Estrov, Z; Faderl, S; Ferrajoli, A; Gandhi, V; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Keating, M; Kwari, M; O'Brien, S; Plunkett, W; Wierda, W | 1 |
| Gandhok, N; Sartor, O | 1 |
| Baer, MR; Block, AW; Bloomfield, CD; Carroll, AJ; Farag, SS; Koduru, PR; Kolitz, JE; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Stamberg, J; Stone, RM; Vardiman, JW | 1 |
| Alymara, V; Bourantas, KL; Chaidos, A; Tsiara, S; Tzouvara, E; Vartholomatos, G | 1 |
| Berdel, WE; Diehl, V; Dörken, B; Engert, A; Glossmann, JP; Hossfeld, DK; Josting, A; Kirchner, HH; Kisro, J; Mapara, M; Metzner, B; Rudolph, C; Sieber, M; Sienawski, M; Sieniawski, M | 1 |
| Asnafi, V; Boiron, JM; Buzyn, A; Cayuela, JM; Dombret, H; Fiere, D; Huguet, F; Lheritier, V; Macintyre, E; Reman, O; Thomas, X; Vernant, JP; Vey, N | 1 |
| Chan, WM; Lam, DS; Liu, DT | 1 |
| Barrette, S; Bernstein, ML; Champagne, J; Champagne, MA; Dalle, JH; David, M; Demers, J; Duval, M; Hume, H; Leclerc, JM; Meyer, P; Moghrabi, A; Rousseau, P | 1 |
| Badowska, W; Balcerska, A; Balwierz, W; Czyzewski, K; Debski, R; Juraszewska, E; Konatkowska, B; Kowalczyk, J; Krawczuk-Rybak, M; Kuzmicz, M; Malinowska, I; Matysiak, M; Olejnik, I; Ploszynska, A; Sońta-Jakimczyk, D; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanski, T; Wachowiak, J; Wieczorek, M; Wysocki, M | 1 |
| Benchekroun, S; Benhmiddoune, L; Harif, M; Madani, A; Quessar, A; Zafad, S | 1 |
| Attal, M; Bauduer, F; Blaise, D; Bordessoule, D; Cailleres, S; Dastugue, N; Fegueux, N; Gastaut, JA; Jourdan, E; Legros, L; Marit, G; Molina, L; Pigneux, A; Rigal-Huguet, F; Vey, N; Zerazhi, H | 1 |
| Chi, HS; Choi, SJ; Jang, S; Kim, S; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Lee, YS; Park, CJ; Ryu, SG; Seol, M | 1 |
| Brandwein, J; Brown, R; Chopra, R; De Angelo, D; Ehmann, WC; Feldman, EJ; Frankel, SR; Jurcic, JC; Kalaycio, M; Miller, C; Moore, J; O'Connor, J; Roboz, GJ; Scheinberg, D; Schulman, P; Stone, R; Wedel, N | 1 |
| Baer, MR; Ford, LA; Greco, WR; Minderman, H; O'Loughlin, KL; Pendyala, L; Smith, PF; Sweeney, KG; Wetzler, M | 1 |
| Anagnostopoulos, A; Fassas, A | 1 |
| Arnaud, P; Bocaccio, C; Bourhis, JH; Carde, P; Ferme, C; Jabbour, E; Koscielny, S; Peslin, N; Ribrag, V; Vantelon, JM | 1 |
| DU, X; Huang, ZL; Li, QH; Lin, W; Luo, CW; Zhong, LY | 1 |
| Avet-Loiseau, H; Chevallier, P; Dubruille, V; Garand, R; Guillaume, T; Harousseau, JL; Juge-Morineau, N; Mahé, B; Milpied, N; Moreau, P; Roland, V; Vigouroux, S | 1 |
| Ahmed, P; Anwar, M; Hashmi, KU; Hussain, I; Iqbal, H; Khan, B; Mahmood, A; Malik, HS; Raza, S | 1 |
| Carluccio, P; Ciuffreda, L; Liso, A; Liso, V; Mestice, A; Pastore, D; Pietrantuono, G; Rizzi, R; Specchia, G | 1 |
| Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R | 1 |
| Brevet, M; Damaj, G; Garidi, R; Gruson, B; Royer, B; Vaida, I | 1 |
| Alpay, R; Disel, U; Paydas, S; Tuncer, I; Yavuz, S | 1 |
| Chauvenet, AR; de Alarcon, PA; London, WB; Schwartz, CL; Villaluna, D; Wimmer, RS | 1 |
| Danilatou, V; Kalmanti, M; Mantadakis, E; Papadhimitriou, S; Paterakis, G; Stiakaki, E | 1 |
| Donadio, A; Dossa, D; Jean, R; Margueritte, G; Montoya, F; Navarro, M; Rieu, D | 1 |
| Ao, ZF; Chen, BA; Gao, F; Shen, HL; Xia, W; Xu, WL; Zhang, YN | 1 |
| Berger, MS; Cheng, SC; Cortes-Franco, JE; Estey, EH; Giles, FJ; Leopold, LH | 1 |
| Disel, U; Paydas, S; Yavuz, S | 1 |
| Camitta, BM; Casper, JT; Eapen, M; Keever-Taylor, CA; Margolis, DA; Murray, KJ; Pierce, KL; Talano, JM | 1 |
| Beitler, B; Bellesso, M; Chamone, D; de Almeida Macedo, MC; Dias, LC; Dorlhiac-Llacer, PE; Dulley, FL; Neto, AE; Pereira, J; Pracchia, LF | 1 |
| Stiefelhagen, P | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Nagy, T; Pintilie, M; Tsang, R | 1 |
| Döhner, H; Döhner, K; Eiwen, K; Fröhling, S; Schlenk, RF; Scholl, C | 1 |
| Gratwohl, A; Rimner, T; Tichelli, A; Went, P | 1 |
| Androutsos, G; Athanassiadou, F; Papadhimitriou, SI; Paterakis, GS; Polychronopoulou, S; Tsakiridou, AA | 1 |
| Donelli, A; Ferrari, A; Giacobbi, F; Imovilli, A; Luppi, M; Morselli, M; Narni, F; Potenza, L; Riva, G; Temperani, P; Torelli, G | 1 |
| Akhtar, S; El Weshi, A; Humaidan, H; Maghfoor, I; Rahal, M; Tbakhi, A | 1 |
| Bartolozzi, F; Chiusolo, P; Laurenti, L; Leone, G; Marra, R; Piccirillo, N; Sica, S; Sorá, F | 1 |
| Bahlis, N; Balogh, A; Brown, C; Jones, A; Morris, DG; Russell, JA; Savoie, L; Stewart, DA; Valentine, K | 1 |
| Andreeff, M; Cahill, A; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Jeha, S; King, I; O'brien, SM; Sznol, M; Thomas, D; Verstovsek, S; Wierda, W; Yee, KW | 1 |
| Asakura, H; Endo, T; Kami, M; Kim, SW; Kumano, K; Minauchi, K; Mori, S; Nakao, S; Nishio, M; Okumura, H; Ozaki, J; Shimadoi, S; Sugimori, N; Takami, A; Takaue, Y; Takemoto, Y; Yamazaki, H | 1 |
| Collisson, E; Emmanouilides, C; Lashkari, A; Lowe, T; Paquette, R; Schiller, G; Territo, M | 1 |
| Blake, M; Broxson, E; Gaynon, PS; Heerema, NA; Hutchinson, R; Kelleher, JF; La, M; Lindemulder, S; Masterson, M; Matloub, Y; Nachman, J; Sather, H; Sorrell, AD; Stork, LC; Wells, LM; Yanofsky, R | 1 |
| Bo, J; DA, WM; Li, HH; Wang, QS; Wang, SH; Wu, XX; Yu, L; Zhao, Y | 1 |
| Adde, M; Enblad, G; Hagberg, H; Laurell, A; Sundström, C | 1 |
| Kotani, T; Nakamura, Y; Ueda, M; Yamaguchi, M | 1 |
| Adamczyk-Cioch, M; Dmoszynska, A; Giebel, S; Holowiecki, J; Jakubas, B; Krawczyk-Kulis, M; Lewandowski, K; Nowak, K; Palynyczko, G; Skotnicki, A | 1 |
| Amato, B; Billio, A; Coser, P; Morello, E; Svaldi, M | 1 |
| Baccarani, M; Candoni, A; Damiani, D; Fanin, R; Michelutti, A; Simeone, E | 1 |
| Chan, GC; Cheuk, DK; Chiang, AK; Ha, SY; Lau, YL; Shek, TW | 1 |
| Caballero, D; Canales, MA; Hernandez-Navarro, F; Martin, A | 1 |
| Selleslag, D | 1 |
| Ishigatsubo, Y; Kanamori, H; Kodama, F; Motomura, S; Tomita, N | 1 |
| Hamaki, T; Harima, A; Hoshi, K; Kajiwara, K; Kodo, H; Kozai, Y; Mizusawa, M; Yamada, K | 1 |
| Alonso Ojembarrena, A; Contra Gómez, T; Díaz Pérez, MA; García Castro, J; González-Vicent, M; Madero López, L; Pérez Martínez, A; Ramírez Orellana, M | 1 |
| Corrado, C; Greco, M; Niccodemi, C; Presas, J; Valsecchi, M; Winkel, M | 1 |
| Cho, SH; Chung, IJ; Kim, HJ; Kim, YK; Lee, JJ; Mun, YC; Seong, CM; Shin, HJ; Yang, DH | 1 |
| Benedetti, F; Boccadoro, M; Chisesi, T; De Blasio, A; Drandi, D; Gallamini, A; Ladetto, M; Locasciulli, A; Majolino, I; Tarella, C | 1 |
| Balzarotti, M; Bramanti, S; Castagna, L; Magagnoli, M; Mazza, R; Nozza, A; Russo, F; Santoro, A; Sarina, B; Siracusano, L; Timofeeva, I; Todisco, E | 1 |
| Arellano, M; Flowers, C; Heffner, LT; Hutcherson, D; Jo Lechowicz, M; Langston, A; Lonial, S; Waller, EK; Winton, E | 1 |
| Adès, L; Fenaux, P | 1 |
| Apperley, J; Chaidos, A; Davis, J; Giles, C; Kanfer, EJ; Lampert, I; Loaiza, S; MacDonald, D; Marin, D; Naresh, K; O'Shea, D; Olavarria, E; Perz, JB; Rahemtulla, A; Samson, D; Sanz, J; Szydlo, R; Wagner, S | 1 |
| Coutinho, F; Dantas, AA; Del Giglio, A; Manhani, AR | 1 |
| Avvisati, G; Breccia, M; Carmosino, I; Cimino, G; Iorio, N; Latagliata, R; Lo-Coco, F; Mandelli, F; Minni, A; Petti, MC; Testi, A | 1 |
| Astolfi, M; Boccadoro, M; Bodoni, CL; De Marco, F; Drandi, D; Gianni, AM; Guidetti, A; Ladetto, M; Magni, M; Mantoan, B; Matteucci, P; Pagliano, G; Ricca, I; Tarella, C; Zanni, M | 1 |
| Crump, M | 1 |
| Flieger, D; Glasmacher, AG; Gorschlueter, M; Hensel, M; Mey, UJ; Olivieri, A; Orlopp, KS; Rabe, C; Schmidt-Wolf, IG; Strehl, JW | 1 |
| Cinatl, J; Hollatz, G; Koehl, U; Kornhuber, B; Kreuter, J; Mutschler, E; Rohrbach, E; Schwabe, D; Visschedyk, K | 1 |
| Alvarez, C; Bolufer, P; Brunet, S; Colomer, D; Díaz-Mediavilla, J; Escoda, L; Esteve, J; González San Miguel, JD; González, M; Martín, G; Rivas, C; Rubio, V; Sánchez Godoy, P; Sanz, MA; Sayas, MJ; Tomás, JF; Tormo, M | 1 |
| Herring, RA; Lee, DA; McClain, KL; Tatevian, N | 1 |
| Baratè, C; Cafro, AM; Camaggi, CM; Intropido, L; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Strocchi, E; Tedeschi, A; Tresoldi, E | 1 |
| Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O | 1 |
| Abrahamsson, J; Clausen, N; Forestier, E; Gustafsson, G; Hasle, H; Heldrup, J; Hovi, L; Jonmundsson, G; Zeller, B | 1 |
| Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A | 1 |
| Alimara, V; Bourantas, KL; Tsabouri, S; Tsiara, S; Vassiou, A | 1 |
| Chen, H; Han, W; Huang, XJ; Liu, DH; Liu, KY; Xu, LP | 1 |
| Ainoon, O; Cheong, SK; Fazlina, N; Hamidah, H; Hamidah, NH; Jamal, R; Maha, A; Zarina, AL; Zulkifli, SZ | 1 |
| Barbu, V; Carbonne, B; Garderet, L; Gorin, NC; Santacruz, R; van den Akker, J | 1 |
| Abdelkefi, A; Ben Abdeladhim, A; Ben Othman, T; Ladeb, S; Lakhal, A; Torjman, L | 1 |
| Blundell, E; Goldstone, AH; Linch, DC; Peggs, KS; Thomson, KJ | 1 |
| Fujishima, M; Fujishima, N; Hirokawa, M; Inomata, M; Kameoka, Y; Saitoh, H; Saitoh, K; Sawada, K; Takahashi, N; Yamanaka, Y; Yoshioka, T | 1 |
| Fyles, G; Hasegawa, W; Kiss, T; Lipton, JH; Loach, D; Lockwood, G; Messner, H; Minden, M; Rifkind, J; Tejpar, I; Tsang, R; Zaretsky, Y | 1 |
| Breda, L; Chiarelli, F; De Sanctis, S; Di Marzio, D; La Barba, G; Rollo, V | 1 |
| Fibbe, WE; Huijgens, PC; Lugtenburg, PJ; van 't Veer, MB; van Imhoff, GW; van Oers, MH; van Putten, WL; Vellenga, E; Verdonck, LF; Wijermans, PW; Zijlstra, JM | 1 |
| Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N | 1 |
| Cebula, B; Giebel, S; Grosicki, S; Hołowiecki, J; Kiełbiński, M; Kuliczkowski, K; Kyrcz-Krzemień, S; Kłoczko, J; Piatkowska-Jakubas, B; Pluta, A; Robak, T; Skotnicki, AB; Wawrzyniak, E; Wierzbowska, A; Wrzesień-Kuś, A; Zawilska, K | 1 |
| Joseph, M; Layden, BT; Platanias, LC; Tallman, MS | 1 |
| Gaynon, PS; La, MK; Malempati, S; Sather, H; Stork, LC | 1 |
| Delaney, SM; Dolan, ME; Gajria, D; Karrison, TG; Larson, RA; Odenike, OM; Ratain, MJ; Stock, W | 1 |
| Alessandrino, EP; Arcaini, L; Bernasconi, P; Bonfichi, M; Bottelli, C; Brusamolino, E; Cairoli, R; Calatroni, S; Gargantini, L; Lazzarino, M; Majolino, I; Merli, M; Montanari, F; Morra, E; Pascutto, C; Passamonti, F; Rossi, G; Troletti, D; Tucci, A; Zoli, V | 1 |
| Bouyer, C; Doyen, J; Italiano, A; Peyrade, F; Thyss, A | 1 |
| Borthakur, G; Estey, E; Garcia-Manero, G; Kantarjian, H; Ravandi, F; Yanada, M | 1 |
| Fujimoto, J; Kikuchi, A; Kumagai, M; Mori, T; Okimoto, Y; Sunami, S; Tsuchida, M | 1 |
| Auberger, J; Clausen, J; Erdel, M; Gastl, G; Gunsilius, E; Nachbaur, D; Petzer, A; Willenbacher, W | 1 |
| Araújo, AG; dos Santos, GA; Falcão, RP; Garcia, AB; Jácomo, RH; Lima, AS; Lucena-Araujo, AR; Panepucci, RA; Rego, EM; Santana-Lemos, BA | 1 |
| Craig, CM; Schiller, GJ | 1 |
| Abali, H; Budakoğlu, B; Güler, T; Oksüzoğlu, B; Ozet, G; Urün, Y; Yildirim, N; Zengin, N | 1 |
| Boccia, R; Champlin, R; Elashoff, R; Foon, K; Gale, RP; Jacobs, A; Zighelboim, J | 1 |
| Bertino, J; Cadman, E; Farber, L; Fischer, D; Spiro, P; Todd, M; Waldron, J | 1 |
| Obrecht, JP | 1 |
| Glick, JH; Hines, JD; Keller, AM; Mazza, JJ; Oken, MM; Streeter, RR | 1 |
| Ahmann, GB; Armitage, JO; Burns, CP; Gingrich, RD; Klassen, LW; Kugler, JW; Ray, TL; Tewfik, HH | 1 |
| Beaujean, F; Hartmann, O; Kalifa, C; Lemerle, J; Parmentier, C; Patte, C; Pein, F | 1 |
| Burke, PJ; Karp, JE; Vaughan, WP | 2 |
| Basrur, VS; Chitnis, MP; Joshi, SS; Shetty, PA | 1 |
| Dörffel, W; Grulich, M; Reuter, G | 1 |
| De Vassal, F; Dorval, T; Gaget, H; Goldschmidt, E; Lemaigre, G; Machover, D; Misset, JL; Rappaport, H; Ribaud, P; Schwarzenberg, L | 1 |
| Cantini, E; Yanes, B | 1 |
| Azarnia, N; Brennan, JK; Browman, G; Goldberg, J; Gottlieb, AJ; Miller, KB; Preisler, HD; Priore, RL; Vogler, WR; Winton, EF | 1 |
| Anderson, T; Frick, J; Hansen, RM; Ritch, PS | 1 |
| Bloomfield, CD; Peterson, BA | 1 |
| Aloe Spiriti, MA; Amadori, S; Giona, F; Mandelli, F; Meloni, G | 1 |
| Davis, LE; McLaren, LC | 1 |
| Jedrzejewski, D; Katski, W | 1 |
| Hitchcock-Bryan, S; Sallan, SE | 1 |
| Coral, FS; Frei, E; Mayer, RJ; Nathan, DG; Rosenthal, DS; Weinstein, HJ | 1 |
| Adachi, T; Hamasaki, K; Hara, M; Kimura, I; Kitajima, K; Kohi, F; Lai, M; Sanada, H; Takahashi, I; Takaoka, K; Tokioka, M; Uchida, K; Watanabe, S; Yorimitsu, S | 1 |
| Fehr, J; Frick, P; Gmuer, J; Honegger, H; Martz, G; Sauter, C | 1 |
| Aur, RJ; Avery, TL; Dahl, GV; Pratt, CB; Rivera, G; Wood, A | 1 |
| Bron, D; Cahn, JY; Gisselbrecht, C; Guglielmi, C; Hagenbeek, A; Harousseau, JL; Philip, T; Somers, R; Sonneveld, P; Van der Lelie, H | 1 |
| Akbulut, H; Arican, A; Cay, F; Demirkazik, A; Dinçol, D; Içli, F; Karaoğuz, H | 1 |
| Kaya, H; Matano, S; Matsuda, T; Nakamura, S; Ohtake, S; Okafuji, K; Tanaka, N; Yoshida, T | 1 |
| Ikebuchi, K; Irie, S; Matsudaira, T; Matsuishi, E; Okamoto, SI; Shimane, M; Shirafuji, N; Takahashi, S; Tani, K; Tsuruta, T | 1 |
| Akashi, K; Harada, M; Inaba, S; Niho, Y; Takamatsu, Y; Teshima, T | 1 |
| Löwenberg, B; Sonneveld, P; te Boekhorst, PA | 1 |
| Aoyagi, A; Arimura, H; Furusawa, S; Koike, T; Noguchi, M; Saito, K; Sakuma, H; Waga, K; Yamada, K; Yamato, H | 1 |
| Anzai, S; Fujimaki, K; Fujisawa, S; Fukawa, H; Hattori, M; Motomura, S; Okubo, T | 1 |
| Aricò, M; Basso, G; Colella, R; Conter, V; Messina, C; Miniero, R; Mori, PG; Rizzari, C; Testi, AM; Valsecchi, MG | 1 |
| Cabanillas, FC; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Swan, F; Velasquez, W | 2 |
| Björkholm, M; Gahrton, G; Grimfors, G; Gruber, A; Hast, R; Järnmark, M; Juliusson, G; Killander, A; Kimby, E; Liliemark, J | 1 |
| Andersson, B; Dimopoulos, M; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Rodriguez, M; Suki, S; Tabocoff, J; van Besien, K | 1 |
| Asou, N; Fujimoto, K; Hiraoka, A; Kobayashi, T; Kuriyama, K; Ohno, R; Saito, H; Tanimoto, M; Teshima, H; Yoshida, M | 1 |
| Hagemeister, FB | 1 |
| Hara, A; Niitsu, N; Shirai, T; Umeda, M | 1 |
| Cancelas, JA; Cerveró, C; García-Laraña, J; Hernández-Jodra, M; Lasa, E; López-Jimenez, J; Megido, M; Pérez-Oteyza, J; Sastre, JL; Zamora, C | 1 |
| Crooks, GM; Sato, JK | 1 |
| Hołowiecki, J; Kachel, L; Krawczyk, M; Krzemień, S; Rudzka, E; Wojnar, J | 1 |
| Kadin, M; Kersey, JH; King, D; Krailo, MD; Meadows, AT; Morse, M; Rosenstock, J; Steinherz, PG; Tubergen, DG | 1 |
| Eguchi, H; Ikuno, Y; Inada, H; Ishii, E; Koga, H; Matuzaki, A; Miyazaki, S; Nibu, K; Okamura, J; Ueda, K | 1 |
| Archimbaud, E; Cordonnier, C; Dreyfus, F; Fenaux, P; Jaubert, J; Leblond, V; Michallet, M; Thomas, X; Travade, P; Troussard, X | 1 |
| Phillips, GL; Reece, DE | 1 |
| Fenaux, P | 1 |
| Gadner, H; Henze, G; Ludwig, WD; Müller-Weihrich, S; Parwaresch, R; Reiter, A; Riehm, H; Sauter, S; Schrappe, M; Sykora, KW | 1 |
| Brandwein, JM; Colwill, R; Couture, F; Crump, M; Danish, R; Keating, A; Scott, JG; Stewart, AK; Sutcliffe, SB; Sutton, DM | 1 |
| Chopra, R; Goldstone, AH; Linch, DC; McMillan, A; Mills, W; Pearce, R | 1 |
| Cairo, MS; Feusner, J; Gold, SH; Knoppell, E; Krill, CE; Moulton, TA; Odom, LF; Waldron, P; Wells, RJ; White, ML | 1 |
| Welborn, JL | 1 |
| Armstrong, SG; Benger, AM; Browman, GP; McKay, KL; Meyer, RM; Singh, G | 1 |
| Byrd, RL; Cairo, MS; Cornelius, AS; Feusner, J; Gold, SH; Krill, CE; Ruymann, FB; Wells, RJ; White, ML | 1 |
| Abgrall, JF; Flesch, M; Genne, P; Maloisel, F; Moreau, P; Pignon, B; Quiquandon, I; Saddoun, A; Solary, E; Witz, F | 1 |
| Atamer, MA; Büyükkeçeci, F; Keskin, A; Tombuloğlu, M | 1 |
| Johnson, PW; Sweetenham, JW | 1 |
| Amadori, S; Annino, L; Arcese, W; Camera, A; Di Montezemolo, LC; Giona, F; Ladogana, S; Liso, V; Meloni, G; Testi, AM | 1 |
| Dusenbery, K; Haake, R; Kersey, JH; Kim, T; Nesbit, ME; Ramsay, NK; Thomas, W; Uckun, F; Weisdorf, DJ; Woods, WG | 1 |
| Aikawa, K; Furukawa, T; Gotoh, J; Ishibashi, T; Maruyama, Y; Shichishima, T; Shiga, Y; Yamagiwa, A | 1 |
| Gardner, FH; Jodhani, M; Juneja, HS; Schottstedt, M; Trevarthen, D | 1 |
| Estey, EH; Freireich, EJ; Ghaddar, HM; Kantarjian, HM; Keating, MJ; Pierce, S; Plunkett, W | 1 |
| Abdel-Warith, A; Berry, J; Ezzat, AA; Khalifa, F; Khan, B; Raja, MA | 1 |
| Almeida, MT; Britto, JL; Cristofani, LM; Maksoud, JG; Maluf, PT; Manissadjian, A; Odone Filho, V; Pontes, E | 1 |
| Chan, LC; Chan, TK; Chiu, EK; Kwong, YL; Liang, R; Lie, A; Todd, D | 1 |
| Cork, A; Jeha, S; Lockhart, S; Pinkel, D; Plunkett, W; Ramirez, I; Zipf, T | 1 |
| Damon, LE; Linker, CA; Ries, CA; Rugo, HS | 1 |
| Bairey, OS; Sandbank, Y; Shaklai, M | 1 |
| Belloc, F; Bernard, P; Boiron, JM; Cony-Makhoul, P; Dumain, P; Lacombe, F; Laurent, G; Marit, G; Puntous, M; Reiffers, J | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, J; Rubenstein, E; Swan, F; Tucker, S; Velasquez, WS | 1 |
| Baruchel, A; Deméocq, F; Guillot, T; Leblanc, T; Lemerle, S; Leverger, G; Nelken, B; Schaison, G; Vannier, JP | 1 |
| Breneman, JC; Cherlow, JM; Gaynon, PS; Grossman, NJ; Hammond, GD; Johnstone, HS; Kersey, JH; Sather, HN; Steinherz, PG; Trigg, ME | 1 |
| Dartsch, PC; Hannekum, A; Hombach, V; Kochs, M; Roth, D; Seitzer, U; Voisard, R | 1 |
| Gassmann, W; Glass, B; Haferlach, T; Löffler, H | 1 |
| Gerrits, WB; Haak, HL; Kerkhofs, H; Wijermans, PW | 1 |
| Fujioka, K; Funabiki, T; Hanzawa, N; Ikuta, K; Kai, S; Kajigaya, Y; Okuyama, T; Sekiguchi, H; Sumita, H; Takahashi, H | 1 |
| Delmer, A; Marie, JP; Suberville, AM; Thevenin, D; Zittoun, R | 1 |
| Bennett, J; Browman, GP; Goldberg, J; Kukla, C; Larson, RA; Miller, KA; Preisler, HD; Raza, A; Rustum, YM; Vogler, R | 1 |
| Busca, A; Cesaro, S; Colleselli, P; Messina, C; Miniero, R; Rossetti, F; Scotti G [corrected to Sotti, G]; Sotti, G; Zanesco, L | 1 |
| Advani, SH; Gopal, R; Hegde, UP; Iyer, RS; Kurkure, PA; Nadkarni, KS; Nair, CN; Pai, SK; Pai, VR; Saikia, TK | 1 |
| Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Carella, AM; Carlier, P; Iacopino, P; Liso, V; Mirto, S; Montillo, M; Pagano, L; Pungolino, E; Resegotti, L; Stasi, R | 1 |
| Buchanan, GR; Rivera, GK; Sadowitz, PD; Shuster, J; Smith, SD; Wharam, MD | 1 |
| Akerman, S; Allen, SL; Barile, B; Budman, DR; DeMarco, LC; Kreis, W; Marsh, JH; Schulman, P; Schuster, MW | 1 |
| Heinemann, V; Jehn, U | 2 |
| Barnett, MJ; Klingemann, HG; Nantel, SH; Phillips, GL; Reece, DE; Shepherd, JD; Sutherland, HJ | 1 |
| Estey, EH; Kantarjian, H; Keating, MJ; Plunkett, W; Rios, MB | 1 |
| Aul, C; Balleisen, L; Bartholomäus, A; Becker, K; Bettelheim, P; Hiddemann, W; Lathan, B; Ludwig, WD; Maschmeyer, G; Schönrock-Nabulsi, R | 2 |
| Becher, R; Fonatsch, C; Gassmann, W; Haase, D; Haferlach, T; Jürgensen, C; Löffler, H; Ludwig, WD; Noak, J; Thiel, E | 1 |
| Harousseau, JL | 1 |
| Groenewegen, A; Löwenberg, B; Sonneveld, P; Vellenga, E; Wielenga, JJ | 1 |
| Arborio, M; De Revel, T; Desangles, F; Flandrin, G; Vilain, E | 1 |
| Ahmed, T; Akhtar, T; Chun, H; Feldman, E; Grima, K; Helson, L; Lake, D; Mittelman, A; Puccio, C; Seiter, K | 1 |
| Falk, RE; Fuerst, MM; Giles, FJ; Kusuanco, DA; Lawrence, GN; Lim, SW; Look, RM | 1 |
| Chubachi, A; Endo, K; Kuriya, S; Maruyama, Y; Meguro, K; Narigasawa, Y; Sasaki, H; Sato, S; Shiga, T; Takami, H | 1 |
| Annino, L; Mandelli, F; Rotoli, B | 1 |
| Amadori, S; Bendandi, M; Falini, B; Gherlinzoni, F; Mandelli, F; Martelli, M; Martelli, MF; Pileri, SA; Sabattini, E; Tura, S; Zinzani, PL | 1 |
| Bessell, EM; Firth, JL; Graus, F; Hope, DT; Lopez-Guillermo, A; Moloney, AJ; Punt, JA; Villa, S | 1 |
| Carella, AM; Frassoni, F | 1 |
| Niitsu, N; Umeda, M | 1 |
| Huismans, DR; Klumper, E; Loonen, AH; Ossenkoppele, GJ; Pieters, R; Rottier, A; Veerman, AJ; Westra, G | 1 |
| Billingham, LJ; Knechtli, CJ; Long, SG; Lumley, MA; McDonald, DF; Milligan, DW | 1 |
| Chai, A; Forman, SJ; Lee, J; Lipsett, J; Margolin, KA; Molina, A; Nademanee, A; Niland, J; O'Donnell, MR; Parker, PM; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Vora, N | 1 |
| Horton, C; Mehta, J; Meller, S; Pinkerton, CR; Powles, R; Singhal, S; Tait, D; Treleaven, J | 1 |
| Gray, RG; Rees, JK; Wheatley, K | 1 |
| Nishikawa, K | 1 |
| Saito, K | 1 |
| Andreeff, HM; Beran, M; Estey, E; Gandhi, V; Kantarjian, HM; Koller, CA; Kornblau, SM; O'Brien, S; Plunkett, W | 1 |
| Borowitz, M; Bowman, WP; Buchanan, GR; Farrow, A; Jacaruso, D; Kamen, BA; Shuster, JJ; Winick, N | 1 |
| Görg, C; Havemann, K; Köppler, H; Pflüger, KH; Wacker, HH; Weide, R | 1 |
| Gonzalez-Gonzalez, A; Pinilla, J; Requena, A; Velasco, JG | 1 |
| Allford, S; Glynne, P; Hamblin, M; Horton, C; Mackay, H; Mehta, J; Powles, R; Prendiville, J; Saso, R; Singhal, S; Treleaven, J; Zomas, A | 1 |
| Hicke, A; Sońta-Jakimczyk, D; Tomaszewska, R; Wieczorek, M | 1 |
| Bonanad, S; Carral, A; de la Rubia, J; Jarque, I; Larrea, L; López, F; Martín, G; Martínez, J; Picón, I; Sanz, GF; Sanz, MA; Sempere, A; Soler, MA | 1 |
| Lemez, P; Maresová, J | 1 |
| Boesen, AM; de Nully Brown, P; Grønbaek, K; Hansen, OP; Hippe, E; Hoffmann, T; Jensen, MK; Pedersen-Bjergaard, J; Storm, HH; Thorling, K | 1 |
| Chomienne, C; Degos, L; Fenaux, P | 1 |
| Ahmed, T; Akhtar, T; Ascensao, J; Beer, M; Coleman, M; Cook, P; Feldman, EJ; Goldberg, R; Helson, L; Kancherla, R; Lake, DE; Mittelman, A; Preti, RA; Seiter, K | 1 |
| Goldberg, SL; Klumpp, TR; Mangan, KF; Ming, PL; Mullaney, MT; Rao, PN; Redei, I | 1 |
| Behringer, D; Fetscher, S; Finke, J; Kanz, L; Lange, W; Lübbert, M; Mertelsmann, R | 1 |
| Hanada, R; Hongo, T; Horikoshi, Y; Sakurai, M; Yajima, S | 1 |
| Weiss, MA | 1 |
| Batan, ZE; Milanovich, NF; Skriagin, AE; Snegir', VM; Uss, AL; Zmachinskiĭ, VA | 1 |
| Amadori, S; Annino, L; Arcese, W; Camera, A; Fioritoni, G; Giona, F; Ladogana, S; Leoni, P; Liso, V; Mandelli, F; Meloni, G; Moleti, ML; Resegotti, L; Rondelli, R; Tabilio, A; Testi, AM | 1 |
| Ohnishi, K; Ohno, R; Shinjyo, K; Takeshita, A; Tobita, T; Yanagi, M | 1 |
| Hiraoka, A; Karasuno, T; Kitamura, K; Miyawaki, S; Naoe, T; Ohnishi, K; Ohno, R; Takeshita, A; Takeuchi, M; Tobita, T; Ueda, R; Yanagi, M | 1 |
| Brandwein, J; Crump, M; Dufresne, J; Girouard, C; Imrie, K; Keating, A; Pantolony, D; Prince, HM; Stewart, AK | 1 |
| Alpdoğan, O; Alpdoğan, TB; Bayik, M; Demirçay, Z; Gürbüz, O; Kurtkaya, O; Yücelten, D | 1 |
| Hallahan, D; Mundt, AJ; Williams, SF | 1 |
| Aisner, J; Carey, RW; Eaton, WL; Green, MR; Hammond, S; Herndon, JE; Hollis, DR; Maurer, LH; Perry, MC; Skarin, AT; Zacharski, LL | 1 |
| Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S | 1 |
| Azuma, E; Higashigawa, M; Hirayama, M; Hori, H; Ido, M; Kawasaki, H; Sakurai, M | 1 |
| Amadori, S; Arcese, W; Ceci, A; Comis, M; Giona, F; Madon, E; Mandelli, F; Meloni, G; Moleti, ML; Pession, A; Pillon, M; Rondelli, R; Testi, AM | 1 |
| Gieseler, F; Gullis, E; Nuessler, V; Pelka-Fleischer, R; Stötzer, O; Wilmanns, W; Zwierzina, H | 1 |
| Amin, K; Anderlini, P; Andersson, B; Cabanillas, F; Champlin, R; Claxton, D; de Lima, M; Donato, M; Gajewski, J; Giralt, S; Khouri, I; Mehra, R; Popat, U; Preti, A; Przepiork, D; Pugh, W; Rodriguez, A; Rodriguez, J; Romaguera, J; van Besien, K | 1 |
| Bleyer, WA; Breneman, JC; Cherlow, JM; Gaynon, PS; Grossman, NJ; Johnstone, HS; Kersey, JH; Sather, HN; Steinherz, PG; Trigg, ME; Uckun, FM | 1 |
| Andreeva, LA; Batan, ZE; Chervonobab, IuV; Chimishkian, KL; Demina, EA; Kondrat'eva, NE; Larionova, VB; Milanovich, NF; Mkheidze, DM; Ptuskin, VV; Snegir', VM; Tupitsyn, NN; Uss, AL; Zmachinskiĭ, VA | 1 |
| Feig, SA; Harris, RE; Sather, HN | 1 |
| Buckner, CD; Rhinehart, S; Schwartzberg, L; Weaver, CH; West, J; West, WH; Zhen, B | 1 |
| Andreeff, M; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, CA; Kornblau, SM; O'Brien, S | 1 |
| Gray, RG; Hann, IM; Stevens, RF; Wheatley, K | 1 |
| Apel, D; Maj, S; Mariańska, B; Seferyńska, I | 1 |
| Kusama, H; Matsuoka, T; Ohsaka, A; Taguchi, H; Takagi, S | 1 |
| Ferrara, F; Latagliata, R; Magrin, S; Mele, G; Mirto, S; Montillo, M; Petti, MC; Pinto, A; Tedeschi, A; Zagonel, V | 1 |
| Behm, FG; Evans, WE; Hancock, ML; Head, DR; Kun, LE; Mahmoud, HH; Pui, CH; Relling, MV; Ribeiro, RC; Rivera, GK; Rubnitz, JE; Sandlund, JT | 1 |
| Barbui, T; Bassan, R; Bellavita, P; Borleri, G; Buelli, M; Lerede, T; Rambaldi, A | 1 |
| Andreu, G; Aoudjhane, M; Bauters, F; Belkacemi, Y; Cheron, N; Douay, L; Fenaux, P; Fouillard, L; Gorin, NC; Isnard, F; Jouet, JP; Labopin, M; Laporte, JP; Lemonnier, MP; Lesage, S; Lopez, M; Morel, P; Najman, A; Noël-Walter, MP; Stachowiak, J; Zunic, P | 1 |
| Behm, FG; Borowitz, MJ; Carroll, AJ; Harris, MB; Land, VJ; Pullen, DJ; Shuster, JJ | 1 |
| Abboud, CN; Brasacchio, R; Constine, LS; DiPersio, JF; Duerst, RE; Eberly, S; Lancet, JE; Liesveld, JL; Linder, T; Muhs, A; Packman, CH; Rapoport, AP; Raubertas, RF; Rowe, JM | 1 |
| Bordigoni, P; Boutard, P; Cornu, G; Esperou, H; Gandemer, V; Gratecos, N; Jouet, JP; Lacour, B; Leverger, G; Lutz, P; Michel, G; Milpied, N; Pico, J; Plouvier, E; Reiffers, J; Rohrlich, P; Rubie, H; Sadoun, A; Souillet, G; Stephan, JL; Vannier, JP; Vernant, JP | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Brusamolino, E; Canevari, A; Castagnola, C; Castelli, G; Lazzarino, M; Pagnucco, G | 1 |
| Armesto, A; Bello, JA; del Río, D; García Torremocha, S; Rodríguez, M; Sastre, JL; Ulibarrena, C; Vázquez, O | 1 |
| Fusaoka, T; Kataoka, A; Tunamoto, K; Wakazono, Y | 1 |
| Bron, D; Cahn, JY; Chauvin, F; Gisselbrecht, C; Gomez, F; Guglielmi, C; Hagenbeek, A; Martelli, M; Milpied, N; Philip, T; Sebban, C; Somers, R; Sonneveld, P; Van Der Lelie, H | 1 |
| Bernasconi, C; Castagnola, C; Corso, A; Dabusti, M; Lazzarino, M; Lunghi, M; Tajana, M; Zappasodi, P | 1 |
| Arguiñano, JM; Gorosquieta, AM; Pérez Equiza, E | 1 |
| Aul, C; Büchner, T; Eimermacher, H; Grote-Metke, A; Hiddemann, W; Kerkhoff, A; Kern, W; Kubica, U; Kuse, R; Maschmeyer, G; Wörmann, B | 1 |
| Bachelot, T; Biron, P; Blay, J; Chauvin, F; Gomez, F; Guglielmi, C; Hagenbeek, A; Philip, T; Sebban, C; Somers, R | 1 |
| Avramis, VI; Carcich, S; Ortega, JA; Ozkaynak, MF | 1 |
| Benner, A; Haas, R; Martin, S; Moos, M; Schulz, R | 1 |
| Barta, A; Batai, A; Kelemen, E; Lengyel, L; Paloczi, K; Petranyi, GG; Sipos, A; Torbagyi, E | 1 |
| Harada, M; Kibata, M; Ohno, R; Omoto, E; Shudo, K; Takahashi, K; Takeuchi, M; Ueda, R; Yano, T | 1 |
| Advani, SH; Bapna, A; Gladstone, B; Gopal, R; Kadam, P; Nair, CN; Nair, R; Parekh, PM; Saikia, TK | 1 |
| Bennett, JM; Lee, S; Paietta, E; Rowe, JM; Sikic, BI; Tallman, MS; Wiernik, PH | 1 |
| Adamson, PC; Balis, FM; Gillespie, AJ; Moser, AM; Poplack, DG | 1 |
| Bauters, F; Detourmignies, L; Dupriez, B; Fenaux, P; Jouet, JP; Morel, P; Plantier-Colcher, I; Simon, M | 1 |
| Annino, L; Arcese, W; Giona, F; Mandelli, F; Meloni, G; Moleti, ML; Rondelli, R; Testi, AM | 1 |
| Bachier, C; Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, H; Rodriguez, MA; Romaguera, JE; Sarris, AH; Weber, D; Younes, A | 1 |
| Chen, PM; Chiou, TJ; Fan, FS; Liu, JH; Tung, SL; Wang, WS; Yen, CC | 1 |
| Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
| Amess, J; Carter, M; Howe, K; Lister, TA; Rohatiner, AZ; Slater, S | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Colombo, A; Malcovati, L; Martinelli, G; Pagnucco, G; Salvaneschi, L | 1 |
| Dias Wickramanayake, P; Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Scheid, C; Tesch, H; Wolf, J | 1 |
| Andersson, B; Cabanillas, F; Fayad, L; Hagemeister, FB; McLaughlin, P; Rodriguez, J; Rodriguez, MA; Romaguera, J; Sarris, A; Swan, F | 1 |
| Hamaguchi, H; Hara, M; Ito, U; Nagata, K; Tomita, H; Tone, O; Yamamoto, K | 1 |
| Albin, N; Binet, JL; Boccaccio, C; Charlotte, F; Delort, J; Gabarre, J; Leblond, V; Merle-Béral, H; Souleau, B; Soussain, C; Sutton, L; Zouabi, H | 1 |
| Boqué, C; Cancelas, JA; Garcia, J; Grañena, A; Muñoz, J; Petit, J; Sarrà, J | 1 |
| Hann, IM; McCarthy, AJ; Oakhill, A; Pitcher, LA | 1 |
| Ahmad, YH; Becker, P; Doria, R; Holmes, W; Jillella, AP; Khan, K; Rappeport, JM; Roberts, KB; Smith, BR; Zelterman, D | 1 |
| Atkinson, ME; Hamielec, M; Kinsella, TJ; Longo, WL; Mineishi, S; Schuening, FG; Smith, EP; Wiersma, SR | 1 |
| Archimbaud, E; Bordessoule, D; Cony-Makhoul, P; Cordonnier, C; de Revel, T; Delair, S; Dombret, H; Dreyfus, F; Fenaux, P; Ffrench, M; Janvier, M; Leblond, V; Marie, JP; Nicolini, F; Rousselot, P; Simon, M; Stoppa, AM; Thomas, X; Tilly, H; Troussard, X; Vekhoff, A | 1 |
| Avigdor, A; Ben-Bassat, I; Ben-Yehuda, D; Berkowicz, M; Chetrit, A; Gillis, S; Hardan, I; Lossos, I; Raanani, P; Shpilberg, O; Sofer, O | 1 |
| Algara, P; Díaz, MA; Madero, L; Martínez, P; Tutor-Ureta, O | 1 |
| Appelbaum, FR; Grever, MR; Head, DR; Hynes, HE; Karanes, C; Kopecky, KJ; Kraut, EH; Lichtin, A; Nand, S; Samlowski, WE; Vial, RH | 1 |
| Alvarez Román, MT; Canales Albendea, MA; Hernández Navarro, F; Villanueva Pavón, R | 1 |
| Avvisati, G; Biondi, A; Carlo-Stella, C; Diverio, D; Lo Coco, F; Mandelli, F; Martino, B; Meloni, G; Petti, MC; Pogliani, EM; Rossi, G; Selleri, C; Specchia, G | 1 |
| Frost, BM; Larsson, R; Liliemark, E; Lönnerholm, G; Nygren, P; Peterson, C | 1 |
| Dias Wickramanayake, P; Diehl, V; Franklin, J; Glasmacher, A; Neufang, A; Scheid, C; Schulz, A; Staib, P; Steinmetz, HT; Tesch, H | 1 |
| Aguado, MJ; Canales, MA; de Bustos, JG; Fernández-Jiménez, MC; Hernández-Navarro, F; Ojeda, E | 1 |
| Beran, M; Cortes, J; Estey, E; Kantarjian, H; Koller, C; O'Brien, S; Vey, N | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, J; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A | 1 |
| Gujral, S; Kochupillai, V; Kumar, L; Mohanti, BK; Wadhwa, J | 1 |
| Ahmed, T; Burke, HB; Darzynkiewicz, Z; Deptala, A; Dorota Halicka, H; Feldman, EJ; Goff, H; Hoang, A; Kancherla, R; Pozzuoli, M; Seiter, K; Traganos, F | 1 |
| Sarper, N; Yalman, N | 1 |
| Bourhis, JH; Brice, P; Brousse, N; Decaudin, D; Gisselbrecht, C; Haioun, C; Morel, P; Quesnel, B; Souleau, B; Van Hoof, A | 1 |
| Braess, J; Büchner, T; Haferlach, T; Hiddemann, W; Kern, W; Schoch, C; Unterhalt, M; Wörmann, B | 1 |
| Bergeron, C; Brugières, L; Delsol, G; Hartmann, O; Landmann, J; Le Deley, MC; Pacquement, H; Patte, C; Perel, Y; Quartier, P; Schmitt, C; Terrier-Lacombe, MJ | 1 |
| Boyett, JM; Buchanan, GR; Chauvenet, AR; Crist, WM; Maybee, DA; Pinkel, D; Pollock, BH; Rivera, GK; Wagner, H | 1 |
| Ascari, E; Avanzini, P; Baldini, L; Broglia, C; Ghirardelli, ML; Gobbi, PG; Loni, C; Quarta, G; Silingardi, V; Stelitano, C | 1 |
| Brodsky, I; Case, D; Crilley, P; Damon, LE; Linker, CA; Navarro, W; Ries, CA; Rubin, A; Rugo, HS; Sayre, P; Topolsky, D; Wolfe, JL; Zamkoff, K | 1 |
| Appelbaum, FR; Boldt, DH; Head, DR; Karanes, C; Luthardt, FW; Norwood, T; Pugh, RP; Rankin, C; Rosen, PJ | 1 |
| Feldman, EJ | 1 |
| Child, JA; Johnson, PW; Johnson, SA; Morgan, GJ; Prentice, AG; Rule, S; Smith, GM; Tollerfield, SM; Wareham, E | 1 |
| Darbyshire, PJ; Eden, OB; Harrison, G; Lawson, SE; Oakhill, A; Richards, S; Stevens, R | 1 |
| Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S | 1 |
| Abdallah, A; Haas, R; Ho, AD; Hohaus, S; Martin, S; Schlenk, RF; Voso, MT | 1 |
| Berthou, C; Buzyn, A; Cahn, JY; Chomienne, C; Cordonnier, C; de Revel, T; Degos, L; Dombret, H; Fegueux, N; Fenaux, P; Gardin, C; Gratecos, N; Guerci, A; Huguet, F; Kotoucek, P; Maloisel, F; Naccache, P; Pigneux, A; Reman, O; Sadoun, A; Stamatoullas, A; Thomas, X; Travade, P; Vekhoff, A; Vilque, JP | 1 |
| Boros, B; Egyed, M; Földi, J; Páldi-Haris, P; Rumi, G | 1 |
| Döhner, H; Döhner, K; Schlenk, RF; van der Reijden, BA | 1 |
| Braumann, D; Fiedler, F; Hänel, A; Hänel, M; Hoffknecht, MM; Hossfeld, DK; Illiger, HJ; Kröger, N; Krüger, WH; Metzner, B; Peters, SO; Schubert, JC; Weh, HJ; Zander, AR; Zeller, W | 1 |
| Chen, MG; Gastineau, DA; Gertz, MA; Greipp, PR; Inwards, DJ; Lacy, MQ; Litzow, MR; Tefferi, A; Witzig, TE | 1 |
| Argiris, A; Cooper, DL; Seropian, S | 1 |
| Bennett, JM; Cassileth, PA; Kim, KM; Letendre, L; O'Connell, MJ; Oken, MM; Robles, C; Wiernik, PH | 1 |
| Avvisati, G; Barbui, T; Bernasconi, C; Bolufer, P; Colomer, D; Díaz-Mediavilla, J; Esteve, J; Ferrara, F; Fioritoni, G; González, JD; Gonzalez, M; Liso, V; Lo Coco, F; Mandelli, F; Martín, G; Petti, MC; Rayón, C; Ribera, JM; Rodeghiero, F; Sanz, MA | 1 |
| Dmoszyńska, A; Kowal, M; Lech-Marańda, E; Robak, T; Wrzesień-Kuś, A | 1 |
| Dzhumabaeva, BT; Efimov, IV; Kaplanskaia, IB; Margolin, OV; Moiseeva, TN; Pivnik, AV; Rasstrigin, NA; Roshchina, LS; Shavlokhov, VS; Sotnikov, VM; Stroiakovskiĭ, DL | 1 |
| Chiusolo, P; Di Febo, AL; La Barbera, EO; Laurenti, L; Leone, G; Marra, R; Menichella, G; Piccirillo, N; Sica, S; Sorà, E; Teofili, L | 1 |
| Avigdor, A; Ben-Bassat, I; Grotto, I; Hardan, I; Raanani, P; Shpilberg, O | 1 |
| Archimbaud, E; Cambier, N; Ecstein-Fraïssé, E; Leblond, V; Pautas, C; Reman, O; Soler-Michel, P; Taksin, AL; Thomas, X; Vekhoff, A | 1 |
| Abgrall, JF; Colombat, P; Cornillet, P; Deconinck, E; Delain, M; Gardembas, M; Kootz, C; Milpied, N; Tourani, JM | 1 |
| Dobie, D; Hastings, M; Mahendra, P; Richardson, G; Tauro, S | 1 |
| Cantón, I; García-Torremocha, S; Iglesias, M; Sastre, JL; Ulibarrena, C; Vázquez, MO | 1 |
| Brookes, J; Carey, P; Chu, P; Deane, M; Duncombe, A; Ganly, PS; Hutchinson, M; Jackson, G; Johnson, SA; Littlewood, TJ; MacKie, MJ; Marcus, R; Mehta, AB; Schey, S; Smith, A; Smith, GM; Taylor, P; Tollerfield, SM; Turner, GE; Wilson, MP | 1 |
| Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA | 1 |
| Ahn, JH; Bahng, H; Kim, SH; Kim, WK; Lee, JH; Lee, JS; Lee, KH | 1 |
| Kim, S; Kim, SH; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Seol, M | 1 |
| Atra, A; Gerrard, M; Hann, IM; Hobson, R; Imeson, JD; Pinkerton, CR | 1 |
| Chiusolo, P; Leone, G; Mazzotta, S; Mele, L; Pagano, L; Putzulu, R; Voso, MT | 1 |
| Caballero, MD; Canales, MA; Fernández-Jiménez, MC; García de Bustos, J; Hernández-Navarro, F; Martín, A; Pérez-Simón, JA; San Miguel, JF; Vázquez, L | 1 |
| Ancín, I; Berlanga, JJ; Ferrá, C; Gallardo, D; González, JR; Grañena, A; Marín, D; Muñoz, J; Peris, J; Sarrá, J | 1 |
| Kuijpers, M; Pieters, R; Sonneveld, P; van den Heuvel-Eibrink, MM; Wiemer, EA | 1 |
| Auperin, A; Behrendt, H; Coze, C; Frappaz, D; Leverger, G; Lutz, P; Michon, J; Patte, C; Perel, Y; Raphaël, M; Terrier-Lacombe, MJ | 1 |
| Abonour, R; Kim, K; Longo, WL; Mosher, DF; Turman, NJ; Vidarsson, B; Wiersma, SR; Williams, EC; Woodson, RD | 1 |
| Cuneo, A; Liso, V; Mestice, A; Pannunzio, A; Rocchi, M; Specchia, G; Storlazzi, CT; Surace, C | 1 |
| Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Shen, Y; Thomas, D | 1 |
| Bardy, P; Horvath, N; Hughes, T; Hui, CH; To, LB | 1 |
| Croockewit, AJ; Fibbe, WE; Kingma, T; Uyl-de Groot, CA; van Agthoven, M; van Imhoff, GW; van Oers, MH; Vellenga, E; Verdonck, LF; Volkers, CP; Wijermans, PJ | 1 |
| Cobos, E; Keung, YK; Morgan, D | 1 |
| Aivado, M; Aul, C; Germing, U; Giagounidis, AA; Heinsch, M; Hildebrandt, B | 1 |
| Craddock, C; Garg, M; Lawler, M; Pawson, R; Potter, MN; Prentice, HG; Rassam, S; Rezvani, K; Theocharous, P; Yin, JA | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; O'Brien, S; Pierce, SA; Thall, PF; Wang, X | 1 |
| Bi, J; Boswell, W; Espina, BM; Levine, AM; Tulpule, A | 1 |
| Beran, M; Dong, L; Kantarjian, HM; Keating, MJ; Onida, F; Scappini, B; Verstovsek, S | 1 |
| Boulefdaoui, B; Debuire, B; Delmas-Marsalet, B; Emile, JF; Farrokhi, P; Frénoy, N; Goldschmidt, E; Guettier, C; Gumus, Y; Jasmin, C; Machover, D; Misra, SC; Norol, F; Parquet, N; Schilf, A; Ulusakarya, A | 1 |
| Kamath, PS; Letendre, L; Tack, DK; Tefferi, A | 1 |
| Berger, F; Brice, P; Colin, P; Diviné, M; Fermé, C; Jaubert, J; Lederlin, P; Mounier, N; Reman, O; Salles, G; Stamatoullas, A; Voillat, L | 1 |
| Delgado, J; Garcia-Grande, A; Hernandez-Navarro, F; Jimenez, MC; Morado, M | 1 |
| Enomoto, S; Ishida, Y; Itoh, S; Kuriya, S; Murai, K; Numaoka, H; Ono, Y; Sugawara, T; Utsugisawa, T | 1 |
| Alessandrino, EP; Arcaini, L; Astori, C; Bernasconi, P; Brusamolino, E; Cairoli, R; Calatroni, S; Colombo, AA; Gargantini, L; Iacona, I; Lazzarino, M; Morra, E; Orlandi, E; Pagnucco, G; Regazzi, MB | 1 |
| Fox, RM; Grigg, AP; Seymour, JF; Szer, J | 1 |
| Cañete, A; Carvajal, E; Castel, V; Fernández, JM; Verdeguer, A | 1 |
| Harris, E; Jackson, N; Jones, L; Mahendra, P; Paneesha, S | 1 |
| Advani, SH; Banavali, SD; Bhatia, KG; Magrath, I; Naresh, KN; Soman, CS | 1 |
| Gerrard, M; Hobson, R; Imeson, J; McCarthy, K; Pinkerton, CR; Williams, DM | 1 |
| Auvrignon, A; Bader-Meunier, B; Baruchel, A; Couillaud, G; Dalle, JH; De Lumley, L; Gandemer, V; Lamagnere, JP; Landman-Parker, J; Leblanc, T; Leverger, G; Michel, G; Nelken, B; Perel, Y; Schaison, G; Schmitt, C; Thuret, I; Vannier, JP | 1 |
| Boissevain, F; Carella, AM; Decker, S; Diehl, V; Goldstone, AH; Haenel, M; Hasenclever, D; Kirchner, H; Koch, B; Lohri, A; Müller, P; Pfistner, B; Schmitz, N; Sextro, M; Sieber, M; Zschaber, R | 1 |
| Feig, SA; Gale, RP; Sarna, G | 1 |
| Anteunis, A; Audebert, AA; Debray, J; Krulik, M; Robineaux, R | 1 |
| Rawls, WE | 1 |
| Blom, J; Law, IP | 1 |
| Castleberry, RP; McCann, WP; Moreno, H | 1 |
| Camitta, BM; Chan, DM; Jaffe, N; Sallan, SE; Traggis, D | 1 |
| Dzherieva, AV | 1 |
| Burgert, EO; Cuttner, J; Degnan, T; Del Duca, V; Falkson, G; Freeman, A; Hakami, N; Holland, J; Koch, K; Kung, FH; Lanzkowsky, P; Leone, LA; Nawabi, IU; Nythan, WL; Pajak, TF; Patterson, RB; Pluess, H; Ruymann, F | 1 |
| Armata, J; Borkowski, W; Cyklis, R | 1 |
| Aur, RJ; Dahl, GV; Mauer, AM; Murphy, SB; Rivera, G; Verzosa, MS | 1 |
| Falletta, JM; Shepherd, DA; Starling, KA; Steuber, CP; Stewart, SJ | 1 |
| Berd, D; Bertino, J; Cadman, E; Farber, L | 1 |
| Jarratt, M; Knox, JM; Smith, R | 1 |
| Pochedly, C | 1 |
| Gärtner, L; Köhler, B; Kunkel, M; Oberender, H | 1 |
| Koutts, J; Marks, R | 1 |
| Nkrumah, FK; Perkins, IV | 1 |
| Egerer, G; Ehrhardt, R; Haas, R; Hohaus, S; Hunstein, W; Witt, B | 1 |
| Berbaum, K; Cragg, AH; Smith, TP; Stoll, LL | 1 |
| Imai, Y; Nagata, K; Nara, N; Shiina, S; Suzuki, T; Tanikawa, S; Tohda, S; Tomiyama, J | 1 |
| Gadner, H; Harbott, J; Henze, G; Lampert, F; Ludwig, WD; Müller-Weihrich, S; Niemeyer, CM; Reiter, A; Ritter, J; Schrappe, M | 1 |
| Ahmed, T; Arlin, Z; Baskind, P; Chun, H; Cook, P; Feldman, E; Mittelman, A; Puccio, C | 1 |
| Isaev, VG; Kucher, RA; Savchenko, VG | 1 |
| Abakumov, EM; Isaev, VG; Kucher, RA; Parovichnikova, EN; Savchenko, VG | 1 |
| Amadori, S; Giona, F; Iori, AP; Mandelli, F; Meloni, G; Miniero, R; Moleti, ML; Pigna, M; Testi, AM | 1 |
| Brinch, L; Evensen, SA; Stavem, P; Tjønnfjord, G | 1 |
| Braunsteiner, H; Dietze, O; Herold, M; Nachbaur, K; Thaler, J; Vogel, W | 1 |
| Bernstein, EF; Spielvogel, RL; Topolsky, DL | 1 |
| Di Mario, A; Etuk, B; Leone, G; Pagano, L; Salutari, P; Sica, S | 1 |
| Attal, M; Blaise, D; Cony-Makhoul, P; Corront, B; Gastaut, JA; Marit, G; Michallet, M; Reiffers, J; Rigal-Huguet, F; Stoppa, AM | 1 |
| Amess, J; Bassan, R; Battista, R; Buelli, M; Carter, M; D'Emilio, A; Love, S; MacCallum, P; Rohatiner, AZ; Viero, P | 1 |
| Andrien, JM; Bury, J; De Witte, T; Fillet, G; Hayat, M; Jaksic, B; Marie, JP; Muus, P; Peetermans, M; Stryckmans, P | 1 |
| Alessandrino, EP; Bacigalupo, A; Bernasconi, C; Carella, AM; Ficarra, F; Lazzarino, M; Locatelli, F; Morra, E; Pagnucco, G; Resegotti, L | 1 |
| Amadori, S; Giona, F; Giuliano, M; Mandelli, F; Moleti, ML; Pession, A; Rolla, M; Rondelli, R; Testi, AM | 1 |
| Gray, R; Hann, IM; Stevens, RF; Wheatley, K | 1 |
| Aul, C; Büchner, T; Hiddemann, W; Hossfeld, D; Löffler, H; Ludwig, WD; Maschmeyer, G; Nowrousian, M; Schaefer, UW; Wörmann, B | 1 |
| Elmhorn-Rosenborg, A; Eriksson, LC; Hao, XY; Mannervik, B; Paul, C; Tidefelt, U | 1 |
| Borowitz, MJ; Crist, WM; Falletta, JM; Foreman, E; Patterson, R; Pullen, DJ; Shuster, JJ; Vietti, TJ; Wharam, M | 1 |
| Oguro, M; Sakai, C; Takagi, T | 2 |
| Browman, GP; Preisler, HD | 1 |
| Diedrich, H; Freund, M; Ganser, A; Gramatzki, M; Haas, R; Heil, G; Henke, M; Heyll, A; Hiddemann, W; Kuse, R | 1 |
| Brandalise, S; De Bellis, R; Fernández, I; Jiménez-Fonseca, E; Palau, V; Pavlovsky, S; Ruiz-Argüelles, G; Santarelli, MT | 1 |
| Holowiecki, J; Kachel, L; Lawniczek, T; Pajak, J; Rudzka, E | 1 |
| Goudsmit, R; Thomas, BL; van der Lelie, H; van Ketel, RJ; van Oers, RH; von dem Borne, AE | 1 |
| Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C | 1 |
| Diedrich, H; Freund, M; LeBlanc, S; Link, H; Poliwoda, H; Wilke, HJ | 1 |
| Ben-Bassat, I; Ra'anani, P; Ramot, B; Shpilberg, O | 1 |
| Behrendt, H; Dufillot, D; Gentet, JC; Lamagnère, JP; Otten, J; Patte, C; Pein, F; Philip, T; Rodary, C; Zucker, JM | 1 |
| Brecher, M; Crist, W; Harris, MB; Krance, RA; Land, VJ; Newman, EM; Pullen, J; Ravindranath, Y; Shuster, JJ; Wimmer, R | 1 |
| Brodsky, I; Bulova, S; Conroy, J; Crilley, P; Gryn, J; Kahn, SB; Topolsky, D; Weiss, J | 1 |
| Civin, C; Culbert, S; Krischer, J; Leventhal, B; Ragab, A; Ravindranath, Y; Ruymann, FB; Steuber, CP; Vietti, TJ; Wilkinson, R | 1 |
| Hiddemann, W | 1 |
| Chan, TK; Chiu, E; Liang, R; Todd, D | 1 |
| Boyett, JM; Buchanan, GR; Crist, WM; Ghim, T; Johnson, W; Pollock, BH; Smith, SD; Vietti, TJ; Wharam, MD; Yanofsky, RA | 1 |
| Bleher, E; Civin, CI; Ducore, J; Inoue, S; Krischer, J; Pitel, P; Ravindranath, Y; Sexauer, C; Steuber, CP; Vega, R | 1 |
| Amadori, S; Carella, AM; Carotenuto, M; Colella, R; Giona, F; Grotto, P; Leoni, P; Meloni, G; Resegotti, L; Testi, AM | 1 |
| Cuttner, J; Holland, JF; Paciucci, PA | 1 |
| Belasco, JB; Luery, N; Scher, C | 1 |
| Mkheidze, DM; Perilov, AA; Volkova, MA | 1 |
| Aul, CH; Büchner, T; Heinecke, A; Hiddemann, W; Maschmeyer, G; Schleyer, E; Uhrmeister, C | 1 |
| Brière, J; Desablens, B; Ghandour, C; Harousseau, JL; Milpied, N | 1 |
| Amara, F; Colonna, P | 1 |
| Bergeron, C; Demaille, MC; Gentet, JC; Patte, C; Pein, F; Philip, T; Quintana, E; Raybaud, C; Rubie, H | 1 |
| Büchner, T; Heinecke, A; Hiddemann, W; Martin, WR; Sauerland, CM | 1 |
| Bär, BM; de Pauw, BE; de Witte, T; Haanen, C | 1 |
| Festa, RS; Lanzkowsky, P; Shende, A | 1 |
| Auzanneau, G; Gisselbrecht, C; Gratecos, N; Harousseau, JL; LeBlond, V; Michallet, M; Milpied, N; Sebban, C; Troussard, X; Witz, F | 1 |
| Chen, ZJ; Liu, WG; Ma, ZX; Song, JZ | 1 |
| Bates, SE; Cohen, S; McKeever, P; Poplack, DG; Price, RA; Raphaelson, MI | 1 |
| Akahoshi, Y; Asou, N; Fujimoto, K; Fukuda, S; Ishimaru, S; Kawano, F; Murai, C; Sawatari, T; Taen, A; Takatsuki, K | 1 |
| Wahlin, A | 1 |
| Dufour, P; Facon, T; Guy, H; Harousseau, JL; Hurteloup, P; Ifrah, N; Milpied, N; Reiffers, J; Rigal-Huguet, F | 1 |
| Forgeson, G; Gore, M; Goss, G; Lakhani, A; Maitland, J; Milan, S; Nandi, A; Perren, T; Powles, R; Treleaven, J | 1 |
| Horiuchi, H; Kobayashi, Y; Kondo, M; Nishimura, S; Ozawa, M; Shigeta, M; Shirakata, S; Tashiro, K | 1 |
| Akagi, K; Asou, N; Goto, J; Hamasaki, N; Hidaka, M; Kawano, F; Kurisaki, H; Sawatari, T; Suzushima, H; Takatsuki, K | 1 |
| Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, SJ; Kolitz, J; Raymond, V; Young, CW | 1 |
| Filling-Katz, MR; Scherokman, B; Tell, D | 1 |
| Blaise, D; Gaspard, MH; Gastaut, JA; Maraninchi, D; Michel, G; Novakovitch, G; Rossi, JF; Stoppa, AM; Tubiana, N; Weiller, PJ | 1 |
| Estey, E; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Smith, T; Walters, R | 1 |
| Balaban, EP; Cox, JV; Frenkel, EP; Haley, BB; Harth, CA; Schneider, NR; Sheehan, R | 1 |
| Bezanilla Regato, JL; Moya Calderón, E; Navajas Gutiérrez, A; Piñán, MA | 1 |
| Cheung, NK; Coccia, PF; Gordon, EM; Herzig, RH; Novak, LJ; Shina, DC; Strandjord, SE; Warkentin, PI | 1 |
| Chan, TK; Liang, R; Todd, D | 1 |
| Göldel, N; Jehn, U; Rienmüller, R; Wilmanns, W | 1 |
| Larson, RA; Robertson, MJ | 1 |
| Abe, T; Hirose, M; Koyama, T; Ninomiya, T; Ouchi, T; Sato, J; Suzue, T; Takaue, Y; Watanabe, T | 1 |
| Miura, Y; Owada, N; Sakamoto, S; Sasaki, R; Yoshida, M | 1 |
| Lihou, MG; Smith, PJ | 1 |
| Chyosa, M; Kawano, F; Lee, SY; Maeda, Y; Mizokuni, T; Nakai, R; Sawada, T; Shiozaki, A; Tajima, H; Tejima, Y | 1 |
| Hirose, M; Miyao, M; Miyazaki, M; Ninomiya, T; Sato, J | 1 |
| Aoki, I; Naganuma, Y; Sai, M; Toyama, K | 1 |
| Baba, N; Karasawa, M; Miyawaki, S; Nakura, M; Nemoto, K; Takada, M; Tanaka, H; Uchida, S; Wakamatsu, R; Yashiro, K | 1 |
| Chosa, M; Kawano, F; Matsuoka, M; Oyamada, N; Takatsuki, K | 1 |
| Danhauser, L; Gandhi, V; Iacoboni, S; Keating, M; Liliemark, J; Plunkett, W | 1 |
| Andreeff, M; Arlin, ZA; Berman, E; Clarkson, BD; Dinsmore, RE; Gee, T; Kempin, SJ; Little, C; Mertelsmann, R; O'Reilly, RJ | 1 |
| Bleyer, A; Evans, RG; Finklestein, J; Gaynon, P; Meyers, P; Miller, DR; Reaman, G; Sather, H; Steinherz, LJ; Steinherz, PG | 1 |
| Beaujean, F; Benhamou, E; Ghalie, R; Hartmann, O; Hayat, M; Kalifa, C; Maraninchi, D; Mascret, B; Novakovitch, G; Pico, JL | 1 |
| Gassmann, W; Kayser, W; Löffler, H; Schmitz, N | 1 |
| Chan, HY; Lewis, JP; Meyers, FJ | 1 |
| Durie, BG; Garewal, H; Greenberg, B | 1 |
| Aoyama, S; Hayashi, N; Inagaki, T; Nakada, H; Nishimura, M; Ohmoto, E; Sekito, N; Takahashi, I; Uchida, K; Yorimitsu, S | 1 |
| Benson, WJ; Buck, M; Vincent, PC; Young, GA | 1 |
| Hamajima, N; Kawashima, K; Nagura, E; Yamada, K | 1 |
| Campos, L; Coiffier, B; Extra, JM; Ffrench, M; Fiere, D; Guyotat, D; Huan, VV; Ritouet, D | 1 |
| Barnett, MJ; Bragman, KS; Ganesan, TS; Lister, TA; Richards, MA; Rohatiner, AZ; Waxman, JH | 1 |
| Asano, S; Miura, Y; Miwa, S; Mizoguchi, H; Sakamoto, S; Takaku, F; Urabe, A; Wakabayashi, Y; Yamada, O; Yoshida, M | 1 |
| Avramis, VI; Biener, R; Ettinger, LJ; Finklestein, JZ; Holcenberg, JS; Jones, GR; Kamalakar, P | 1 |
| Lie, SO; Slørdahl, S | 1 |
| Cairo, MS; Devney, R; Ettinger, LJ; Feusner, J; Jones, GR; Nachman, J; Odom, LF; Provisor, AJ; Wells, RJ; Woods, WG | 1 |
| Galicich, J; Jereb, B; Steinherz, P | 1 |
| Ettinger, LJ; Jones, GR | 1 |
| Champlin, RE; Elashoff, R; Feig, SA; Gale, RP; Ho, WG; Lenarsky, C; Mitsuyasu, R; Selch, M; Winston, D; Zighelboim, J | 1 |
| Grier, HE; Weinstein, HJ | 1 |
| Drenthe-Schonk, A; Haanen, C; Muus, P; Raymakers, R; Salden, M; Wessels, J | 1 |
| Champlin, R; Feig, SA; Gale, RP; Ho, W; Jacobs, A; Lenarsky, C; Selch, M | 1 |
| Bordessoule, D; Castaigne, S; Daniel, MT; Degos, L; Monconduit, M; Sigaux, F; Tilly, H | 1 |
| Flexner, JM; Herzig, GP; Herzig, RH; Lazarus, HM; Marion, J; Phillips, GL; Spitzer, TR; Stein, RS; Wolff, SN | 1 |
| Amadori, S; Anselmo, AP; Biagini, C; Cimino, G; Guglielmi, C; Mandelli, F; Papa, G; Ruco, LP | 1 |
| Barnett, MJ; Dhaliwal, HS; Gallagher, CJ; Lister, TA; Richards, MA; Rohatiner, AZ; Waxman, JH | 1 |
| Browman, G; Preisler, HD; Raza, A; Rustum, Y | 1 |
| Beguin, Y; Bury, J; Fillet, G; Lennes, G | 1 |
| Sorice, F | 1 |
| Morris, TH; Rees, JR; Wilson, RS | 1 |
| Feldman, S; Hughes, WT; Kim, HY | 1 |
| Higgins, PG | 1 |
| Mandelli, F | 1 |
| Amar, M; Boivin, P; Hakim, J; Kahn, A | 1 |
| Kjeldsberg, CR; Ward, HP | 1 |
| Delamore, IW; Freeman, CB; Geary, CG; Harris, R; Leyland, MJ; MaCiver, JE | 1 |
| Benöhr, HC; Frommhold, W; Oehmichen, M; Peiffer, J; Rückle, H; Waller, HD; Wilmans, W; Wilms, K | 1 |
| Brun, B; Dreyfus, B; Gluckman, E; Reyes, F; Rochant, H | 1 |
| Armata, J; Wyszkowski, J | 1 |
| Brilliant, MD | 1 |
| Ahlendorf, W; Aurich, G; Kob, D; Zintl, F | 1 |
| Frei, E; Freireich, EJ; George, SL; Hart, JS; Trujillo, JM | 1 |
| Armata, J | 1 |
62 review(s) available for cytarabine and Recrudescence
| Article | Year |
|---|---|
Golgi nucleotide sugar transport and leukocyte adhesion deficiency II.
Topics: Amino Acid Substitution; Animals; Arabs; Biological Transport; Carbohydrate Metabolism, Inborn Errors; Carrier Proteins; Cell Line; Child, Preschool; Consanguinity; Dimerization; DNA Mutational Analysis; Dogs; Ethnicity; Eukaryotic Cells; Fetal Growth Retardation; Fucose; Genetic Heterogeneity; Genetic Predisposition to Disease; Glycoproteins; Glycosylation; Golgi Apparatus; Guanosine Diphosphate Fucose; Humans; Infections; Intellectual Disability; Invertebrates; Lectins; Leukocyte-Adhesion Deficiency Syndrome; Male; Mammals; Monosaccharide Transport Proteins; Nucleoside Diphosphate Sugars; Phenotype; Point Mutation; Protein Processing, Post-Translational; Recurrence; Selection, Genetic; Turkey | 2001 |
Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
Topics: Aged; Aniline Compounds; Azacitidine; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2022 |
The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment.
Topics: Core Binding Factors; Cytarabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Recurrence | 2023 |
Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Receptors, Chimeric Antigen; Recurrence; Single-Cell Gene Expression Analysis | 2023 |
Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cladribine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome | 2020 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Recurrence; Remission Induction; Staurosporine; Sulfonamides | 2020 |
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Safety; Survival Analysis; Topoisomerase II Inhibitors; Treatment Outcome; United States; Young Adult | 2020 |
Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Topics: Aniline Compounds; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Echinocandins; fms-Like Tyrosine Kinase 3; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Mycoses; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Staurosporine; Triazoles | 2020 |
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
Topics: Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Calicheamicins; Chlorides; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Approval; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Middle Aged; Multicenter Studies as Topic; Recurrence; Sialic Acid Binding Ig-like Lectin 3; Tretinoin | 2020 |
Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Asian People; Consolidation Chemotherapy; Cytarabine; Decitabine; Drug Therapy, Combination; Female; Hospitalization; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Retinoic Acid Receptor alpha; STAT5 Transcription Factor; Treatment Outcome; Tretinoin | 2020 |
Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials, Phase III as Topic; Cyclophosphamide; Cytarabine; Etoposide; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous | 2021 |
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Treatment Outcome | 2017 |
Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
Topics: Adult; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid, Acute; Patient Selection; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2018 |
Acute myeloid leukaemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Gemtuzumab; Genomics; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Patient Selection; Recurrence; Remission Induction; Risk Assessment; Risk Factors; Staurosporine | 2018 |
[Advances of Targeting Therapy in Acute Myeloid Leukemia--Review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mutation; Prognosis; Recurrence | 2018 |
A comparative evaluation of gemtuzumab ozogamicin + daunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Publication Bias; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 2019 |
Relapsed acute myeloid leukemia: why is there no standard of care?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Salvage Therapy; Standard of Care; Survival Analysis; Transplantation, Homologous | 2013 |
[Current therapy for acute myeloid leukemia and acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Drug Discovery; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Molecular Targeted Therapy; Mutation; Recurrence; Tretinoin; Vincristine | 2014 |
Translocation t(11;19)(q23;q13.1) without MLL Rearrangement in Acute Myeloid Leukemia: Heterogeneity of the 11q23 Breakpoints.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Breakpoints; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 19; Cytarabine; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Translocation, Genetic | 2015 |
Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Recurrence; Thiazoles; Topoisomerase Inhibitors; Treatment Failure | 2015 |
Relapsed and refractory subcutaneous panniculitis-like T-cell lymphoma with excellent response to cyclosporine: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclosporine; Cytarabine; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Immunosuppressive Agents; Lymphoma, T-Cell, Cutaneous; Male; Methylprednisolone; Multimodal Imaging; Panniculitis; Positron-Emission Tomography; Recurrence; Remission Induction; Salvage Therapy; Skin Neoplasms; Subcutaneous Fat; Tomography, X-Ray Computed | 2016 |
Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Podophyllotoxin; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2016 |
The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Etoposide; Fatal Outcome; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Mitoxantrone; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Recurrence; Remission Induction; Reoperation; Salvage Therapy; Vidarabine; Vincristine; Young Adult | 2009 |
Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Recurrence; Remission Induction; Time Factors; Young Adult | 2009 |
Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Child, Preschool; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Infant; Injections, Spinal; Leukemia; Liposomes; Male; Philadelphia; Recurrence | 2010 |
Modern approaches to treating acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2011 |
[Significance of intensified conditioning regimen for allogeneic hematopoietic stem cell transplantation for treatment of acute leukemias].
Topics: Acute Disease; Cyclophosphamide; Cytarabine; Etoposide; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Recurrence; Risk; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2011 |
[Current treatment of acute myeloid leukaemia in adults].
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2012 |
Relapse of acute myeloid leukemia at the pituitary gland: a case report and review of literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Diabetes Insipidus; Etoposide; Female; Humans; Hypopituitarism; Idarubicin; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Methotrexate; Pituitary Neoplasms; Radiotherapy; Recurrence; Remission Induction; Vision Disorders | 2012 |
Emerging agents for the treatment of mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Prognosis; Pyrazines; Recurrence; Salvage Therapy; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Watchful Waiting | 2012 |
Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Therapy; Etoposide; Gene Expression Profiling; Humans; Idarubicin; Lymphoma, Large B-Cell, Diffuse; Medical Oncology; Prognosis; Recurrence; Rituximab; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2012 |
Autologous stem cell transplantation in patients with mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Finland; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Life Tables; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
Older adults with acute myeloid leukemia.
Topics: Acute Disease; Age Factors; Aged; Aging; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Drug Tolerance; Growth Substances; Humans; Leukemia, Myeloid; Recurrence; Remission Induction | 2002 |
Acute myelogenous leukemia in an adult with thrombocytopenia with absent radii syndrome.
Topics: Abnormalities, Multiple; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cytarabine; Cytokines; Female; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Menorrhagia; Neoplasm Proteins; Platelet Count; Proto-Oncogene Proteins; Radius; Receptors, Cytokine; Receptors, Thrombopoietin; Recurrence; Remission Induction; Risk; Syndrome; Thrombocytopenia | 2003 |
Acute myeloid leukemia with t(8;21)(q22;q22) manifesting as granulocytic sarcomas in the rhinopharynx and external acoustic meatus at relapse after high-dose cytarabine: case report and review of the literature.
Topics: Adult; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Ear; Female; Humans; Leukemia, Myeloid, Acute; Nasopharynx; Peripheral Blood Stem Cell Transplantation; Radiotherapy; Recurrence; Remission Induction; Sarcoma, Myeloid; Translocation, Genetic | 2004 |
Imatinib mesylate in the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cytarabine; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Recurrence; Stem Cell Transplantation | 2004 |
Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Evaluation; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 2004 |
The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 2005 |
Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aminoglycosides; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Gemtuzumab; Humans; Leukemia, Myeloid; Middle Aged; Probability; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2003 |
Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia.
Topics: Adenoma, Sweat Gland; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carcinoma, Acinar Cell; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Male; Mercaptopurine; Methotrexate; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Parotid Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Survivors; Sweat Gland Neoplasms; Vincristine; Whole-Body Irradiation | 2008 |
Secondary central nervous system lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Lymphoma; Male; Recurrence; Rituximab; Stem Cell Transplantation | 2006 |
Is cytarabine required in the treatment of acute promyelocytic leukemia? Updated experience and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Treatment Outcome | 2006 |
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
Intensive therapy and autotransplantation in Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Digestive System Diseases; Etoposide; Heart Diseases; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lung Diseases; Melphalan; Multicenter Studies as Topic; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Whole-Body Irradiation | 1994 |
[A case of acute nonlymphocytic leukemia with leukemic cell infiltration to the uterus followed by bone marrow relapse].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Mercaptopurine; Prednisolone; Recurrence; Remission Induction; Uterus; Vincristine | 1994 |
Is intensive treatment beneficial to elderly patients with ANLL?
Topics: Acute Disease; Aged; Cytarabine; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction | 1993 |
[Chemotherapy of relapsed AML and ALL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mechlorethamine; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Procarbazine; Recurrence; Remission Induction; Vinblastine | 1996 |
Acute promyelocytic leukemia: biology and treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Daunorubicin; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Recurrence; Translocation, Genetic; Tretinoin | 1997 |
Treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1997 |
Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers, Tumor; Cheilitis; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Pilot Projects; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 1998 |
Isolated recurrence of granulocytic sarcoma of the brain: successful treatment with surgical resection, intrathecal injection, irradiation and prophylactic systemic chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Humans; Injections, Spinal; Leukemia, Myeloid; Male; Prednisolone; Recurrence; Remission Induction | 1999 |
Bilateral breast relapse in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine | 2001 |
Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Infant; Lymphoma, Large-Cell, Anaplastic; Male; Methotrexate; Prednisolone; Recurrence; Risk; Thioguanine; United Kingdom; Vincristine | 2002 |
Therapy of herpes simplex infection.
Topics: Cytarabine; Herpes Simplex; Humans; Idoxuridine; Recurrence; Vidarabine; Viral Vaccines | 1979 |
Aggressive chemotherapy for acute leukemia relapsed after bone marrow transplantation: a second chance?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Time Factors; Vincristine | 1992 |
Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.
Topics: Cytarabine; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Recurrence | 1991 |
Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside.
Topics: Arabinofuranosylcytosine Triphosphate; Biological Transport; Cytarabine; Deamination; Drug Administration Schedule; Drug Resistance; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Phosphorylation; Recurrence | 1990 |
Current status of treatment of acute leukemia in adults: an overview of the Memorial experience and review of literature.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Cytarabine; Female; Humans; Leukemia; Leukemia, Lymphoid; Male; Middle Aged; Prognosis; Recurrence; Thioguanine; Time Factors | 1986 |
[Ultrahigh-dosage cytostatics--their possible use in acute leukemias?].
Topics: Antineoplastic Agents; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Melphalan; Recurrence | 1987 |
Acute nonlymphocytic leukemia.
Topics: Adolescent; Adult; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Chromosome Aberrations; Cytarabine; Doxorubicin; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myeloid, Acute; Nervous System Neoplasms; Prednisolone; Prognosis; Recurrence; Risk; Vincristine | 1985 |
Studies on the cytotoxicity of cytosine arabinoside.
Topics: Adolescent; Adult; Arabinofuranosylcytosine Triphosphate; Bone Marrow; Cell Cycle; Cell Differentiation; Cells, Cultured; Clone Cells; Colony-Forming Units Assay; Cytarabine; DNA; Drug Resistance; Female; Granulocytes; Half-Life; Humans; Interphase; Kinetics; Leukemia; Male; Middle Aged; Phosphorylation; Recurrence | 1985 |
[Treatment of acute leukemias].
Topics: Acute Disease; Adult; Age Factors; Antineoplastic Agents; Asparaginase; Child; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methods; Methotrexate; Prednisolone; Recurrence; Remission, Spontaneous; Vincristine | 1973 |
310 trial(s) available for cytarabine and Recrudescence
| Article | Year |
|---|---|
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Drug Resistance, Neoplasm; Everolimus; Female; Germany; Hodgkin Disease; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Recurrence; Remission Induction; Retreatment; Young Adult | 2022 |
A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Topics: Aclarubicin; Adult; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Myelodysplastic Syndromes; Recurrence | 2023 |
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Male; Middle Aged; Recurrence; Salvage Therapy; Sulfonamides; Vidarabine | 2020 |
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Immunoconjugates; Induction Chemotherapy; Ki-1 Antigen; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Young Adult | 2020 |
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cisplatin; Cytarabine; Dexamethasone; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Recurrence; Salvage Therapy; Treatment Outcome | 2021 |
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Recurrence; Salvage Therapy; Triazoles | 2020 |
Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Prospective Studies; Recurrence; Survival Rate | 2020 |
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peptides; Receptors, CXCR4; Recurrence; Remission Induction | 2021 |
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Progression-Free Survival; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; United Kingdom; Vidarabine; Young Adult | 2021 |
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
Topics: Adolescent; Anthracyclines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Cytarabine; Female; Gemtuzumab; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Histone-Lysine N-Methyltransferase; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Myeloid-Lymphoid Leukemia Protein; Progression-Free Survival; Recurrence; Risk Assessment; Risk Factors; Time Factors; United States | 2021 |
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; Decitabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Recurrence; Treatment Outcome; Young Adult | 2017 |
Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Clinical Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm, Residual; Recurrence; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2017 |
Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Consolidation Chemotherapy; Cytarabine; Cytogenetic Analysis; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm, Residual; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tretinoin; Young Adult | 2018 |
Acute Myeloid Leukemia With Central Nervous System Involvement in Children: Experience From the French Protocol Analysis ELAM02.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Central Nervous System Neoplasms; Child; Child, Preschool; Cytarabine; France; Humans; Infant; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukocyte Count; Prognosis; Recurrence; Survival Analysis | 2018 |
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Vidarabine; Young Adult | 2018 |
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
Topics: Adult; Aged; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Cholesterol; Cohort Studies; Combined Modality Therapy; Cytarabine; Cytogenetic Analysis; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pravastatin; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Invasiveness; Podophyllotoxin; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2018 |
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthyridines; Recurrence; Thiazoles | 2018 |
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome | 2019 |
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cisplatin; Cytarabine; Dexamethasone; Disease-Free Survival; Female; Hodgkin Disease; Humans; Male; Middle Aged; Recurrence; Salvage Therapy; Survival Rate | 2019 |
Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Vidarabine | 2019 |
Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carboplatin; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; France; Humans; Ifosfamide; Infant; Leukemia; Lymphoma, Large B-Cell, Diffuse; Male; Prospective Studies; Recurrence; Rituximab; Survival Rate | 2019 |
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cytarabine; Etoposide; Female; Gene Expression Regulation, Leukemic; Humans; Hydroxamic Acids; Karyotype; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Recurrence; Translational Research, Biomedical; Treatment Outcome; Tumor Necrosis Factor Decoy Receptors; Vorinostat; Young Adult | 2013 |
Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.
Topics: Aged; Aged, 80 and over; Anemia, Refractory; Cytarabine; Disease-Free Survival; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Monocytic, Acute; Male; Middle Aged; Recurrence; Remission Induction | 2013 |
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT C
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Prospective Studies; Radioimmunotherapy; Recurrence; Rituximab; Transplantation, Autologous; Young Adult | 2013 |
Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Failure; Treatment Outcome; Young Adult | 2013 |
Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Early Termination of Clinical Trials; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Risk Factors; Treatment Outcome; Tretinoin | 2013 |
Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Harringtonines; Heart Diseases; Homoharringtonine; Humans; Kaplan-Meier Estimate; Kidney Diseases; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Young Adult | 2013 |
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
Topics: Adult; Aged; Busulfan; Case-Control Studies; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cytarabine; Dexamethasone; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Immunotherapy; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Grading; Recurrence; Survival Analysis; Treatment Failure; Young Adult | 2013 |
Outcome of older patients with acute myeloid leukemia in first relapse.
Topics: Age Factors; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gemtuzumab; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome | 2013 |
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Recurrence; Rituximab; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; In Vitro Techniques; Middle Aged; Myelodysplastic Syndromes; Nausea; Neutropenia; Recurrence; Risk Factors; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting; Vorinostat | 2014 |
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Survival Analysis; Vidarabine; Young Adult | 2014 |
Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cholesterol; Cytarabine; Drug Administration Schedule; Electrocardiography; Female; Heart; Humans; Leukemia, Myeloid, Acute; Lipoproteins; Male; Middle Aged; Recurrence; Treatment Outcome | 2014 |
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous | 2014 |
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Recurrence; Remission Induction; Staurosporine; Treatment Outcome; Tretinoin | 2014 |
The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dactinomycin; Dexamethasone; Dog Diseases; Dogs; Female; Lymphoma; Male; Melphalan; Recurrence; Retrospective Studies | 2014 |
Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Treatment Failure; Treatment Outcome; Vidarabine; Young Adult | 2014 |
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.
Topics: Adenine Nucleotides; Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chemical and Drug Induced Liver Injury; Clofarabine; Cytarabine; Febrile Neutropenia; Female; Heart Arrest; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Risk; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Young Adult | 2014 |
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Female; Humans; Hyperbilirubinemia; Hypercholesterolemia; International Cooperation; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Treatment Failure | 2014 |
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pravastatin; Recurrence; Time Factors; Treatment Outcome; Young Adult | 2014 |
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Decitabine; Dexamethasone; DNA Methylation; DNA, Neoplasm; Doxorubicin; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Hyperglycemia; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Vincristine; Young Adult | 2014 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Recurrence; Remission Induction; Survival Analysis | 2015 |
SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytarabine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Leukemia, Monocytic, Acute; Male; Middle Aged; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2014 |
Resveratrol plus carboxymethyl-β-glucan in children with recurrent respiratory infections: a preliminary and real-life experience.
Topics: Anti-Inflammatory Agents, Non-Steroidal; beta-Glucans; Child; Cytarabine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Life Change Events; Male; Recurrence; Respiratory Tract Infections; Resveratrol; Stilbenes; Treatment Outcome; Vasodilator Agents | 2014 |
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Patient Selection; Prospective Studies; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Young Adult | 2015 |
Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Asian People; ATP Binding Cassette Transporter, Subfamily B; Cytarabine; Female; Genotype; Haplotypes; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Recurrence; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Time Factors; Transplantation, Autologous | 2015 |
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Idarubicin; Indoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Neoplasm, Residual; Panobinostat; Prognosis; Recurrence; Treatment Outcome | 2015 |
Family History and Relapse in Pediatric Acute Myeloid Leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Survival Rate | 2015 |
Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.
Topics: Antineoplastic Agents; Child, Preschool; Cladribine; Cytarabine; Female; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Infant; Langerhans Cells; Liver; Male; Recurrence; Spleen; Survival Analysis; Survival Rate; Vinblastine | 2015 |
Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Induction Chemotherapy; Male; Methotrexate; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Survival Analysis; Transplantation, Homologous; Vincristine | 2015 |
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Recurrence; Risk Factors; Sorafenib; Time Factors; Transplantation, Homologous; Treatment Outcome | 2015 |
Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Female; Germany; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Recurrence; Retreatment; Salvage Therapy; Treatment Outcome | 2016 |
Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Prednisone; Recurrence; Retreatment; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Cladribine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Time Factors | 2008 |
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Recurrence; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Time Factors; Vidarabine | 2009 |
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Mercaptopurine; Methotrexate; Multivariate Analysis; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Prednisone; Prognosis; Prospective Studies; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 2008 |
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; France; Gemtuzumab; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Time Factors; Treatment Failure; Treatment Outcome | 2008 |
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Rituximab; Salvage Therapy; Vincristine | 2008 |
CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.
Topics: 3' Untranslated Regions; Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; CTLA-4 Antigen; Cytarabine; Disease-Free Survival; Etoposide; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Polymorphism, Single Nucleotide; Proportional Hazards Models; Recurrence; Remission Induction; Young Adult | 2009 |
Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy; Survival Rate; Time Factors | 2009 |
Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study.
Topics: Adult; Alemtuzumab; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukopenia; Longitudinal Studies; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Prospective Studies; Recurrence; Salvage Therapy; Survival Analysis; T-Lymphocytes; Thrombocytopenia; Treatment Outcome; Young Adult | 2009 |
Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2009 |
[Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Young Adult | 2009 |
[Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 2009 |
Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Agranulocytosis; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Nausea; Recurrence; Remission Induction; Young Adult | 2009 |
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Oligonucleotides; Peripheral Nervous System Diseases; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Treatment Outcome; X-Linked Inhibitor of Apoptosis Protein | 2009 |
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Female; Humans; Hydrazines; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Sulfonamides; Young Adult | 2009 |
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Gemtuzumab; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Topotecan | 2010 |
[Clinical study on regimen cyclophosphamide, Ara-C and topotecan (CAT) in treatment of patients with refractory or relapsed acute myelogenous leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Topotecan; Young Adult | 2009 |
Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study.
Topics: Adolescent; Adult; Age Distribution; Antimetabolites, Antineoplastic; Child; Child, Preschool; Cytarabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Risk Factors; Survival Analysis; Transplantation, Homologous | 2010 |
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisolone; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vincristine; Young Adult | 2010 |
Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Female; Humans; Infant; Infant, Newborn; Leukemia, Promyelocytic, Acute; Male; Neoplasms, Second Primary; Recurrence; Survival Analysis; Treatment Outcome; Tretinoin | 2010 |
[Effectiveness of remission induction with high-dose cytarabine for relapsed or refractory pediatric acute leukemia].
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Child, Preschool; Cytarabine; Female; Humans; Infant; Invasive Pulmonary Aspergillosis; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pulse Therapy, Drug; Recurrence; Remission Induction; Treatment Outcome | 2010 |
Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Child; Child, Preschool; Cranial Irradiation; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Europe; Female; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Radiotherapy, Adjuvant; Recurrence; Risk Assessment; Risk Factors; Stem Cell Transplantation; Time Factors; Treatment Outcome | 2010 |
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Daunorubicin; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; STAT5 Transcription Factor | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Australia; Carboplatin; Chemotherapy, Adjuvant; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Europe; Female; Humans; Ifosfamide; Israel; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; New York City; Proportional Hazards Models; Recurrence; Risk Assessment; Risk Factors; Rituximab; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome; Young Adult | 2010 |
Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Recurrence; Republic of Korea; Salvage Therapy; Stem Cell Transplantation; Time Factors; Treatment Outcome; Young Adult | 2012 |
Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Cytarabine; Epidemiologic Methods; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Neoplasm, Residual; Neutropenia; Prognosis; Recurrence; Treatment Outcome; Tretinoin | 2011 |
Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; China; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neuromyelitis Optica; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Spinal Cord; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.
Topics: Aged; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cytarabine; Drug Administration Schedule; Drug Dosage Calculations; Female; Gene Expression; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Progenitor Cells; Oligonucleotides; Recurrence; RNA, Messenger; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Connective Tissue Growth Factor; Cytarabine; Female; Humans; Male; Neoplasm Proteins; Nucleoside Transport Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Treatment Outcome | 2010 |
Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21).
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Salvage Therapy; Translocation, Genetic; Young Adult | 2011 |
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Assessment; Treatment Outcome; United Kingdom; Vidarabine; Vincristine | 2010 |
Methotrexate- and/or cytarabine-based chemotherapy may be effective and safe in solid-organ transplant recipients with primary central nervous system lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dose-Response Relationship, Drug; Feasibility Studies; Follow-Up Studies; Humans; Immunosuppression Therapy; Lymphoma; Methotrexate; Middle Aged; Organ Transplantation; Recurrence; Remission Induction; Transplantation; Treatment Outcome | 2011 |
FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gene Duplication; Humans; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Nucleophosmin; Prognosis; Recurrence; Stem Cell Transplantation; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome | 2011 |
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Recurrence; Salvage Therapy; Treatment Outcome; Young Adult | 2011 |
Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prospective Studies; Radioimmunotherapy; Recurrence; Rituximab; Salvage Therapy; Stem Cell Transplantation | 2011 |
Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Genes, p53; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligonucleotides; Oligonucleotides, Antisense; Recurrence; Treatment Failure | 2012 |
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Benzenesulfonates; Child; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib | 2011 |
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Checkpoint Kinase 1; Cytarabine; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia; Male; Middle Aged; Protein Kinases; Recurrence; Time Factors | 2011 |
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2011 |
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Proportional Hazards Models; Recurrence; Remission Induction; Risk; Salvage Therapy; Young Adult | 2011 |
Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cytarabine; Daunorubicin; Disease-Free Survival; Dyspepsia; Female; Follow-Up Studies; Headache; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Tretinoin | 2011 |
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Odds Ratio; Prognosis; Proportional Hazards Models; Recurrence; Risk Factors; Sample Size; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Phenylurea Compounds; Recurrence; Treatment Outcome | 2012 |
[CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].
Topics: Aclarubicin; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate | 2012 |
Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cryopreservation; Cytarabine; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lomustine; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2012 |
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Gemtuzumab; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Vidarabine; Young Adult | 2012 |
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Placebos; Recurrence | 2012 |
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Rituximab; Survival Rate; Transplantation, Autologous | 2012 |
Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease.
Topics: Adolescent; Adult; Africa South of the Sahara; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cause of Death; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Methotrexate; Middle Aged; Neoplasm Staging; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Rate; Treatment Outcome; Vincristine; Young Adult | 2012 |
Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Cytarabine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Tumor Cells, Cultured; Young Adult | 2012 |
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Melphalan; Middle Aged; Myeloablative Agonists; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2013 |
Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous | 2013 |
Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Gemtuzumab; Humans; Japan; Leukemia, Myeloid, Acute; Male; Neoplasm Staging; Recurrence; Treatment Outcome | 2012 |
Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prospective Studies; Recurrence; Risk; Rituximab; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine; Whole-Body Irradiation | 2013 |
[The first results of treatment for adult acute myeloid leukemia according to the AML-01.10 protocol of the Research Group of the Hematology Centers of Russia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Russia; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2012 |
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2012 |
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Young Adult | 2012 |
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Everolimus; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2013 |
Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Humans; Infant; Ireland; Male; Methotrexate; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Treatment Outcome; United Kingdom; Vincristine | 2013 |
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demography; Female; Humans; Idarubicin; Inhibitor of Apoptosis Proteins; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligonucleotides; Oligonucleotides, Antisense; Recurrence; Survivin; Treatment Outcome | 2013 |
Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Fever; Humans; Hypotension; Infections; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Treatment Outcome | 2002 |
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Topics: Adult; Amifostine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome | 2002 |
A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate | 2002 |
A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's diseas
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hodgkin Disease; Humans; Melphalan; Prognosis; Recurrence; Stem Cell Transplantation; Transplantation, Autologous | 2002 |
Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Salvage Therapy; Thrombocytopenia; Treatment Outcome | 2002 |
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cytarabine; Daunorubicin; Disease-Free Survival; Follow-Up Studies; Humans; Incidence; Karyotyping; Leukemia, Myeloid; Life Tables; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Translocation, Genetic; Treatment Outcome; Trisomy | 2002 |
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2003 |
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.
Topics: Adolescent; Adoptive Transfer; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lymphocytosis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; T-Lymphocytes | 2003 |
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Drug Resistance, Neoplasm; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Platelet Count; Recurrence; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Vidarabine | 2003 |
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Survival Rate | 2003 |
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis | 2003 |
[Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infant; Male; Mercaptopurine; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Recurrence; Vincristine | 2003 |
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cross-Over Studies; Cytarabine; Cytogenetics; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Recurrence; Risk Factors; RNA, Messenger; Treatment Outcome | 2003 |
A pilot study of cytoreductive chemotherapy combined with infusion of additional peripheral blood stem cells reserved at time of harvest for transplantation in case of relapsed hematologic malignancies after allogeneic peripheral blood stem cell transplan
Topics: Adoptive Transfer; Adult; Combined Modality Therapy; Cytarabine; Female; Graft vs Host Disease; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukocytes; Male; Middle Aged; Pilot Projects; Recurrence; Siblings; Survival Analysis; Tissue Donors; Transplantation Chimera; Transplantation, Homologous | 2004 |
[Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome; Vidarabine | 2003 |
Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Prognosis; Recurrence; Risk Factors; Transplantation Conditioning | 2004 |
Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Patient Selection; Recurrence; Statistics, Nonparametric; Survival Rate; Thioguanine; Time Factors | 2004 |
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
Topics: Acute Disease; Adolescent; Adult; Analysis of Variance; Antimetabolites, Antineoplastic; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Proportional Hazards Models; Recurrence; Survival Analysis; Translocation, Genetic; United States | 2004 |
Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome | 2004 |
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Topotecan; Treatment Outcome; Vidarabine | 2004 |
Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cladribine; Cytarabine; Female; Humans; Infant; Leukemia, Myeloid; Male; Recurrence; Treatment Outcome | 2004 |
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Cell Line, Tumor; Cell Proliferation; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; Male; Microcirculation; Middle Aged; Mitoxantrone; Recombinant Proteins; Recurrence; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2004 |
Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Lymphocyte Transfusion; Male; Middle Aged; Recurrence; Survival Analysis; Transplantation, Homologous | 2004 |
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients.
Topics: Acute Disease; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Hemorrhage; Humans; Leukemia, Myeloid; Middle Aged; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 2004 |
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Vidarabine | 2004 |
Topotecan, Ara-C, cisplatin and prednisolone (TOPOSHAP) for patients with refractory and relapsing lymphomas: results of a phase I trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Glucocorticoids; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Recurrence; Topotecan; Treatment Outcome | 2004 |
Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytarabine; Female; Graft vs Host Disease; Humans; Immunophenotyping; Karyotyping; Male; Melphalan; Organophosphates; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2004 |
Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacteremia; Bone Marrow Neoplasms; Child; Child, Preschool; Cytarabine; Dexamethasone; Etoposide; Female; Flow Cytometry; Humans; Idarubicin; Ifosfamide; Infant; Infusions, Intravenous; Leucovorin; Male; Mesna; Methotrexate; Mouth Mucosa; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Stomatitis; Thioguanine; Treatment Outcome; Vincristine | 2004 |
Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hepatitis B; Hepatitis B Vaccines; Humans; Hydrocortisone; Leucovorin; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisone; Recurrence; Treatment Outcome; Venezuela; Vincristine | 2004 |
Peripheral blood stem cell collection after intermediate-dose cytarabine in adult patients with acute myeloblastic leukemia undergoing autologous blood stem cell transplantation in first complete remission.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Incidence; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Siblings; Stem Cell Transplantation; Stem Cells; Tissue and Organ Harvesting; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Topics: Acute Disease; Adenine Nucleotides; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Karyotyping; Leukemia; Male; Middle Aged; Recurrence; Treatment Outcome | 2005 |
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Splenomegaly; Survival Analysis; Treatment Outcome | 2005 |
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Treatment Outcome; Vincristine | 2005 |
Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Genotype; Humans; Immunophenotyping; Incidence; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Receptors, Antigen, T-Cell; Recurrence; Survival Rate | 2005 |
One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Recurrence; Remission Induction; Risk Factors; Survival Analysis | 2005 |
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Proportional Hazards Models; Recurrence; Survival Analysis; Treatment Outcome | 2005 |
Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cytarabine; DNA Damage; DNA Topoisomerases, Type I; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Female; HL-60 Cells; Humans; Irinotecan; Leukemia, Myeloid; Male; Middle Aged; Recurrence | 2006 |
First-line autologous stem cell transplantation in primary CNS lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompetence; Lymphoma; Male; Melphalan; Middle Aged; Neurotoxicity Syndromes; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Survival Rate; Transplantation, Autologous | 2005 |
APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Hodgkin Disease; Humans; Male; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous | 2006 |
Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Cytarabine; Daunorubicin; Etoposide; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Recurrence | 2006 |
Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brazil; Cytarabine; Developing Countries; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Stem Cell Transplantation; Transplantation, Autologous | 2006 |
Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Recurrence; Salvage Therapy; Transplantation, Autologous | 2006 |
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Vincristine | 2006 |
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Injections, Intravenous; Leukemia, Myeloid; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Pyridines; Recurrence; Risk Factors; Thiosemicarbazones; Treatment Outcome | 2006 |
Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia; Lymphocyte Transfusion; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Recurrence; Remission Induction; Transplantation, Homologous; Treatment Outcome | 2005 |
Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
Topics: Aged; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemi
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Central Nervous System; Central Nervous System Neoplasms; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Humans; Hydrocortisone; Injections, Spinal; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Sex Factors; T-Lymphocytes; Testicular Neoplasms; Time Factors | 2006 |
Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Mitoxantrone; Poland; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Sepsis; Time Factors; Transplantation, Homologous; Vidarabine | 2006 |
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Paclitaxel; Recurrence; Stem Cells; Time Factors; Vinblastine; Vinorelbine | 2006 |
Topotecan, Ara-C, cisplatin and prednisolone (Toposhap) for patients with refractory and relapsing lymphomas: Results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Recurrence; Salvage Therapy; Survival Analysis; Topotecan | 2006 |
DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prospective Studies; Recurrence; Rituximab; Salvage Therapy | 2006 |
Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Oncogene Proteins, Fusion; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Time Factors; Treatment Outcome; Tretinoin | 2007 |
High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Survival Analysis | 2007 |
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gastrointestinal Diseases; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Sepsis; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2007 |
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Haplotypes; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia; Lymphocyte Transfusion; Male; Methotrexate; Mitoxantrone; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Tissue Donors; Treatment Outcome | 2007 |
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, B-Cell; Male; Methotrexate; Middle Aged; Prospective Studies; Recurrence; Remission Induction; Rituximab; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous | 2008 |
Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).
Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 2007 |
Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Humans; Hydrocortisone; Male; Mercaptopurine; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Stem Cell Transplantation; Survival Analysis; Thioguanine; Treatment Outcome | 2007 |
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Monitoring; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Methemoglobinemia; Middle Aged; Pyridines; Recurrence; Thiosemicarbazones | 2008 |
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma.
Topics: Adult; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Purging; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Genes, bcl-2; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Immunologic Factors; Immunosuppressive Agents; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Multivariate Analysis; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Rituximab; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine | 2008 |
Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome | 2008 |
Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children's Cancer Study Group NHL B9604 protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Humans; Infant; Lymphoma, B-Cell; Methotrexate; Neoplasms, Second Primary; Recurrence; Survival Analysis; Treatment Outcome | 2008 |
A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Follow-Up Studies; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Random Allocation; Recurrence; Time Factors; Vincristine | 1984 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Prospective Studies; Recurrence; Salvage Therapy; Survival Analysis; Transplantation, Homologous | 1995 |
Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycosylation; Granulocyte Colony-Stimulating Factor; Humans; In Vitro Techniques; Leukemia, Myeloid; Male; Pilot Projects; Recombinant Proteins; Recurrence; Tumor Cells, Cultured; Whole-Body Irradiation | 1994 |
[Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia
Topics: Aclarubicin; Adolescent; Adult; Aged; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence | 1995 |
Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana d
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Infant; Injections, Spinal; Male; Mercaptopurine; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Regression Analysis; Remission Induction; Survival Analysis; Vincristine | 1995 |
Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Adducts; Doxorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prednisolone; Recurrence; Survival Analysis; Thioguanine; Vincristine | 1995 |
No increase of leukemia relapse in newly diagnosed patients with acute myeloid leukemia who received granulocyte colony-stimulating factor for life-threatening infection during remission induction and consolidation therapy. Japan Adult Leukemia Study Grou
Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Communicable Diseases; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Mercaptopurine; Prednisolone; Recombinant Proteins; Recurrence; Remission Induction; Survival Analysis; Time Factors; Vincristine | 1993 |
Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cause of Death; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Infant; Lymphoma, Non-Hodgkin; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Thioguanine; Treatment Failure; Vincristine | 1995 |
[Treatment results of acute nonlymphocytic leukemia in childhood--Kyushu Yamaguchi Children's Cancer Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisolone; Recurrence; Remission Induction; Survival Rate; Vincristine | 1995 |
Results of APL 91 European trial combining ATRA and chemotherapy: presentation of APL 1993 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Europe; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Mercaptopurine; Methotrexate; Recurrence; Remission Induction; Treatment Outcome; Tretinoin | 1994 |
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Clinical Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Infant; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Time Factors | 1995 |
Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Confidence Intervals; Critical Care; Cytarabine; Erythrocyte Transfusion; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neutropenia; Platelet Transfusion; Podophyllotoxin; Preoperative Care; Prognosis; Recurrence; Salvage Therapy; Time Factors | 1995 |
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Prognosis; Recurrence; Remission Induction; Survival Rate; Transplantation, Autologous | 1995 |
Relation between platinum-DNA adducts and complete remission in adult acute nonlymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Cytarabine; DNA Adducts; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Organoplatinum Compounds; Predictive Value of Tests; Recurrence; Remission Induction | 1994 |
Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy | 1994 |
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 17; Cytarabine; Cytogenetics; Dose-Response Relationship, Drug; Doxorubicin; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Recurrence; Survival Analysis; Time Factors; Translocation, Genetic | 1994 |
High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Mercaptopurine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome | 1994 |
ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methylprednisolone; Middle Aged; Prognosis; Recurrence; Remission Induction; Survival Rate | 1994 |
The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: a report from the Childrens Cancer Group.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Humans; Infant; Leukocyte Count; Lymphoma; Mediastinal Neoplasms; Meningeal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Survival Rate; Thioguanine; Vincristine | 1993 |
Mitoxantrone, teniposide, chlorambucil and prednisone (MVLP) for relapsed non-Hodgkin's lymphoma. The impact of advanced age and performance status.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Teniposide; Vincristine | 1993 |
Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Cytarabine; Female; Humans; Leukocyte Count; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Teniposide; Time Factors; Treatment Failure | 1993 |
Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1993 |
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence | 1993 |
Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Daunorubicin; Humans; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Thioguanine | 1993 |
Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Platelet Count; Recombinant Proteins; Recurrence; Remission Induction | 1996 |
A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Mesna; Middle Aged; Mitoxantrone; Platinum; Prospective Studies; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure | 1995 |
[Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy | 1995 |
The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. GIMEMA Cooperative Group, Italy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Male; Methotrexate; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Analysis; Survival Rate | 1996 |
Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Fluorouracil; Humans; Leucovorin; Lymphoma, Large-Cell, Anaplastic; Male; Methotrexate; Middle Aged; Phenotype; Prednisone; Prospective Studies; Recurrence; Survival Rate; Vincristine | 1996 |
Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Recurrence; Survival Rate; Vincristine | 1996 |
High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; L-Lactate Dehydrogenase; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Survival Rate; Transplantation, Autologous; Treatment Outcome | 1996 |
In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recurrence; Regression Analysis; Remission Induction; Transplantation, Autologous; Whole-Body Irradiation | 1996 |
Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cost-Benefit Analysis; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Infant; Length of Stay; Leukemia, Myeloid; Middle Aged; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Thioguanine | 1996 |
[Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Quality of Life; Recurrence; Remission Induction; Survival Rate | 1996 |
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence | 1996 |
Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Recurrence; Remission Induction | 1996 |
Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Recurrence; Risk; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1996 |
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Remission Induction; Survival Rate; Survivors | 1997 |
Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Life Tables; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retreatment; Salvage Therapy; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vinblastine | 1997 |
Treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1997 |
Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prospective Studies; Recurrence; Survival Analysis; Survival Rate; Treatment Outcome | 1997 |
Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Cell Differentiation; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Pain; Prospective Studies; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor gamma; Retinoids; Salvage Therapy; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin | 1997 |
Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.
Topics: Adult; Aged; Amsacrine; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hemorrhage; Humans; Lung Neoplasms; Male; Middle Aged; Recurrence; Survival Analysis; Warfarin | 1997 |
ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Infant; Leukocyte Count; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prospective Studies; Recurrence; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 1997 |
Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Humans; Infant; Leukemia-Lymphoma, Adult T-Cell; Methotrexate; Prednisone; Prognosis; Recurrence; Remission Induction; Thioguanine; Vincristine | 1998 |
High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Female; Humans; Infections; Infusions, Intravenous; Injections, Intramuscular; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Treatment Outcome | 1998 |
High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Transplantation, Autologous | 1998 |
CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy | 1998 |
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Mitoxantrone; Patient Compliance; Recurrence; Remission Induction; Survival Rate; Thioguanine; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 1998 |
[Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
Topics: Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1998 |
Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Retreatment; Risk Factors; Survival Rate; Transplantation, Autologous; Vidarabine | 1998 |
A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Over Studies; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence | 1998 |
Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child, Preschool; Cytarabine; Female; Humans; Leucovorin; Male; Methotrexate; Recurrence; Remission Induction | 1998 |
Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy:
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Central Nervous System Neoplasms; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Melphalan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Testicular Neoplasms; Transplantation, Homologous; Whole-Body Irradiation | 1998 |
Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gene Rearrangement; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Recurrence; Survival Analysis; Treatment Outcome | 1998 |
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cytarabine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prospective Studies; Recurrence; Time Factors | 1998 |
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Critical Care; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Opportunistic Infections; Recurrence; Salvage Therapy; Time Factors | 1998 |
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Female; Humans; Italy; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Severity of Illness Index; Survival Analysis; Treatment Outcome | 1998 |
Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers, Tumor; Cheilitis; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Pilot Projects; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 1998 |
Acute promyelocytic leukemia: all-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Child; Cytarabine; Daunorubicin; Female; Fever; Humans; Leukemia, Promyelocytic, Acute; Lung; Male; Middle Aged; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Tretinoin; Weight Gain | 1999 |
The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Prednisolone; Prospective Studies; Recurrence; Repressor Proteins; Transplantation, Autologous | 1999 |
Management of advanced acute lymphoblastic leukemia in children and adults: results of the ALL R-87 protocol. AIEOP and GIMEMA Cooperative Groups.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Infant; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1998 |
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1998 |
ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis | 1999 |
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Drug Resistance, Multiple; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Recurrence; Survival Analysis; Time Factors | 1999 |
ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Doxorubicin; Female; Hodgkin Disease; Humans; Infusions, Intravenous; Male; Methylprednisolone Hemisuccinate; Middle Aged; Recurrence; Survival Analysis | 1999 |
Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Recurrence; Survival Analysis | 1999 |
Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Recurrence | 1999 |
FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome; Vidarabine | 1999 |
Addition of high-dose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Leukemia; Male; Middle Aged; Recurrence; Transplantation Conditioning | 1999 |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Disease-Free Survival; Drug Synergism; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia, Myeloid; Male; Mitoxantrone; Recurrence | 1999 |
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Treatment Outcome | 1999 |
Therapy of molecular relapse in acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Middle Aged; Mitoxantrone; Neoplasm Proteins; Oncogene Proteins, Fusion; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Survival Analysis; Time Factors; Tretinoin | 1999 |
Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Fever of Unknown Origin; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Recombinant Proteins; Recurrence; Vidarabine | 1999 |
Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carmustine; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1999 |
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Recurrence; Topotecan; Treatment Outcome | 1999 |
Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Paclitaxel; Recurrence; Taxoids; Time Factors; Treatment Outcome | 1999 |
Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytarabine; Female; Genes, bcl-2; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Recurrence; Survival Analysis; Treatment Outcome; Tretinoin | 2000 |
Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Recurrence; Survival Rate; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: a Pediatric Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Teniposide; Vincristine | 2000 |
Autologous stem cell transplantation for acute myeloid leukemia in first remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytapheresis; Cytarabine; Cytogenetics; Disease-Free Survival; Etoposide; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Middle Aged; Recurrence; Survival Rate; Transplantation, Autologous | 2000 |
A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Treatment Outcome | 2000 |
FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pilot Projects; Recurrence; Salvage Therapy; Survival Rate; Vidarabine Phosphate | 2000 |
The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Epirubicin; Humans; Hydrocortisone; Infant; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Statistics, Nonparametric; Thioguanine; Transplantation, Homologous; Treatment Outcome; United Kingdom; Vincristine | 2000 |
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Humans; Leukemia; Middle Aged; Recurrence; Topotecan; Treatment Outcome | 2000 |
ASHAP--an effective salvage therapy for recurrent and refractory malignant lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone Hemisuccinate; Middle Aged; Recurrence; Salvage Therapy; Survival Analysis | 2000 |
Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483).
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Recurrence; Remission Induction | 2000 |
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Predictive Value of Tests; Recurrence; Risk; Thioguanine; Tretinoin | 2000 |
MiCMA: an alternative treatment for refractory or recurrent Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Treatment Outcome | 2000 |
Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Patient Selection; Recurrence; Ventricular Function, Left | 2000 |
Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Purging; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Genes, bcl-2; Genes, Immunoglobulin; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Polymerase Chain Reaction; Prednisone; Recurrence; Remission Induction; Sepsis; Survival Analysis; Thrombocytopenia; Translocation, Genetic; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2000 |
A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Recurrence; Vidarabine | 2001 |
The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Second Primary; Recurrence; Therapeutic Equivalency; Topotecan; Treatment Outcome | 2001 |
Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Recurrence; Risk Factors; Salvage Therapy; Treatment Outcome | 2000 |
The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Hydrocortisone; Infant; Leucovorin; Lymphoma, B-Cell; Male; Methotrexate; Neoplasm Staging; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Recurrence; Remission Induction; Survival Rate; Vincristine | 2001 |
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Carriers; Humans; Leukemia, Myeloid, Acute; Liposomes; Middle Aged; Recurrence; Treatment Outcome | 2001 |
Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chi-Square Distribution; Cisplatin; Cost-Benefit Analysis; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prospective Studies; Quality of Life; Recurrence; Statistics, Nonparametric; Survival Rate; Transplantation, Autologous | 2001 |
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction; Survival Rate; Time Factors; Topotecan; Treatment Failure; Vidarabine | 2001 |
Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organoplatinum Compounds; Recurrence; Treatment Outcome | 2001 |
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Mitoguazone; Recurrence; Salvage Therapy; Transplantation, Autologous; Vinblastine; Vinorelbine | 2002 |
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Recurrence; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Vidarabine | 2002 |
Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Mitoxantrone; Prospective Studies; Recurrence; Treatment Outcome | 2002 |
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy | 2002 |
Editorial: Treatment of herpesvirus infections.
Topics: Antiviral Agents; Clinical Trials as Topic; Cytarabine; DNA Nucleotidyltransferases; Herpesviridae Infections; Humans; Idoxuridine; Placebos; Purine Nucleosides; Recurrence; Vidarabine | 1976 |
Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse.
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Infant; Leukemia, Lymphoid; Lomustine; Male; Prednisone; Recurrence; Remission, Spontaneous; Vincristine | 1978 |
Combination therapy for diffuse histiocytic lymphoma that includes antimetabolites.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Recurrence; Remission, Spontaneous; Time Factors; Vincristine | 1977 |
Topical treatment of recurrent herpes simplex with cytosine arabinoside.
Topics: Administration, Topical; Clinical Trials as Topic; Cytarabine; Facial Dermatoses; Genitalia; Herpes Simplex; Humans; Pilot Projects; Placebos; Recurrence | 1975 |
Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Male; Melphalan; Middle Aged; Recombinant Proteins; Recurrence; Transplantation, Autologous | 1992 |
Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence | 1992 |
Treatment of adult acute lymphoblastic leukaemia (ALL) over a 16 year period.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Survival Analysis; Vincristine | 1992 |
Therapy of adult ALL: overview of 2 successive EORTC studies: (ALL-2 & ALL-3). The EORTC Leukemia Cooperative Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Humans; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous | 1992 |
Early intensification followed by allo-BMT or auto-BMT or a second intensification in adult ALL: a randomized multicenter study.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Feasibility Studies; Humans; Italy; Methotrexate; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Vincristine | 1992 |
Therapeutic strategies for postremission treatment in childhood acute myeloid leukemia (AML). The AIEOP experience 1987-1991.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Infant; Italy; Leukemia, Myeloid; Male; Pilot Projects; Random Allocation; Recurrence; Remission Induction | 1992 |
Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: progress report on the MRC AML 10 trial. Medical Research Council Working Party on Childhood Leukaemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid; Recurrence; Remission Induction; Thioguanine; United Kingdom | 1992 |
Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Recurrence; Remission Induction; Thioguanine | 1992 |
Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Erythrocytes; Female; Humans; Hydrocortisone; Infant; Injections, Spinal; Leukemia-Lymphoma, Adult T-Cell; Male; Methotrexate; Prednisone; Recurrence; Remission Induction; Rosette Formation; Thioguanine; Treatment Outcome; Vincristine | 1992 |
Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Remission Induction | 1991 |
High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence | 1991 |
High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Humans; Infant; Lymphoma, B-Cell; Male; Methotrexate; Neoplasm Staging; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Survival Rate; Vincristine | 1991 |
A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Female; Fever; Humans; Infant; Infections; Length of Stay; Leukocyte Count; Male; Methotrexate; Neutropenia; Pilot Projects; Platelet Count; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Survival Rate | 1991 |
A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; DNA Nucleotidylexotransferase; Female; Fever; Humans; Infant; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Random Allocation; Receptors, Glucocorticoid; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Thioguanine; Tumor Cells, Cultured; Vincristine | 1991 |
Improved treatment results in boys with overt testicular relapse during or shortly after initial therapy for acute lymphoblastic leukemia. A Pediatric Oncology group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Humans; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Risk Factors; Survival Rate; Teniposide; Testicular Neoplasms; Vincristine | 1991 |
Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Humans; Idarubicin; Infant; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 1990 |
Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia.
Topics: Adult; Aged; Clinical Trials as Topic; Cytarabine; Delayed-Action Preparations; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pilot Projects; Recurrence; Remission Induction; Time Factors | 1990 |
[A trial of the use of high doses of cytosar with autologous bone marrow protection in acute leukemias].
Topics: Acute Disease; Adolescent; Adult; Blood Cells; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Female; Humans; Leukemia; Male; Recurrence; Remission Induction; Time Factors; Transplantation, Autologous | 1990 |
High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence | 1990 |
Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1989 |
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1989 |
Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Child, Preschool; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Lymphoid; Male; Methotrexate; Prednisone; Prognosis; Radiotherapy Dosage; Recurrence; Risk; Thioguanine; Time Factors; Vincristine | 1986 |
Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical Trials as Topic; Cytarabine; Daunorubicin; Female; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Thioguanine | 1985 |
548 other study(ies) available for cytarabine and Recrudescence
| Article | Year |
|---|---|
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cytarabine; Flow Cytometry; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2022 |
Neutropenia in the First Cycle of Consolidation Chemotherapy with High-Dose Cytarabine Is Not Associated with the Incidence of Relapse in Adult Acute Myeloid Leukemia Patients in First Complete Remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Humans; Incidence; Leukemia, Myeloid, Acute; Neutropenia; Recurrence; Remission Induction | 2022 |
Adverse stem cell clones within a single patient's tumor predict clinical outcome in AML patients.
Topics: Clone Cells; Cytarabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Proteomics; Recurrence; Stem Cells | 2022 |
[The efficacy and safety of CLAG-M/I regimen for relapsed or refractory acute myeloid leukemia in children].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Recurrence; Treatment Outcome | 2022 |
[Recurrent and Refractory Langerhans Cell Histiocytosis in Children Treated with the Combination of Cladribine and Cytarabine].
Topics: Child; Cladribine; Cytarabine; Histiocytosis, Langerhans-Cell; Humans; Recurrence; Retrospective Studies | 2022 |
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cytarabine; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Recurrence; Remission Induction; Treatment Outcome; Tretinoin | 2022 |
Molecular Characterization of the Response to Conventional Chemotherapeutics in Pro-B-ALL Cell Lines in Terms of Tumor Relapse.
Topics: Antineoplastic Agents; Cell Line; Cytarabine; Humans; MicroRNAs; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2022 |
Favorable Outcome with Conditioning Regimen of Flu/Bu4/Mel in Acute Myeloid Leukemia Patients in Remission Undergoing Cord Blood Transplantation.
Topics: Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Humans; Leukemia, Myeloid, Acute; Recurrence; Transplantation Conditioning; Transplantation, Homologous | 2022 |
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Topics: Amsacrine; Busulfan; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies | 2023 |
[Acute myeloid leukemia harboring NUP98::DDX10].
Topics: Cytarabine; DEAD-box RNA Helicases; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Nuclear Pore Complex Proteins; Prognosis; Recurrence | 2022 |
Long term follow-up of refractory/relapsed acute myeloid leukemia patients treated with the FLAG-Ida regimen as bridge therapy to allotransplantation: 10-year results from a single centre experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridge Therapy; Cytarabine; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Recurrence; Vidarabine | 2023 |
Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16).
Topics: Child; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction | 2023 |
Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning | 2023 |
The m6A modulator-mediated cytarabine sensitivity and immune cell infiltration signature in acute myeloid leukemia.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Methyltransferases; Recurrence; Tumor Microenvironment | 2023 |
Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignancies.
Topics: Adolescent; Adult; Aged; Allografts; Cytarabine; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Middle Aged; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Survival Rate | 2019 |
Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hemorrhage; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2020 |
Loss of the Y chromosome predicts a high relapse risk in younger adult male patients with t(8;21) acute myeloid leukemia on high-dose cytarabine consolidation therapy: a retrospective multicenter study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Retrospective Studies; Y Chromosome | 2020 |
Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma.
Topics: Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cytarabine; Daunorubicin; Epstein-Barr Virus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Neoplasms, Second Primary; Postoperative Complications; Programmed Cell Death 1 Receptor; Protoporphyria, Erythropoietic; Recurrence; Remission Induction; Virus Activation; Young Adult | 2020 |
Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.
Topics: Aclarubicin; Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Male; Mutation; Neoplasm Proteins; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Sulfonamides | 2020 |
Pregnancy exposure to midostaurin in the first trimester.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Compassionate Use Trials; Cytarabine; Female; Fetal Growth Retardation; fms-Like Tyrosine Kinase 3; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Leukemia, Myeloid, Acute; Mutation; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Protein Kinase Inhibitors; Recurrence; Staurosporine; Tandem Repeat Sequences | 2020 |
Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Oxaliplatin; Prednisone; Recurrence; Rituximab; Salvage Therapy; Transplantation, Autologous; Vincristine | 2020 |
Intravenous methotrexate at a dose of 1 g/m
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cerebrospinal Fluid; Chemical and Drug Induced Liver Injury; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Kidney Diseases; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Mucositis; Neoplasm Invasiveness; Prednisone; Proportional Hazards Models; Prospective Studies; Recurrence; Rituximab; Vincristine | 2020 |
Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
Topics: Adolescent; Adult; Aged; Alleles; Allografts; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Progression-Free Survival; Recurrence; Risk Assessment; Young Adult | 2020 |
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Management; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mitoxantrone; Preoperative Care; Prognosis; Recurrence; Treatment Outcome | 2020 |
UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cause of Death; Cytarabine; Female; Genotype; Glucuronosyltransferase; Humans; Leukemia, Myeloid, Acute; Male; Prognosis; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome | 2020 |
Two successful deliveries of healthy children by a young woman diagnosed and treated during induction and relapsed therapy for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Pregnancy; Recurrence; Tretinoin; Young Adult | 2020 |
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Young Adult | 2020 |
Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lymphoma, Follicular; Male; Methylprednisolone; Middle Aged; Neoplasm Grading; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Spain; Survival Analysis; Treatment Failure; Treatment Outcome; Young Adult | 2020 |
A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
Topics: Abnormal Karyotype; Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Cyclin D1; Cytarabine; Drug Resistance, Neoplasm; Fatal Outcome; Gene Duplication; Genes, myc; Humans; Lymphoma, Mantle-Cell; Male; Oncogene Proteins, Fusion; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Translocation, Genetic | 2020 |
Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.
Topics: Acute Disease; Antibodies, Viral; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Cytarabine; Female; Humans; Immunization, Passive; Immunosuppressive Agents; Middle Aged; Pandemics; Pneumonia, Viral; Polymerase Chain Reaction; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Rituximab; SARS-CoV-2; Steroids; Treatment Outcome | 2020 |
Central nervous system relapse of primary cutaneous CD8
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Autografts; CD8-Positive T-Lymphocytes; Central Nervous System; Cranial Nerve Diseases; Cytarabine; Humans; Lymphoma, T-Cell, Cutaneous; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Recurrence; Referral and Consultation; Remission Induction; Skin Neoplasms; Spinal Puncture; Stem Cell Transplantation; T-Lymphocytes, Cytotoxic; Treatment Outcome | 2021 |
Oral Versus Long-Acting Injectable Antipsychotic Treatment for People With Severe Schizophrenia: A 5-Year Follow-up of Effectiveness.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Cytarabine; Female; Follow-Up Studies; Hospitalization; Humans; Injections; Longitudinal Studies; Male; Middle Aged; Prednisone; Recurrence; Schizophrenia; Suicide, Attempted; Treatment Adherence and Compliance; Vincristine | 2021 |
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Disease Progression; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Outcome Assessment, Health Care; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Recurrence; Retrospective Studies; Rituximab; State Medicine; United Kingdom; Withholding Treatment | 2021 |
Evaluating the use of cytosine arabinoside for treatment for recurrent canine steroid-responsive meningitis-arteritis.
Topics: Animals; Arteritis; Cytarabine; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Glucocorticoids; Male; Meningitis; Prednisolone; Recurrence; Retrospective Studies; Treatment Outcome | 2020 |
Successful Bone Marrow Transplantation With Intensive Post-transplant Intrathecal Chemotherapy for CNS Relapsed AML in 2 Infants.
Topics: Allografts; Bone Marrow Transplantation; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Infant; Injections, Spinal; Leukemia, Myeloid, Acute; Myeloablative Agonists; Recurrence; Transplantation Conditioning | 2022 |
[Lineage switch from T-lymphoblastic leukemia to myeloid leukemia at relapse].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2021 |
Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis.
Topics: Adolescent; Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Transplantation Conditioning; Vincristine; Young Adult | 2021 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Registries; Transplantation Conditioning; Whole-Body Irradiation; Young Adult | 2017 |
Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous | 2017 |
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, B-Cell; Male; Methotrexate; Middle Aged; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogene Proteins c-myc; Recurrence; Remission Induction; Rituximab; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Vincristine | 2017 |
Blastic plasmacytoid dendritic cell neoplasm: a pathological illustration of two clinical cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Dendritic Cells; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Lymphatic Metastasis; Male; Myeloproliferative Disorders; Recurrence; Skin Neoplasms; Vidarabine | 2017 |
Efficacy of intermediate-dose cytarabine in central nervous system-relapsed wild-type BRAF Erdheim-Chester disease.
Topics: Cytarabine; Drug Therapy, Combination; Erdheim-Chester Disease; Frontal Lobe; Gyrus Cinguli; Histiocytes; Humans; Interferon-alpha; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Proto-Oncogene Proteins B-raf; Recurrence | 2018 |
FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Recurrence; Survival Analysis; Vascularized Composite Allotransplantation; Vidarabine | 2017 |
Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.
Topics: Adult; Aged; Aged, 80 and over; Cell Line; Cytarabine; Cytogenetics; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance; Epigenesis, Genetic; Exome; Exome Sequencing; Female; Histone Demethylases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Remission Induction; Young Adult | 2018 |
Acute myeloid leukemia presenting as erythema nodosum: A case report.
Topics: Antineoplastic Agents; Bone Marrow Examination; Cytarabine; Daunorubicin; Erythema Nodosum; Fatal Outcome; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Remission Induction | 2017 |
Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2018 |
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clofarabine; Cohort Studies; Cytarabine; DNA, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Sequence Analysis, DNA; Vidarabine | 2018 |
Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Infant; Infant, Newborn; Male; Prednisone; Recurrence; Vincristine; Young Adult | 2018 |
Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.
Topics: Aged; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Remission Induction; Sulfonamides | 2018 |
Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome.
Topics: Antimetabolites, Antineoplastic; Blood Cell Count; Cell Transformation, Neoplastic; Critical Illness; Cytarabine; DNA Mutational Analysis; Down Syndrome; Exchange Transfusion, Whole Blood; Female; Fetal Diseases; GATA1 Transcription Factor; Humans; Leukapheresis; Leukemoid Reaction; Liver Diseases; Mutation; Neoplasm, Residual; Pregnancy; Prenatal Diagnosis; Prognosis; Recurrence; Risk Factors | 2018 |
High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2019 |
FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine; Young Adult | 2019 |
Cytomegalovirus meningitis in a patient with relapsed acute myeloid leukemia.
Topics: Adult; Antiviral Agents; Cytarabine; Cytomegalovirus Infections; Diagnosis, Differential; Ganciclovir; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Meningitis, Viral; Recurrence; Treatment Outcome | 2019 |
Elevated Serum Exosomal miR-125b Level as a Potential Marker for Poor Prognosis in Intermediate-Risk Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Exosomes; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Mitoxantrone; Prognosis; Proportional Hazards Models; Recurrence; Young Adult | 2018 |
Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy; Treatment Outcome; Young Adult | 2019 |
Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cladribine; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Neutropenia; Prognosis; Proportional Hazards Models; Recurrence; Survival Rate; Treatment Outcome | 2019 |
FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Vidarabine | 2019 |
Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease.
Topics: Adult; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Cytarabine; Humans; Hydrocortisone; Male; Methotrexate; Neurotoxicity Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2019 |
FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Middle Aged; Pakistan; Progression-Free Survival; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; Vidarabine; Young Adult | 2019 |
Significance of Granulocyte Colony-Stimulating Factor-Combined High-Dose Cytarabine, Cyclophosphamide, and Total Body Irradiation in Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignant Neoplasms.
Topics: Adolescent; Adult; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Unrelated Donors; Whole-Body Irradiation; Young Adult | 2019 |
The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia.
Topics: Antineoplastic Agents; Autophagy; Cell Line, Tumor; Chemotaxis; Cytarabine; Drug Discovery; Drug Resistance, Neoplasm; Humans; Ligands; Mitochondrial Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2019 |
Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cyclophosphamide; Cytarabine; Dexamethasone; Humans; Inotuzumab Ozogamicin; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Vascular Diseases | 2019 |
Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Young Adult | 2019 |
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Longitudinal Studies; Male; Middle Aged; Mitoxantrone; Mutation; Neoplasm Proteins; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Recurrence; Salvage Therapy; Survival Rate | 2019 |
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Aberrations; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cytarabine; Cytogenetic Analysis; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Pilot Projects; Recurrence; Risk; Rituximab; Sequence Deletion; Survival Analysis | 2013 |
Meningoencephalitis of unknown origin: investigation of prognostic factors and outcome using a standard treatment protocol.
Topics: Animals; Cerebrospinal Fluid; Cytarabine; Dog Diseases; Dogs; Female; Magnetic Resonance Imaging; Male; Meningoencephalitis; Prednisolone; Prognosis; Recurrence; Treatment Outcome | 2013 |
Primary treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the original donor.
Topics: Adolescent; Adult; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2013 |
Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; China; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2013 |
ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Europe; Hematopoietic Stem Cell Transplantation; Humans; Mercaptopurine; Methotrexate; Multicenter Studies as Topic; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Retreatment; Survival Rate; Vincristine | 2013 |
Long-term remission after multiple relapses in an elderly patient with lymphomatoid granulomatosis after rituximab and high-dose cytarabine chemotherapy without stem-cell transplantation.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Lung Neoplasms; Lymphomatoid Granulomatosis; Recurrence; Rituximab | 2013 |
Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia.
Topics: Antimetabolites, Antineoplastic; Arabinonucleosides; Cerebellum; Child; Cyclophosphamide; Cytarabine; Etoposide; Fatal Outcome; Guillain-Barre Syndrome; Humans; Magnetic Resonance Imaging; Male; Medulla Oblongata; Methotrexate; Necrosis; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Seizures; Spinal Cord | 2013 |
Intrathecal liposomal cytarabine and leptomeningeal medulloblastoma relapse: a valuable therapeutic option.
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Female; Humans; Injections, Spinal; Liposomes; Magnetic Resonance Imaging; Male; Medulloblastoma; Meningeal Neoplasms; Recurrence | 2013 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Recurrence; Retreatment; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2013 |
Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myelomonocytic, Juvenile; Male; Mitoxantrone; Recurrence; Retreatment; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2014 |
High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Survival Analysis; Sweden; Transplantation, Homologous; Vincristine | 2014 |
Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Treatment Outcome; Young Adult | 2014 |
High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Nitrosourea Compounds; Recurrence; Retrospective Studies; Survival Analysis; Transplantation, Autologous | 2014 |
Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Young Adult | 2014 |
R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Cisplatin; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies | 2014 |
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Chlorambucil; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Melphalan; Multicenter Studies as Topic; Neoplasm Staging; Prednisolone; Prednisone; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vincristine | 2014 |
Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Child; Child, Preschool; Cytarabine; Etoposide; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2014 |
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Consensus Development Conferences as Topic; Cytarabine; Europe; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Neoplasm, Residual; Positron-Emission Tomography; Recurrence; Remission Induction; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2015 |
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
Topics: Acute Kidney Injury; Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prednisone; Recurrence; Retrospective Studies; Risk Assessment; Rituximab; Survival Rate; Vincristine; Young Adult | 2014 |
Single-unit cord blood transplant for acute lymphoblastic leukemia and lymphoma using an intensified conditioning regimen of total body irradiation, high-dose cytarabine and cyclophosphamide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Humans; Lymphoma; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation; Young Adult | 2015 |
When the eye gives it all: diagnosis of relapsing acute myeloblastic leukemia with anterior chamber tap of a chronic hypopyon.
Topics: Adult; Anterior Chamber; Antimetabolites, Antineoplastic; Cytarabine; Humans; Iridectomy; Iris; Karyotyping; Leukemia, Myeloid, Acute; Male; Recurrence | 2014 |
Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2015 |
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult | 2016 |
Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Feasibility Studies; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation, Homologous; Treatment Failure | 2015 |
[Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Core Binding Factor Alpha 2 Subunit; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; Recurrence; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Treatment Outcome; Young Adult | 2014 |
[The comparative study of the effects between modified FLAG and CAG on relapsed or refractory acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Recurrence | 2014 |
B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lymphoma, B-Cell; Prednisone; Recurrence; Remission Induction; Risk; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Virus Activation | 2014 |
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2015 |
[Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Topics: Adolescent; Adult; Allografts; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Dyspnea; Female; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infections; Kaplan-Meier Estimate; Keratitis; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Xerophthalmia; Young Adult | 2016 |
Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Disease-Free Survival; Female; Finland; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Recurrence; Retrospective Studies; Rituximab; Survival Rate; Treatment Outcome | 2015 |
Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Prednisone; Recurrence; Regression Analysis; Risk; Rituximab; Treatment Failure; Tumor Burden; Vincristine; Young Adult | 2015 |
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Cisplatin; Clinical Trials as Topic; Cost Savings; Cost-Benefit Analysis; Cytarabine; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hospital Charges; Hospital Costs; Humans; Lymphoma; Male; Middle Aged; Quality-Adjusted Life Years; Recurrence | 2015 |
[Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Cohort Studies; Cytarabine; Doxorubicin; Granulocyte Colony-Stimulating Factor; Granulocytes; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Thrombocytopenia | 2015 |
[Efficacy Analysis of MAC Regimen as Salvage Treatment Protocol for Acute Myeloid Leukemia Patients Older Than 55 Years].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cytarabine; Dactinomycin; Humans; Leukemia, Myeloid, Acute; Methotrexate; Middle Aged; Recurrence; Remission Induction; Salvage Therapy | 2015 |
Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vincristine; Young Adult | 2015 |
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Risk; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2015 |
[Clinical Efficacy of Bleomycin, Cyclophosphamide, Vindesine, Ara-C and Dexamethasone for Treatment of Patients with Relapsed Refractory Diffuse Large B Cell Lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Recurrence; Treatment Outcome; Vincristine; Vindesine | 2015 |
High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2015 |
Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight; Cohort Studies; Cytarabine; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Obesity; Overweight; Recurrence; Remission Induction; Retrospective Studies; Young Adult | 2015 |
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Genome, Human; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Mutation; Outcome Assessment, Health Care; Polymorphism, Genetic; Prognosis; Recurrence; RNA, Messenger; Sequence Analysis, RNA | 2015 |
[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Karyotype; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancytopenia; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Severity of Illness Index; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2016 |
Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cardiomyopathies; Chemical and Drug Induced Liver Injury; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Kidney Diseases; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2015 |
Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000-2013).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Dog Diseases; Dogs; Female; Lymphoma; Male; Neutropenia; Recurrence; Retrospective Studies; Thrombocytopenia; Treatment Failure | 2017 |
High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Methylprednisolone; Middle Aged; Recurrence; Retrospective Studies; Survival Rate; Transplantation, Autologous; Young Adult | 2016 |
[Sequential intensified conditioning followed by graft-versus-leukemia induction could prevent relapse of refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Topics: Cyclophosphamide; Cytarabine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Recurrence; Remission Induction; Transplantation, Homologous; Transplants; Whole-Body Irradiation | 2015 |
Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Time Factors; Treatment Failure; Young Adult | 2016 |
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Cytarabine; Drug Monitoring; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retreatment; Staurosporine; Treatment Outcome; Young Adult | 2016 |
DHAP plus filgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory lymphoma: A single center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Female; Filgrastim; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Recurrence; Transplantation, Autologous | 2016 |
Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Lineage; Central Nervous System; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Multivariate Analysis; Prednisone; Proportional Hazards Models; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Recurrence; Risk; Rituximab; Tissue Array Analysis; Translocation, Genetic; Treatment Outcome; Vincristine; Young Adult | 2016 |
[Clinic Outcome of FLAG Regimen treating Patients with Refractory and Relapse Acute Myeloid Leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retreatment; Treatment Outcome; Young Adult | 2016 |
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Hodgkin Disease; Humans; Male; Melphalan; Recurrence; Transplantation Conditioning; Young Adult | 2016 |
[The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia].
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Mycophenolic Acid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
[Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate | 2016 |
Central nervous system involvement in T-cell lymphoma: A single center experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Female; Glioblastoma; Humans; Incidence; Injections, Spinal; Lactate Dehydrogenases; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Methotrexate; Middle Aged; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Recurrence; Retrospective Studies; Risk Factors; Young Adult | 2016 |
Central diabetes insipidus as a very late relapse limited to the pituitary stalk in Langerhans cell histiocytosis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Diabetes Insipidus, Neurogenic; Female; Histiocytosis, Langerhans-Cell; Humans; Japan; Magnetic Resonance Imaging; Organ Size; Pituitary Gland; Recurrence; Treatment Outcome | 2016 |
[Efficacy analysis of CAG priming regimen combined with talidomide, interferon and interleukin 2 as the induction therapy for relapsed refractory acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Interferons; Interleukin-2; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Thalidomide | 2016 |
[Treatment of relapsed and refractory acute lymphocytic leukemia by modified CAG regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2016 |
[Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia].
Topics: Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Sorafenib; Treatment Outcome | 2016 |
[Clinical features and prognostic analysis of high-risk acute promyelocytic leukemia patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Oncogene Proteins, Fusion; Platelet Count; Prognosis; Protein Isoforms; Recurrence; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A.
Topics: Antineoplastic Agents; Bone Marrow; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Karyotype; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Nucleophosmin; Real-Time Polymerase Chain Reaction; Recurrence; Remission Induction; Retrospective Studies; Sequence Analysis, DNA | 2016 |
Leukaemic infiltration and cytomegalovirus retinitis in a patient with acute T-cell lymphoblastic leukaemia in complete remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Cytomegalovirus Retinitis; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemic Infiltration; Papilledema; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retina; Retinal Hemorrhage; Vidarabine | 2017 |
[Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Recurrence; Retrospective Studies; Young Adult | 2016 |
Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vidarabine | 2016 |
Extensive cardiac infiltration in acute T-cell lymphoblastic leukemia: occult extra-medullary relapse and remission after salvage chemotherapy.
Topics: Adult; Arabinonucleosides; Cytarabine; Diplopia; Humans; Hypertrophy, Left Ventricular; Leukemic Infiltration; Male; Myocardium; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous | 2017 |
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cause of Death; Clofarabine; Cytarabine; Daunorubicin; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Treatment Outcome | 2017 |
High-dose cytarabine added to CY/TBI improves the prognosis of cord blood transplantation for acute lymphoblastic leukemia in adults: a retrospective cohort study.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Fetal Blood; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Proportional Hazards Models; Recurrence; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation; Young Adult | 2016 |
A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
The central nervous system microenvironment influences the leukemia transcriptome and enhances leukemia chemo-resistance.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Central Nervous System; Coculture Techniques; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Mice; Mice, Inbred NOD; Neoplasm Proteins; Neoplasm Transplantation; Neurons; Pre-B-Cell Leukemia Transcription Factor 1; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Signal Transduction; Transcriptome; Transplantation, Heterologous; Tumor Microenvironment | 2017 |
Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Core Binding Factors; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Japan; Leukemia, Myeloid, Acute; Mitoxantrone; Proto-Oncogene Proteins c-kit; Recurrence; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Vidarabine | 2017 |
Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gene Dosage; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Proto-Oncogene Proteins; Recurrence; Remission Induction; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Transcription Factors | 2008 |
Relapse of acute myeloid leukemia as isolated bilateral testicular granulocytic sarcoma in an adult.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Daunorubicin; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; Male; Middle Aged; Orchiectomy; Recurrence; Remission Induction; Sarcoma, Myeloid; Testicular Neoplasms | 2008 |
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carmustine; Chi-Square Distribution; Cohort Studies; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Mucositis; Recurrence; Risk; Statistics, Nonparametric; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2008 |
Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Injections, Spinal; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Oxides; Recurrence | 2008 |
The impact of histopathologic diagnosis on the proper management of testis neoplasms.
Topics: Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain; Cisplatin; Cytarabine; Diagnosis, Differential; Etoposide; Fatal Outcome; Humans; Immunohistochemistry; Interferon Regulatory Factors; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Orchiectomy; Radiography; Recurrence; Remission Induction; Seminoma; Testicular Neoplasms | 2008 |
Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.
Topics: Adult; Anaplastic Lymphoma Kinase; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clathrin; Cyclophosphamide; Cytarabine; Doxorubicin; Follow-Up Studies; Humans; Immunohistochemistry; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Oncogene Proteins, Fusion; Prednisone; Protein-Tyrosine Kinases; Receptor Protein-Tyrosine Kinases; Recurrence; Remission Induction; STAT3 Transcription Factor; Stem Cell Transplantation; Time Factors; Treatment Outcome; Vincristine | 2009 |
Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Drug Evaluation; Epidemiologic Methods; Female; Gemtuzumab; Humans; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Treatment Outcome | 2008 |
Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions.
Topics: Adolescent; Antimetabolites, Antineoplastic; Cerebrospinal Fluid; Child; Child, Preschool; Cytarabine; Drug Carriers; Drug Evaluation; Female; Humans; Infant; Injections, Spinal; Liposomes; Male; Meningeal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome | 2008 |
Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cladribine; Cytarabine; Histiocytosis, Langerhans-Cell; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Radiography; Recurrence; Survival Rate | 2009 |
Autologous stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of three cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; HIV Infections; Humans; Lymphoma, AIDS-Related; Male; Melphalan; Nitrosourea Compounds; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2009 |
[Relapsed acute myeloid leukemia with Down syndrome showing long disease-free survival after bone marrow transplantation].
Topics: Adolescent; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Chromosomes, Human, Pair 7; Cytarabine; Disease-Free Survival; Down Syndrome; GATA1 Transcription Factor; Humans; Leukemia, Myeloid, Acute; Male; Monosomy; Mutation; Recurrence; Remission Induction; Risk; Time Factors | 2009 |
Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dasatinib; Dexamethasone; Female; Humans; Imatinib Mesylate; Immunotherapy, Adoptive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Radiotherapy; Recurrence; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2009 |
Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cisplatin; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Methylprednisolone; Middle Aged; Neutropenia; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation, Autologous; Young Adult | 2009 |
Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Etoposide; Feasibility Studies; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy | 2009 |
The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2009 |
[Prophylaxis and treatment of modified BFM-90 regimen for lymphoblastic lymphoma in children and adolescents accompanied with infection].
Topics: Adolescent; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Cephalosporins; Child; Child, Preschool; Cross Infection; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Female; Humans; Itraconazole; Male; Mercaptopurine; Methotrexate; Mouth Diseases; Mycoses; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Respiratory Tract Infections; Vincristine | 2009 |
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2009 |
Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell trans
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Central Nervous System; Cytarabine; Disease-Free Survival; Female; Germinal Center; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2009 |
Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2009 |
Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Male; Middle Aged; Mitoguazone; Periodicity; Prednisone; Recurrence; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Failure; Vinblastine; Young Adult | 2010 |
Jumping translocation involving 1q21 during long-term complete remission of acute myeloid leukemia.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Recurrence; Time Factors; Translocation, Genetic | 2010 |
[Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Vidarabine | 2009 |
Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Egypt; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Male; Mercaptopurine; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasm Proteins; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Stomatitis; Vincristine | 2010 |
Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Female; Humans; Hydrazines; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Sulfonamides | 2010 |
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Hematology; Humans; Italy; Lymphoma, Non-Hodgkin; Melphalan; Podophyllotoxin; Practice Guidelines as Topic; Recurrence; Societies, Medical; Time Factors | 2010 |
Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence | 2010 |
Immunomagnetic selection of CD34(+) cells carried out in cryopreserved cell concentrates from a paediatric patient affected with non-Hodgkin lymphoma.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Preservation; Carmustine; Cell Count; Child, Preschool; Combined Modality Therapy; Cryopreservation; Cyclophosphamide; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunomagnetic Separation; Leukapheresis; Lymphoma, Large-Cell, Anaplastic; Melphalan; Podophyllotoxin; Recurrence; Transplantation, Autologous | 2010 |
Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, B-Cell; Male; Middle Aged; Recurrence; Rituximab | 2010 |
CNS relapse in acute promyeloctyic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Neoplasms; Brain Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cranial Irradiation; Cytarabine; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Mercaptopurine; Methotrexate; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins | 2010 |
Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Lymphoma, B-Cell; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Recurrence; Rituximab; Salvage Therapy; Treatment Outcome | 2010 |
Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infections; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Postoperative Complications; Recurrence; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Secondary adrenal insufficiency in an infant after intrathecal triple chemotherapy.
Topics: Adrenal Insufficiency; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hydrocortisone; Immunosuppressive Agents; Injections, Spinal; Leukemia, Myeloid, Acute; Methotrexate; Recurrence | 2010 |
LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Diarrhea; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lomustine; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Recurrence; Stomatitis; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vomiting; Young Adult | 2011 |
Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Cytarabine; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Treatment Outcome; Young Adult | 2010 |
Childhood acute lymphoblastic leukemia in Turkey: factors influencing treatment and outcome: a single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infant; Male; Mercaptopurine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Recurrence; Retrospective Studies; Risk Factors; Turkey; Vincristine | 2010 |
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Staging; Recurrence; Retrospective Studies; Risk; Salvage Therapy; Treatment Outcome; Young Adult | 2011 |
ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Prednisone; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2011 |
Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Receptors, CXCR4; Recurrence | 2011 |
Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Young Adult | 2011 |
Erythroleukemia relapsing as precursor B-cell lymphoblastic leukemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cell Lineage; Cell Transformation, Neoplastic; Chromosome Deletion; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Cytarabine; Drug Therapy, Combination; Humans; Immunophenotyping; Karyotyping; Leukemia, Erythroblastic, Acute; Male; Middle Aged; Monosomy; Naphthacenes; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2011 |
Pretreatment serum level of 15-kDa granulysin might have a prognostic value in patients with diffuse large B cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Molecular Weight; Prednisone; Prognosis; Protein Isoforms; Recurrence; Reproducibility of Results; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Vincristine | 2011 |
Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Infections; Leukemia, Myeloid, Acute; Recurrence; Treatment Failure | 2011 |
Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Retrospective Studies; Transplantation, Homologous | 2012 |
Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2012 |
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Remission Induction; Sorafenib; Survival Rate | 2011 |
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Female; fms-Like Tyrosine Kinase 3; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplasms, Second Primary; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Risk; Stem Cell Transplantation; Transplantation, Homologous; Young Adult | 2012 |
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Germinal Center; Humans; Ifosfamide; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lymphoma, Large B-Cell, Diffuse; Male; Microarray Analysis; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Proteins; Neoplasm, Residual; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Rituximab; Salvage Therapy | 2011 |
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Agents; Child; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factors; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Predictive Value of Tests; Recurrence; Translocation, Genetic; Treatment Outcome | 2011 |
Acute isolated transmural neutropenic gastritis.
Topics: Acute Disease; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Daunorubicin; Factor VII Deficiency; Female; Furans; Gastritis; Granulocyte Colony-Stimulating Factor; Humans; Incidental Findings; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2012 |
Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis.
Topics: Aged; Antineoplastic Agents; Autopsy; Brain; Brain Injuries; Chlorambucil; Cytarabine; Disease Progression; Fatal Outcome; Humans; Injections, Spinal; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Methotrexate; Nervous System Diseases; Positron-Emission Tomography; Recurrence; Waldenstrom Macroglobulinemia | 2012 |
Nine years interval between first and second bone marrow transplantations and subsequent long-term survival--a case of acute myeloid leukemia with MLL-AF6 fusion gene.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clone Cells; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Mercaptopurine; Myeloid-Lymphoid Leukemia Protein; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Prednisolone; Recurrence; Remission Induction; Reoperation; Time Factors; Transplantation, Homologous; Vincristine | 2012 |
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Young Adult | 2012 |
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2012 |
High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Methylprednisolone; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2013 |
Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Topotecan | 2012 |
Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukaemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance, Multiple, Fungal; Etoposide; Fatal Outcome; Female; Fusariosis; Fusarium; Humans; Immunocompromised Host; Itraconazole; Leukemia, Myeloid, Acute; Mitoxantrone; Neutropenia; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Premedication; Pyrimidines; Recurrence; Salvage Therapy; Transplantation, Homologous; Triazoles; Voriconazole | 2013 |
Durable complete remission in a patient with recurrent DLBCL receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Recurrence; Remission Induction; Rituximab; Stem Cell Transplantation; Vincristine | 2012 |
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Severity of Illness Index; Survival Analysis | 2012 |
Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Japan; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Prognosis; Recurrence; Treatment Outcome; Tretinoin | 2012 |
Isolated central nervous system relapse presenting as myeloid sarcoma of acute myeloid leukemia after allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellopontine Angle; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Humans; Idarubicin; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Magnetic Resonance Imaging; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Recurrence; Salvage Therapy; Sarcoma, Myeloid; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2013 |
Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Methylprednisolone; Middle Aged; Multivariate Analysis; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2013 |
[Effects of IAT and MAT chemotherapeutic regimens in patients with refractory or relapsed acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Vidarabine; Young Adult | 2012 |
Outcome of risk adapted therapy for relapsed/refractory acute lymphoblastic leukemia in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Treatment Outcome | 2013 |
Recurrent endobronchial diffuse large B-cell lymphoma. Diagnosed by cryoprobe.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bronchi; Cisplatin; Combined Modality Therapy; Cryosurgery; Cyclophosphamide; Cytarabine; Diagnosis, Differential; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Prednisone; Recurrence; Remission Induction; Rituximab; Spleen; Splenectomy; Splenomegaly; Vincristine | 2013 |
Complete remission following chemotherapy with low-dose cytosine arabinoside and macrophage colony-stimulating factor/granulocyte colony-stimulating factor in a patient with relapsed acute myeloid leukemia after stem cell transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Macrophage Colony-Stimulating Factor; Male; Recurrence; Remission Induction; Stem Cell Transplantation | 2012 |
Successful treatment of primary central nervous system lymphoma without irradiation in children: single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Hydrocortisone; Infant; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisone; Recurrence; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2012 |
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Topics: Adult; Aneuploidy; Cytarabine; Daunorubicin; DNA Repair; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Recurrence; Remission Induction; Transplantation, Homologous; Vidarabine; Xeroderma Pigmentosum | 2013 |
Successful allogeneic stem cell transplantation for Lennert lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epstein-Barr Virus Infections; Etoposide; Female; Humans; Immunosuppressive Agents; Lymphoma, T-Cell, Peripheral; Melphalan; Methotrexate; Middle Aged; Nitrosourea Compounds; Pharyngitis; Prednisolone; Recurrence; Rituximab; Salvage Therapy; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vincristine; Whole-Body Irradiation | 2013 |
Hypopyon as the first sign of relapse in acute lymphoblastic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cyclophosphamide; Cytarabine; Doxorubicin; Eye Neoplasms; Fatal Outcome; Female; Humans; Mercaptopurine; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vincristine | 2013 |
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confusion; Cytarabine; Etoposide; Fatal Outcome; Female; Gemtuzumab; Humans; Idarubicin; Immunotherapy; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Middle Aged; Mitoxantrone; Myocardial Infarction; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Therapeutics; Vidarabine | 2002 |
High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Recurrence; Salvage Therapy; Stem Cell Transplantation; Time Factors | 2002 |
ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Cytarabine; Disease-Free Survival; Drug Tolerance; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy | 2002 |
Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.
Topics: Acute Disease; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cladribine; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Neoplastic Stem Cells; Recurrence; Remission Induction; Tetrazolium Salts; Thiazoles; Translocation, Genetic; Trisomy | 2002 |
Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission.
Topics: Adolescent; Amsacrine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carmustine; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neutrophils; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2003 |
Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cytarabine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Leukemia, Myeloid; Recurrence | 2002 |
Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Female; Humans; Hydrocortisone; Injections, Spinal; Karyotyping; Leucovorin; Life Tables; Lymphocytes; Male; Mercaptopurine; Methotrexate; Neoplastic Stem Cells; Polyglutamic Acid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pteroylpolyglutamic Acids; Recurrence; Remission Induction; Survival Analysis; Tumor Cells, Cultured; Vincristine | 2002 |
Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation.
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Deoxycholic Acid; Drug Combinations; Drug Resistance, Fungal; Etoposide; Fatal Outcome; Humans; Immunocompromised Host; Itraconazole; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelomonocytic, Acute; Liposomes; Lung Diseases, Fungal; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Triazoles; Voriconazole | 2002 |
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Remission Induction; Salvage Therapy | 2003 |
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Female; Gemtuzumab; Hepatic Veno-Occlusive Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Recurrence | 2003 |
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; California; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Infant; Leukemia, Myeloid; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Single-Blind Method; Survival Analysis; Thioguanine; Treatment Outcome | 2003 |
Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Burkitt Lymphoma; Child; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Humans; Immunotherapy; Leukemic Infiltration; Male; Meninges; Methotrexate; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Testis; Topotecan; Transplantation, Autologous; Vindesine | 2003 |
HLA-DR antigen-negative acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Female; Flow Cytometry; HLA-DR Antigens; Humans; Idarubicin; Immunophenotyping; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Prospective Studies; Recurrence; Treatment Outcome | 2003 |
Multiple complete remissions in a patient with acute myeloid leukemia (M4eo) with low-dose cytosine arabinoside and all-trans retinoic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Female; Humans; Leukemia, Myelomonocytic, Acute; Middle Aged; Recurrence; Remission Induction; Tretinoin | 2003 |
Severe hyperglycemia as a complication of big ICE chemotherapy in a patient with acute myeloblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cytarabine; Etoposide; Female; Humans; Hyperglycemia; Idarubicin; Insulin; Leukemia, Myeloid, Acute; Recurrence; Time Factors | 2002 |
[The therapeutic effects of FLAG regime for refractory and relapsing acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Male; Middle Aged; Recurrence; Vidarabine | 2003 |
Acute pericarditis and pleural effusion complicating cytarabine chemotherapy.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Pericarditis; Pleural Effusion; Recurrence | 2003 |
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Vidarabine | 2003 |
Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Neutropenia; Recurrence; Remission Induction; Thrombocytopenia; Tomography, X-Ray Computed; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2003 |
[Acute myeloblastic leukemia in adults: evaluation of the AML 06/96 protocol].
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Lomustine; Male; Middle Aged; Prospective Studies; Recurrence; Remission Induction; Time Factors | 2003 |
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Salvage Therapy; Transplantation, Autologous | 2003 |
MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Cytarabine; Daunorubicin; Enzyme Inhibitors; Etoposide; Fatal Outcome; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 2003 |
[Salvage combination chemotherapy with cytarabine, carboplatin and steroids for relapsed or refractory non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Recurrence; Salvage Therapy; Treatment Outcome | 2004 |
[Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Eye Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, T-Cell; Middle Aged; Prognosis; Recurrence; Thiotepa | 2004 |
Isolated hyperbilirubinemia following standard dose cytosine arabinoside in a patient with relapsed acute myeloid leukemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Hyperbilirubinemia; Leukemia, Myeloid; Middle Aged; Recurrence | 2004 |
Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction | 2004 |
Treatment of isolated central nervous system relapse in high-risk lymphoid malignancy with allogeneic bone marrow transplantation and extended intrathecal therapy.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Central Nervous System Diseases; Chemotherapy, Adjuvant; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Humans; Hydrocortisone; Injections, Spinal; Lymphoma, Non-Hodgkin; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Homologous | 2004 |
Aggressive systemic mastocytosis mimicking sclerosing cholangitis.
Topics: Abdominal Pain; Adrenal Cortex Hormones; Adult; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow; Budd-Chiari Syndrome; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Clone Cells; Cytarabine; Diagnosis, Differential; Diarrhea; Fatal Outcome; Female; Flushing; Histamine H1 Antagonists; Humans; Idarubicin; Liver; Lymphoma; Mast Cells; Mastocytosis, Systemic; Mutation, Missense; Point Mutation; Prednisone; Proto-Oncogene Proteins c-kit; Recurrence | 2004 |
Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen.
Topics: Adenocarcinoma; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Goserelin; Humans; Immunocompromised Host; Male; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasms, Second Primary; Neutropenia; Nitriles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostate-Specific Antigen; Prostatic Neoplasms; Recurrence; Sepsis; Tosyl Compounds; Vincristine | 2004 |
A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome; Tretinoin | 2004 |
Images in haematology. Combined central retinal artery and vein occlusions as the presenting signs of ocular relapse in acute lymphoblastic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemic Infiltration; Methotrexate; Middle Aged; Ophthalmoscopy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retinal Artery Occlusion; Retinal Vein Occlusion | 2005 |
Second induction in pediatric patients with recurrent acute lymphoid leukemia using DFCI-ALL protocols.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Doxorubicin; Female; Humans; Infant; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vincristine | 2005 |
In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
Topics: Adolescent; Adult; Antineoplastic Agents; Cell Death; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tumor Cells, Cultured; Vidarabine | 2005 |
[Treatment of childhood Burkitt lymphoma according to LMB89 protocol in Casablanca].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Hydrocortisone; Infant; Leucovorin; Male; Methotrexate; Prednisone; Recurrence; Remission Induction; Survival Analysis; Vincristine | 2005 |
Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukocyte Transfusion; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Tissue Donors; Transplantation, Homologous; Treatment Outcome | 2005 |
Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Medical Oncology; Melphalan; Middle Aged; Prednisolone; Prognosis; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2005 |
[Therapeutic effects of chemotherapeutic regimens containing pirarubicin on the treatment of high-risk or refractory and relapsed acute leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vincristine | 2005 |
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute mye
Topics: Acute Disease; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Leukemia, Myeloid; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3 | 2005 |
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vidarabine | 2005 |
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukocyte Count; Liver; Male; Middle Aged; Mucositis; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Odds Ratio; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome | 2005 |
Bilateral ear Sweet's syndrome in a case with relapse acute myeloblastic leukemia.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Ear, External; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Methylprednisolone; Neutropenia; Recombinant Proteins; Recurrence; Sweet Syndrome; Vidarabine | 2006 |
T-cell acute lymphoblastic leukemia relapsing as acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Antigens, CD7; Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cell Differentiation; Cell Lineage; Core Binding Factor Alpha 2 Subunit; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Diagnosis, Differential; Doxorubicin; Etoposide; Fatal Outcome; Female; Gene Dosage; Histone-Lysine N-Methyltransferase; Humans; Immunophenotyping; Karyotyping; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Neoplastic Stem Cells; Proto-Oncogenes; Recurrence; T-Lymphocyte Subsets; Vincristine | 2007 |
[Subacute encephalopathy of early onset during treatment of relapse of lymphoblastosis in a young infant].
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrophy; Brain; Cerebellum; Cerebral Ventricles; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Epilepsy; Humans; Infant; Injections, Spinal; Leukemia, Lymphoid; Male; Neurotoxicity Syndromes; Paraventricular Hypothalamic Nucleus; Recurrence; Remission Induction | 1977 |
Feasibility of FLAG-IDA regimen in cases with relapsed/refractory acute leukemia cases.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Liver Diseases; Male; Mucositis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine | 2006 |
Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease-Free Survival; Donor Selection; Female; Glioblastoma; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Male; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Retrospective Studies; Transplantation Conditioning; Whole-Body Irradiation | 2006 |
[What was the cause of fever, neck pain and arm paresis? Normal blood picture led to error].
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arm; Cytarabine; Fever; Humans; Leukemia, Myeloid; Male; Mitoxantrone; Neck Pain; Paresis; Prognosis; Recurrence; Remission Induction | 2005 |
Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2006 |
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Survival Analysis; Translocation, Genetic; Treatment Outcome; Tretinoin | 2005 |
Concomitant hairy cell and acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Genetic Predisposition to Disease; Humans; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Stem Cell Transplantation | 2006 |
p16 inactivation associated with aggressive clinical course and fatal outcome in TEL/AML1-positive acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Chromosomes, Human, Pair 9; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Cyclin-Dependent Kinase Inhibitor p16; Cyclophosphamide; Cytarabine; Daunorubicin; Fatal Outcome; Gene Deletion; Genes, p16; Humans; Male; Mercaptopurine; Methotrexate; Neoplasm Proteins; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Recurrence; Vincristine | 2005 |
Isolated extramedullary relapse after autologous bone marrow transplantation for acute myeloid leukemia: case report and review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Central Nervous System; Chromosome Aberrations; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Radiography; Recurrence; Registries; Transplantation, Autologous; Transplantation, Homologous | 2006 |
ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Cisplatin; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Peripheral Blood Stem Cell Transplantation; Recurrence; Retrospective Studies; Transplantation, Autologous | 2006 |
[IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoguazone; Recurrence | 2006 |
Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prednisolone; Recombinant Proteins; Recurrence; Retrospective Studies; Rituximab; Vincristine | 2006 |
Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Methylprednisolone; Neoplasms, Second Primary; Prednisone; Recurrence; Remission Induction; Time Factors; Vidarabine; Vincristine | 2006 |
A case of relapsed meningeal Burkitt's leukemia/lymphoma treated with intraventricular rituximab combined with high-dose cytarabine.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cytarabine; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Injections, Intraventricular; Male; Recurrence; Remission Induction; Rituximab; Treatment Outcome | 2006 |
Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Liposomes; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2006 |
Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist too.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Administration Schedule; Etoposide; Hodgkin Disease; Humans; Melphalan; Recurrence; Salvage Therapy | 2006 |
A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B.
Topics: Abscess; Amphotericin B; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytarabine; Foot Dermatoses; Fusarium; Humans; Imatinib Mesylate; Immunocompromised Host; Liposomes; Male; Middle Aged; Muscular Diseases; Onychomycosis; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Reoperation; Rituximab; Teniposide; Triazoles; Voriconazole | 2006 |
Induction of remission of relapsed acute myeloid leukemia after unrelated donor cord blood transplantation by concomitant low-dose cytarabine and calcitriol in adults.
Topics: Aclarubicin; Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cord Blood Stem Cell Transplantation; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Middle Aged; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
[Twenty years of treating childhood acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Male; Mercaptopurine; Methotrexate; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Prognosis; Recurrence; Risk Factors; Survival Rate; Time Factors; Vincristine | 2006 |
[Limphomatous meningitis as recurrence site in Hodgkin's disease].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Diagnosis, Differential; Doxorubicin; Etoposide; Fatal Outcome; Hodgkin Disease; Humans; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Paraneoplastic Syndromes; Prednisone; Procarbazine; Recurrence; Vinblastine; Vincristine | 2006 |
Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CD56 Antigen; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Predictive Value of Tests; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Translocation, Genetic; Transplantation, Homologous | 2007 |
High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Recurrence; Remission Induction; Stem Cells; Treatment Outcome; Vidarabine | 2006 |
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Prospective Studies; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Autologous; Vinblastine; Vinorelbine | 2007 |
LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Lomustine; Male; Middle Aged; Recurrence; Retrospective Studies; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Late relapses in acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mastoid; Mitoxantrone; Recurrence; Time Factors; Tretinoin | 2007 |
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Evaluation; Follow-Up Studies; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Immunoglobulin Heavy Chains; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prednisone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous; Vincristine | 2006 |
What is the role of rituximab in salvage treatment for patients with diffuse large B-cell lymphoma?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cytarabine; Dexamethasone; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Prospective Studies; Recurrence; Rituximab; Salvage Therapy; Treatment Outcome | 2006 |
Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes.
Topics: Adolescent; Arabinofuranosylcytosine Triphosphate; Cell Line; Cell Line, Tumor; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cytarabine; Half-Life; Humans; Infant; Inhibitory Concentration 50; Lymphocytes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2007 |
EBV+ lymphoproliferative disease following prolonged chemotherapy for refractory LCH.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Doxorubicin; Drug Therapy, Combination; Epstein-Barr Virus Infections; Fatal Outcome; Female; Herpesvirus 4, Human; Histiocytosis, Langerhans-Cell; Humans; Immunocompromised Host; Infant; Lymphoma, Large B-Cell, Diffuse; Mercaptopurine; Methotrexate; Mycoses; Prednisone; Recurrence; Rituximab; Vinblastine; Vincristine; Virus Activation | 2008 |
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes | 2007 |
Improved outcome after relapse in children with acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Cytogenetics; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Recurrence; Remission Induction; Statistics, Nonparametric; Stem Cell Transplantation; Survival Rate; Sweden; Treatment Outcome; Vidarabine | 2007 |
Multiple complete remissions over a period of 6 years in a patient with acute myeloid leukemia after intensive chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Monocytic, Acute; Male; Recurrence; Remission Induction | 2007 |
Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Survival; Child; Child, Preschool; Coloring Agents; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Infant; Inhibitory Concentration 50; Leukemia; Leukemia, Myeloid; Male; Methylphenazonium Methosulfate; Middle Aged; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Staining and Labeling; Tetrazolium Salts; Thiazoles; Treatment Outcome; Tumor Cells, Cultured | 2007 |
Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Feeding; Cytarabine; Embryonic Development; Female; Humans; Imatinib Mesylate; Immunologic Factors; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines; Recurrence; Remission Induction | 2007 |
High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Data Interpretation, Statistical; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Follow-Up Studies; Hodgkin Disease; Humans; Melphalan; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Podophyllotoxin; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2007 |
[Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Ifosfamide; Methotrexate; Recurrence; Remission Induction; Rituximab; Translocation, Genetic; Vincristine | 2007 |
Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2007 |
Acute myeloid leukaemia presenting as recurrent generalized urticaria in infancy.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Diagnosis, Differential; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Urticaria | 2008 |
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Odds Ratio; Poland; Recurrence; Salvage Therapy; Stem Cell Transplantation; Treatment Outcome | 2008 |
Acute lymphoblastic leukemia in a patient with chronic cyanoacrylate exposure.
Topics: Adhesives; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyanoacrylates; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Humans; Male; Mercaptopurine; Methotrexate; Mouth Mucosa; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Salvage Therapy; Self Care; Tooth Fractures; Vincristine | 2007 |
Relapse and death during first remission in acute myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Risk; Survival Analysis; Treatment Outcome | 2008 |
Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Recurrence; Risk Factors; Survival Rate; Transplantation, Homologous; Vidarabine | 2008 |
The expression of DeltaNTP73, TATP73 and TP53 genes in acute myeloid leukaemia is associated with recurrent cytogenetic abnormalities and in vitro susceptibility to cytarabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Chromosome Aberrations; Cytarabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression; Gene Rearrangement; Genes, p53; Humans; Leukemia, Myeloid, Acute; Nuclear Proteins; Polymerase Chain Reaction; Recurrence; Tumor Suppressor Proteins | 2008 |
Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Immunotherapy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 2008 |
Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Thioguanine; Time Factors | 1984 |
[Treatment of acute myeloid leukemia].
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Delayed-Action Preparations; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Prednisone; Recurrence; Thioguanine; Vincristine | 1984 |
High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Eruptions; Hemorrhage; Humans; Leukemia; Middle Aged; Nausea; Recurrence; Vomiting | 1984 |
A comparison of bone marrow transplantation with maintenance chemotherapy for patients with acute nonlymphoblastic leukemia in first complete remission.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Leukemia; Male; Recurrence; Thioguanine | 1984 |
High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Female; Humans; Lymphoma; Male; Nervous System Neoplasms; Recurrence; Thioguanine | 1984 |
Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia.
Topics: Acute Disease; Adult; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia; Recurrence | 1984 |
Modified combination chemotherapy of leukemia. An attempt to overcome drug resistance.
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Drug Resistance; Drug Therapy, Combination; Female; Humans; In Vitro Techniques; Leukemia, Lymphoid; Male; Prednisolone; Recurrence; Time Factors; Vincristine | 1983 |
[Treatment of recurrence in children with acute lymphoblastic leukemias].
Topics: Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Mercaptopurine; Methotrexate; Prednisolone; Prognosis; Recurrence; Vincristine | 1983 |
Treatment of acute myeloid leukemia with a combination of intensive induction chemotherapy, early consolidation, splenectomy and long-term maintenance chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Doxorubicin; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pancytopenia; Recurrence; Splenectomy; Time Factors; Vincristine | 1984 |
Acute myelogenous leukemia in pregnancy.
Topics: Adult; Cesarean Section; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Leukemia, Myeloid, Acute; Pregnancy; Pregnancy Complications, Neoplastic; Recurrence | 1984 |
The clonogenic assay as a reproducible in vitro system to study predictive parameters of treatment outcome in acute nonlymphoblastic leukemia.
Topics: Acute Disease; Bone Marrow Cells; Clone Cells; Colony-Forming Units Assay; Cytarabine; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance; Humans; Leukemia; Prognosis; Recurrence | 1983 |
Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside.
Topics: Acute Disease; Adult; Aged; Cytarabine; Drug Evaluation; Female; Humans; Injections, Intravenous; Leukemia; Male; Meningeal Neoplasms; Middle Aged; Recurrence | 1984 |
Long-term disease-free survival in acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Female; Humans; Leukemia; Long-Term Care; Male; Middle Aged; Prednisone; Recurrence; Thioguanine | 1981 |
Late intensification therapy for childhood acute lymphocytic leukemia.
Topics: Child; Child, Preschool; Cytarabine; Humans; Leukemia, Lymphoid; Long-Term Care; Recurrence; Thioguanine | 1982 |
Relapsing herpes simplex encephalitis following antiviral therapy.
Topics: Adult; Cytarabine; Encephalitis; Herpes Simplex; Humans; Male; Recurrence | 1983 |
[A case of recurrent viral blepharitis treated with cytosine arabinoside].
Topics: Adult; Blepharitis; Cytarabine; Eyelid Diseases; Female; Herpes Simplex; Humans; Recurrence | 1983 |
Acute leukemia: early recognition can spell survival.
Topics: Aged; Antibiotics, Antineoplastic; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence | 1981 |
Relapse in childhood acute lymphoblastic leukemia after elective cessation of initial treatment: failure of subsequent treatment with cyclophosphamide, cytosine arabinoside, vincristine and prednisone (COAP).
Topics: Antineoplastic Agents; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Male; Prednisone; Prognosis; Recurrence; Time Factors; Vincristine | 1981 |
VAPA10: a treatment program for acute myelocytic leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Child; Child, Preschool; Cytarabine; Doxorubicin; Drug Therapy, Combination; Humans; Infant; Leukemia, Myeloid, Acute; Middle Aged; Prednisolone; Probability; Recurrence; Vincristine | 1981 |
Treatment of relapsed acute myelocytic leukemia with a combination of aclarubicin and cytosine arabinoside.
Topics: Aclarubicin; Antineoplastic Agents; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Naphthacenes; Recurrence | 1982 |
Acute myelogenous leukemia: successful treatment of relapse with cytosine arabinoside, VP 16-213, vincristine and vinblastine (A-triple-V).
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Thrombocytopenia; Vinblastine; Vincristine | 1982 |
Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia.
Topics: Adolescent; Adult; Bone Marrow; Child; Child, Preschool; Cytarabine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hypotension; Leukemia, Lymphoid; Male; Podophyllotoxin; Recurrence; Remission, Spontaneous; Teniposide | 1980 |
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematuria; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Neutropenia; Prednisone; Prospective Studies; Recurrence; Survival Rate; Vincristine | 1995 |
Acute nonlymphocytic leukemia complicated by Garcin's syndrome.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cranial Nerve Neoplasms; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Paralysis; Prednisolone; Recurrence; Syndrome; Zinostatin | 1995 |
Successful second autologous blood stem cell transplantation after G-CSF-combined conditioning for the treatment of high-risk acute myelogenous leukemia.
Topics: Adult; Blood Transfusion, Autologous; Combined Modality Therapy; Cytarabine; DNA, Neoplasm; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Recurrence; Remission Induction; Risk Factors; Thymidine; Tritium | 1994 |
Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.
Topics: Adult; Aged; Bromodeoxyuridine; Cytarabine; DNA, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
[Intermittent-dose ara-C/daunomycin therapy combined with cyclosporin-A and G-CSF led to a fourth remission in a patient with acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Recurrence; Remission Induction | 1995 |
Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisolone; Prospective Studies; Recurrence; Salvage Therapy; Vincristine | 1995 |
High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 1995 |
Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; HIV Seropositivity; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Recurrence; Survival Rate; Vincristine | 1993 |
[Treatment with ACVP-16 for relapsed and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Procarbazine; Recurrence; Remission Induction; Vincristine | 1993 |
Posttransfusion hepatitis after induction chemotherapy in acute nonlymphoblastic leukemia: implications for long-term management and outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hepatitis; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Time Factors; Transfusion Reaction; Treatment Outcome | 1995 |
Ifosfamide and etoposide in recurrent childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Mesna; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 1995 |
[Central nervous system relapses in acute lymphoblastic leukemia and different methods of prophylaxis].
Topics: Adolescent; Adult; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Female; Humans; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Risk Factors; Survival Analysis | 1995 |
Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Remission Induction; Treatment Outcome | 1995 |
Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Carrier Proteins; Child; Child, Preschool; Cytarabine; Drug Evaluation; Drug Resistance; Female; Gene Expression; Humans; Infant; Leukemia; Leukemia, Myeloid, Acute; Male; Membrane Glycoproteins; Mitoxantrone; Molecular Sequence Data; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1994 |
Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Aspartate-Ammonia Ligase; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Incidence; Methotrexate; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy | 1994 |
[Mitoxantrone-aracytine with or without quinine in the treatment of refractory or relapsed acute leukemia].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Quinine; Recurrence | 1994 |
Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Time Factors | 1994 |
ESHAP chemotherapy for relapsed/refractory non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Humans; Lymphoma, Non-Hodgkin; Methylprednisolone; Prognosis; Recurrence; Survival Rate; Treatment Outcome | 1994 |
Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Associazione Italiana Ematologìa ed Ocologia Pediatrica.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Infant; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Recurrence | 1994 |
Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Humans; Infant; Infant, Newborn; Leukocyte Count; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Risk Factors; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 1994 |
Low-dose ARA-C consistently induces hematologic responses in the clinical 5q- syndrome.
Topics: Aged; Biopsy; Bone Marrow; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Treatment Outcome | 1994 |
E-SHAP: an effective treatment in selected patients with relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Neutropenia; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia | 1994 |
Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Methotrexate; Prednisone; Recurrence; Remission Induction; Survival Rate; Teniposide; Thioguanine; Vincristine | 1994 |
Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Leucovorin; Male; Mercaptopurine; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Teniposide; Vincristine | 1994 |
Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neutropenia; Recurrence; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome | 1994 |
Relapse of aggressive myeloma after complete remission in secondary acute leukemia: coincidence or consequence?
Topics: Antigens, CD; Bone Marrow; Cytarabine; Female; HLA-DR Antigens; Humans; Leukemia, Myelomonocytic, Acute; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Recurrence | 1993 |
Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Cell Cycle; Cytarabine; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Recurrence; Treatment Outcome | 1993 |
Treatment of relapsed or refractory acute leukemia in childhood with bisantrene combined with high dose aracytine.
Topics: Adolescent; Adult; Anthracenes; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Follow-Up Studies; Heart Diseases; Hematologic Diseases; Humans; Infant; Kidney Diseases; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1994 |
The in-vitro effect of antineoplastic agents on proliferative activity and cytoskeletal components of plaque-derived smooth-muscle cells from human coronary arteries.
Topics: Aged; Antineoplastic Agents; Cell Division; Cells, Cultured; Coronary Artery Disease; Cytarabine; Cytoskeletal Proteins; Cytoskeleton; Doxorubicin; Female; Humans; Male; Middle Aged; Muscle, Smooth, Vascular; Recurrence; Vincristine | 1993 |
Repeated complete remission in a patient with acute promyelocytic leukemia after treatment with 13-cis-retinoic acid first and with all-trans-retinoic acid in relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Isotretinoin; Leukemia, Promyelocytic, Acute; Middle Aged; Recurrence; Remission Induction; Tretinoin | 1993 |
[Treatment and prognosis after late relapse in childhood acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Administration Schedule; Female; Humans; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Recurrence; Time Factors; Vincristine | 1993 |
Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clonogenic leukemic cell drug sensitivity.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Pilot Projects; Prospective Studies; Recurrence; Salvage Therapy; Tumor Stem Cell Assay | 1993 |
Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays.
Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Predictive Value of Tests; Prognosis; Recurrence; Remission Induction; Treatment Outcome; Tumor Stem Cell Assay | 1993 |
ABMT for early isolated extramedullary relapse of childhood ALL.
Topics: Adolescent; Bone Marrow Purging; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Humans; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Transplantation, Autologous; Whole-Body Irradiation | 1993 |
Prognostic significance of myeloperoxidase containing blast cells in acute myelogenous leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peroxidase; Prognosis; Recurrence; Remission Induction | 1993 |
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 1993 |
Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Drug Administration Schedule; Drug Resistance; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction | 1993 |
Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Carboplatin; Cytarabine; Drug Resistance; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Tetrahydrouridine; Treatment Outcome | 1993 |
Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction | 1993 |
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.
Topics: Adult; Aged; Arabinofuranosylcytosine Triphosphate; Clinical Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Remission Induction | 1993 |
t(15;17) hypergranular acute promyelocytic leukemia (M3) developing into a t(3;6) M3 without t(15;17) at relapse.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Mapping; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 6; Cytarabine; Daunorubicin; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Polymerase Chain Reaction; Recurrence; Translocation, Genetic; Tretinoin | 1995 |
Factors influencing prognosis after dose-intensive therapy for recurrent or refractory Hodgkin's disease. Results of sequential trials: a case for treating patients with resistant disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carmustine; Clinical Trials as Topic; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Survival Rate; Thiotepa; Treatment Outcome; Vinblastine | 1995 |
Translocation (12;15)(p13;q13) in a patient with relapsed acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 15; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Recurrence; Translocation, Genetic | 1996 |
Collection, analysis and transplantation of Ph-negative blood precursor cells in chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Recurrence; Remission Induction; Transplantation, Autologous | 1996 |
Evaluation of cytosine arabinoside, carboplatin and etoposide chemotherapy in the treatment of relapsing and refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Drug Evaluation; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Time Factors | 1996 |
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antigens, CD34; Antineoplastic Agents; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Risk Factors; Treatment Outcome | 1996 |
Central nervous system relapse after bone marrow transplantation for acute leukemia in first remission.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cerebrospinal Fluid; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Disease-Free Survival; Female; Humans; Hydrocortisone; Injections, Spinal; Leukemia; Leukemic Infiltration; Male; Meninges; Methotrexate; Prospective Studies; Recurrence; Remission Induction; Risk; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Male; Mercaptopurine; Methotrexate; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 1996 |
Cutaneous monoblastic leukemia as a first sign of relapse six years after autologous bone marrow transplantation for acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Female; Humans; Idarubicin; Leukemia, Monocytic, Acute; Middle Aged; Recurrence; Skin; Skin Neoplasms; Time Factors; Transplantation, Autologous | 1996 |
Acute leukemia during pregnancy: obstetric management and perinatal outcome of two cases.
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Etoposide; Fatal Outcome; Female; Humans; Leukemia, Promyelocytic, Acute; Mitoxantrone; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Recurrence; Thioguanine | 1995 |
[Obesity as the first manifestation of central nervous system involvement in acute lymphoblastic leukemia].
Topics: Antineoplastic Agents; Body Mass Index; Child; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Methotrexate; Obesity; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiation Dosage; Recurrence | 1996 |
Protective effects of cardioxane against anthracycline-induced cardiotoxicity in relapsed acute myeloid leukemias.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Cytarabine; Daunorubicin; Female; Heart; Humans; Leukemia, Myeloid; Male; Middle Aged; Razoxane; Recurrence | 1996 |
Detection of a dormant 20q- leukemia clone in bone marrow cultures with hematopoietic growth factors: implications for secondary leukemia post-transplant.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Chromosome Deletion; Chromosomes, Human, Pair 20; Clone Cells; Combined Modality Therapy; Cytarabine; Dacarbazine; Doxorubicin; Female; Hematopoietic Cell Growth Factors; Hodgkin Disease; Humans; Mechlorethamine; Neoplasm, Residual; Neoplasms, Second Primary; Neoplastic Stem Cells; Prednisone; Procarbazine; Radiotherapy; Recurrence; Transplantation, Autologous; Vinblastine; Vincristine | 1997 |
Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Injections, Spinal; Lymphoma, B-Cell, Marginal Zone; Male; Melphalan; Methotrexate; Prednisone; Recurrence; Remission Induction; Retreatment; Salvage Therapy; Stomach Neoplasms; Transplantation Conditioning; Tumor Lysis Syndrome; Vincristine | 1997 |
In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Topics: Aclarubicin; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Bone Marrow; Cell Survival; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Follow-Up Studies; Humans; Infant; Infant, Newborn; Life Tables; Melphalan; Methotrexate; Mitomycin; Mitoxantrone; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Recurrence; Remission Induction; Tumor Cells, Cultured; Vincristine | 1997 |
[Hemopoietic stem cell transplantation in lymphogranulomatosis].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carmustine; Child; Cytarabine; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Length of Stay; Male; Melphalan; Podophyllotoxin; Recurrence; Treatment Outcome | 1997 |
Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Cytarabine; Daunorubicin; Ear Canal; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Mercaptopurine; Middle Aged; Mitoxantrone; Neoplasm Proteins; Oncogene Proteins, Fusion; Radiotherapy; Recurrence; Remission Induction; Salvage Therapy; Tretinoin; Vindesine | 1997 |
Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Treatment Outcome | 1997 |
Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Erythema; Female; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recurrence | 1997 |
High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of failure and implications for involved-field radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Middle Aged; Mitoguazone; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Treatment Failure | 1997 |
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine | 1995 |
Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Fever; Gastrointestinal Diseases; Humans; Hydrocortisone; Hydroxyurea; Leucovorin; Male; Methotrexate; Mitoxantrone; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome | 1997 |
Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bence Jones Protein; beta 2-Microglobulin; C-Reactive Protein; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Humans; Immunoglobulin G; Immunoglobulin M; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Recurrence; Survival Rate; Vincristine | 1997 |
High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Mediastinal Neoplasms; Middle Aged; Recurrence; Retrospective Studies; Treatment Outcome | 1998 |
[Superhigh-dosage chemotherapy with the transplantation of autologous hemopoietic precursor cells in patients with a prognostically unfavorable relapse and resistant course of lymphogranulomatosis].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Prognosis; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Transplantation, Autologous | 1997 |
Pyoderma gangrenosum following cytosine arabinoside, aclarubicin and granulocyte colony-stimulating factor combination therapy in myelodysplastic syndrome.
Topics: Aclarubicin; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biopsy; Cytarabine; Drug Therapy, Combination; Follow-Up Studies; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Humans; Male; Myelodysplastic Syndromes; Prednisolone; Pyoderma Gangrenosum; Recurrence; Skin | 1998 |
Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Child; Child, Preschool; Cytarabine; Humans; Hydrocortisone; Injections, Spinal; Leukemic Infiltration; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 1998 |
Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Remission Induction; Retrospective Studies | 1998 |
Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Prognosis; Radiotherapy, Adjuvant; Recurrence; Transplantation, Autologous | 1998 |
[Testicular granulocytic sarcoma as a form of relapse in a patient with acute megakaryoblastic leukemia].
Topics: Aged; Antimetabolites, Antineoplastic; Cytarabine; Fatal Outcome; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Megakaryoblastic, Acute; Male; Recurrence; Testicular Neoplasms | 1998 |
[Successful treatment with idarubicin in a pediatric case of t(8;21) acute myelogenous leukemia with additional chromosomal abnormalities at relapse].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Recurrence; Remission Induction; Translocation, Genetic; Treatment Outcome | 1998 |
Management of acute promyelocytic leukemia relapse in the ATRA era.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Thioguanine; Treatment Outcome; Tretinoin | 1998 |
Pulmonary multinodular relapse of non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Diagnosis, Differential; Etoposide; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Radiography; Recurrence; Remission Induction; Tuberculosis, Pulmonary | 1998 |
Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cytarabine; Etoposide; Female; Humans; Infant; Infusions, Intravenous; Leukemia, Myeloid; Male; Mitoxantrone; Recurrence; Remission Induction | 1998 |
The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Polymerase Chain Reaction; Prognosis; Recurrence; Remission Induction; Translocation, Genetic | 1998 |
Haemopoietic cell transplantation activity and results: a single institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Hungary; Leukemia; Melphalan; Podophyllotoxin; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1998 |
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Leukemia, Myeloid; Leukopenia; Liver; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1999 |
Intraventricular concentration times time (C x T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Cytarabine; Female; Humans; Injections, Intraventricular; Male; Meningeal Neoplasms; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Treatment Outcome | 1999 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
Acute promyelocytic leukaemia: a retrospective analysis of patients treated at St. Bartholomew's Hospital 1969-1995.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Chromosome Aberrations; Cytarabine; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retinoids; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Survival Rate; Time Factors; United Kingdom | 1999 |
Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Mitoxantrone; Recurrence; Time Factors; Tissue Donors; Transplantation Chimera; Transplantation, Homologous | 1999 |
Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Leukemia; Male; Middle Aged; Prospective Studies; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 1999 |
Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 1999 |
[The presence of minimal residual disease during induction therapy is a reliable factor for the prognosis of recurrence in children with standard-risk B-cell precursor acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabine; DNA Primers; Genes, T-Cell Receptor delta; Humans; Mercaptopurine; Methotrexate; Molecular Sequence Data; Neoplasm, Residual; Polymerase Chain Reaction; Prednisone; Prognosis; Recurrence; Retrospective Studies; Risk Factors; Sensitivity and Specificity; Vincristine | 1999 |
[Severe esophageal stenosis secondary to the administration of chemotherapy in a patient with acute myeloblastic leukemia].
Topics: Anti-Infective Agents; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dilatation; Esophageal Stenosis; Esophagitis; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Recurrence; Remission Induction; Transplantation Conditioning; Ulcer | 1999 |
In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia.
Topics: Amsacrine; Antineoplastic Agents; Blast Crisis; Bone Marrow; Cell Survival; Child; Cytarabine; Doxorubicin; Drug Screening Assays, Antitumor; Erythrocytes; Etoposide; Humans; Leukemia, Myeloid, Acute; Recurrence; Scandinavian and Nordic Countries; Thioguanine | 1999 |
Extramedullary myeloid cell tumour: presentation as anterior chest wall mass during AML relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Soft Tissue Neoplasms; Thoracic Neoplasms | 1999 |
FLAG (fludarabine, high-dose cytarabine and G-CSF) for refractory and high-risk relapsed acute leukemia in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Recurrence; Risk Factors; Vidarabine | 2000 |
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Austria; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Germany; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasm, Residual; Prognosis; Prospective Studies; Recurrence; Risk Factors; Salvage Therapy; Survival Analysis; Treatment Outcome | 2000 |
Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Bone Marrow Transplantation; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; France; Humans; Infant; Lomustine; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Prednisone; Recurrence; Retrospective Studies; Survival Rate; Transplantation, Autologous; Transplantation, Homologous; Vinblastine; Vincristine | 2000 |
A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Italy; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Pilot Projects; Prednisone; Recurrence; Survival Rate; Vincristine | 2000 |
High-dose cytarabine-based therapy in adults with acute lymphoblastic leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome | 2000 |
Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Transplantation, Autologous | 2000 |
Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Tretinoin | 2000 |
Interferon may reduce minimal residual disease of acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Interferons; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Recurrence; Remission Induction; Tretinoin | 2000 |
Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; DNA-Binding Proteins; Etoposide; Gene Deletion; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Mitoxantrone; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Prognosis; Prospective Studies; Recurrence; Remission Induction | 2000 |
Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Female; Graft Survival; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Survival Rate; Time Factors; Transplantation, Autologous; Vincristine | 2000 |
High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; L-Lactate Dehydrogenase; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Transplantation, Autologous | 2000 |
Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Neutropenia; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 2000 |
[The 1st results of the combined therapy of recurrent and refractory forms of lymphogranulomatosis (polychemotherapy, radiation therapy and the removal of the residual mediastinal formation)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cytarabine; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Male; Mediastinal Neoplasms; Melphalan; Middle Aged; Neoplasm, Residual; Prognosis; Radiotherapy, Adjuvant; Recurrence; Salvage Therapy | 2000 |
[High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cytarabine; Dacarbazine; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Procarbazine; Recurrence; Retrospective Studies; Survival Rate; Time Factors; Vinblastine; Vincristine | 2000 |
Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor (MUD) transplantation for refractory T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Transplantation; Carmustine; Cefotaxime; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Idarubicin; Immunocompromised Host; Immunosuppressive Agents; Levofloxacin; Lymphoma, T-Cell; Male; Melphalan; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Prednisone; Recurrence; Rifampin; Splenectomy; Streptococcus pneumoniae; Transplantation Conditioning; Vincristine | 2000 |
Low dose cytarabine and Granulocyte / Macrophage-Colony Stimulating Factor induced long-term remission in a patient with acute myeloid leukemia in early relapse after intensive chemotherapy.
Topics: Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction | 2000 |
Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2001 |
Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia; Leukocyte Transfusion; Male; Recurrence; Survival Rate; Transplantation, Homologous | 2001 |
Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Burkitt Lymphoma; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Lymphoma, B-Cell; Palliative Care; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Treatment Outcome; Vincristine | 2001 |
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Salvage Therapy; Sex Factors; Survival Analysis; Transplantation, Autologous | 2001 |
Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML).
Topics: Cytarabine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Mutation; Recurrence | 2001 |
Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infections; Infusion Pumps; Leukemia; Lung Diseases; Male; Middle Aged; Nervous System Diseases; Prognosis; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome; Vidarabine | 2001 |
Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Cytarabine; Humans; Idarubicin; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Kidney Transplantation; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Polycystic Kidney Diseases; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2001 |
Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Recombinant Proteins; Recurrence; Salvage Therapy; Transplantation, Homologous; Vidarabine | 2001 |
Cocaine-contaminated allogeneic bone marrow transplantation.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bone Marrow Transplantation; Cocaine-Related Disorders; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Female; Graft Survival; Humans; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Male; Marijuana Abuse; Middle Aged; Recurrence; Salvage Therapy; Thrombocythemia, Essential; Tissue and Organ Procurement; Tissue Donors; Transplantation, Homologous | 2001 |
Acute basophilic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Coloring Agents; Cytarabine; Cytoplasmic Granules; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Karyotyping; Leukemia, Basophilic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Periodic Acid-Schiff Reaction; Peroxidase; Recurrence; Tolonium Chloride; Translocation, Genetic | 2001 |
Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Filgrastim; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Recurrence; Reoperation; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cisplatin; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Humans; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2001 |
Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
Topics: Benzamides; Cell Division; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Interleukin-3; Kinetics; Leukemia, Myeloid, Acute; Leukocyte Count; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; Signal Transduction; Stem Cell Factor | 2001 |
Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia.
Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Idarubicin; Immunotherapy; Infusions, Intravenous; Leukemia, Monocytic, Acute; Recurrence; Tomography, X-Ray Computed; Transplantation, Autologous | 2001 |
CD56 expression in myeloperoxidase-negative FAB M5 acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow Transplantation; CD56 Antigen; Chromosome Aberrations; Chromosomes, Human, Pair 11; Cytarabine; Fatal Outcome; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Male; Middle Aged; Peroxidase; Recurrence; Remission Induction | 2002 |
Clonal evolution of blasts in an elderly patient with CD56(+) relapsed acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Agents; CD56 Antigen; Chromosome Aberrations; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 8; Cytarabine; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Prognosis; Recombinant Proteins; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic | 2002 |
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Purging; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Gene Rearrangement; Genes, bcl-2; Half-Life; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Metabolic Clearance Rate; Middle Aged; Polymerase Chain Reaction; Prednisone; Recurrence; Rituximab; Transplantation, Autologous; Vincristine | 2002 |
Herpesvirus-6 encephalitis complicated by Wernicke-Korsakoff syndrome in a pediatric recipient of unrelated cord blood transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Encephalitis, Viral; Etoposide; Fatal Outcome; Female; Fetal Blood; Foscarnet; Ganciclovir; Hematopoietic Stem Cell Transplantation; Herpesvirus 6, Human; Humans; Immunocompromised Host; Korsakoff Syndrome; Leukemia, Myeloid, Acute; Recurrence; Roseolovirus Infections; Transplantation Conditioning; Transplantation, Homologous; Virus Activation | 2001 |
Burkitt's lymphoma: single-centre experience with modified BFM protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infections; Lymphoma, AIDS-Related; Male; Mercaptopurine; Methotrexate; Prednisone; Recurrence; Remission Induction; Treatment Outcome; Vincristine | 2002 |
Expression of P53 and bcl-2 proteins in T-cell lymphoblastic lymphoma: prognostic implications.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Immunohistochemistry; Logistic Models; Longitudinal Studies; Male; Methotrexate; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Proto-Oncogene Proteins c-bcl-2; Recurrence; Retrospective Studies; Survival Analysis; Tumor Suppressor Protein p53; Vincristine | 2002 |
A cytoreductive conditioning program for bone marrow transplantation in resistant leukemia (SCARI).
Topics: Adolescent; Adult; Bone Marrow Cells; Bone Marrow Transplantation; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Graft vs Host Reaction; Humans; Leukemia, Lymphoid; Middle Aged; Recurrence; Thioguanine; Transplantation, Homologous | 1977 |
Acute eosinophilic leukemia. An ultrastructural study.
Topics: Adult; Bone Marrow; Cytarabine; Daunorubicin; Eosinophils; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Prednisone; Recurrence | 1978 |
Adult acute leukemia: frequency of central system involvement in long term survivors.
Topics: Adolescent; Adult; Brain Neoplasms; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia; Leukemia, Lymphoid; Male; Meningeal Neoplasms; Methotrexate; Recurrence; Remission, Spontaneous; Time Factors | 1977 |
Cytosine arabinoside and 6-thioguanine in the treatment of childhood acute myeloblastic leukemia.
Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Cytarabine; Drug Therapy, Combination; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Pregnancy; Pregnancy Complications, Hematologic; Prospective Studies; Recurrence; Remission, Spontaneous; Thioguanine; Time Factors | 1977 |
Chemotherapy with cyclophosphamide, vincristine, cytosine arabinoside, and prednisone (COAP) in childhood acute lymphoblastic leukemia (ALL).
Topics: Child; Child, Preschool; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Male; Prednisone; Recurrence; Remission, Spontaneous; Time Factors; Vincristine | 1977 |
[Prevention and treatment of neuroleukemia].
Topics: Adolescent; Adult; Brain Neoplasms; Child; Child, Preschool; Cytarabine; Humans; Leukemia, Lymphoid; Methotrexate; Neoplasm Metastasis; Recurrence; Spinal Cord Neoplasms | 1977 |
Pyrimethamine in prevention of relapses of meningeal leukemia: report of two cases.
Topics: Central Nervous System; Child; Cytarabine; Female; Humans; Injections, Spinal; Leukemia, Lymphoid; Male; Meningeal Neoplasms; Methotrexate; Pyrimethamine; Recurrence; Remission, Spontaneous | 1978 |
Recurrent childhood lymphocytic leukemia: clinical and cytokinetic studies of cytosine arabinoside and methotrexate for maintenance of second hematologic remission.
Topics: Adolescent; Bone Marrow; Child; Child, Preschool; Cytarabine; Drug Therapy, Combination; Female; Humans; Infant; Kinetics; Leukemia, Lymphoid; Male; Methotrexate; Mitosis; Recurrence; Remission, Spontaneous | 1978 |
Dissimilar courses of twins with leukemia.
Topics: Antineoplastic Agents; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Leukemia, Lymphoid; Mercaptopurine; Methotrexate; Prednisone; Recurrence; Remission, Spontaneous; Vincristine | 1977 |
Preventing central nervous system leukemia.
Topics: Animals; Brain; Central Nervous System Diseases; Child; Child, Preschool; Cytarabine; Humans; Hydrocortisone; Injections, Spinal; Leukemia; Methotrexate; Recurrence; Spine; Time Factors | 1976 |
[Human infections with herpes simplex virus].
Topics: Bone Marrow; Bone Marrow Cells; Cytarabine; Encephalitis; Female; Herpes Simplex; Humans; Hydrogen Peroxide; Idoxuridine; Immunity, Cellular; Recurrence; Uterine Cervical Neoplasms; Vidarabine; Viral Vaccines | 1976 |
Relapse in Burkitt's lymphoma.
Topics: Abdominal Neoplasms; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Facial Neoplasms; Follow-Up Studies; Humans; Methotrexate; Recurrence; Remission, Spontaneous; Vincristine | 1976 |
Effect of antineoplastic agents on smooth muscle cell proliferation in vitro: implications for prevention of restenosis after transluminal angioplasty.
Topics: Angioplasty, Balloon; Animals; Antineoplastic Agents; Cell Division; Cells, Cultured; Constriction, Pathologic; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Fluorouracil; Muscle, Smooth, Vascular; Pulmonary Artery; Recurrence; Swine | 1992 |
Comparison of the proliferative activity and sensitivity to cytosine arabinoside of leukemic blast progenitors in acute myeloblastic leukemia at diagnosis and in relapse.
Topics: Blast Crisis; Cell Division; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Recurrence; Tumor Cells, Cultured | 1992 |
Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Ifosfamide; Infant; Male; Methotrexate; Prednisone; Prognosis; Recurrence; Remission Induction; Teniposide; Vincristine | 1992 |
["Small doses" of cytosar in the therapy of acute nonlymphoblastic leukemias].
Topics: Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Time Factors | 1992 |
[The programmed therapy of acute lymphoblastic leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Vincristine | 1992 |
Treatment of primary refractory or relapsed acute lymphoblastic leukemia (ALL) in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1992 |
Survival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive courses of chemotherapy.
Topics: Actuarial Analysis; Adolescent; Adult; Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bone Marrow Transplantation; Cause of Death; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Middle Aged; Norway; Recurrence; Remission Induction; Survival Analysis; Survival Rate; Thioguanine | 1992 |
Fulminant hepatic failure after high-dose cytosine arabinoside and mitoxantrone treatment for relapse of acute myelogenous leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Liver; Liver Failure, Acute; Mitoxantrone; Necrosis; Recurrence; Thioguanine | 1992 |
Recurrent neutrophilic eccrine hidradenitis.
Topics: Adult; Cytarabine; Eccrine Glands; Female; Hidradenitis; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Methylprednisolone; Mitoxantrone; Recurrence; Skin | 1992 |
Is allogeneic bone marrow transplantation the best treatment for young adult patients with acute myeloid leukemia in first complete remission. The BGMT Group.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Evaluation Studies as Topic; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Recurrence; Remission Induction; Transplantation, Homologous | 1992 |
Expression of glutathione transferase pi as a predictor for treatment results at different stages of acute nonlymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Glutathione Transferase; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Thioguanine; Time Factors | 1992 |
[BH-AC.nitrosourea-therapy for refractory or relapsed malignant lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nimustine; Nitrosourea Compounds; Recurrence | 1992 |
Predicting remission outcome in acute non-lymphocytic leukemia: general principles and their application to residual marrow leukemia.
Topics: Bone Marrow; Bone Marrow Examination; Cytarabine; Humans; Leukemia, Myeloid, Acute; Likelihood Functions; Predictive Value of Tests; Prognosis; Recurrence; Remission Induction | 1992 |
Treatment of relapsed or refractory adult acute lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Vindesine | 1992 |
Skin manifestation of extramedullary relapse in adult with acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Immunotherapy; Leukemic Infiltration; Mercaptopurine; Methotrexate; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Radiotherapy; Recurrence; Remission Induction; Skin; Vincristine | 1991 |
Incidence and clinical epidemiology of streptococcal septicemia during treatment of acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Humans; Incidence; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Sepsis; Streptococcal Infections | 1991 |
Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia.
Topics: Amsacrine; Cardiac Output, Low; Cytarabine; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Myeloid, Acute; Myocardium; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Stroke Volume | 1991 |
High-dose ara-C and etoposide in refractory or relapsing acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Recurrence; Time Factors | 1991 |
Recurrent bilateral parotitis in acute myeloid leukemia.
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Parotitis; Recurrence | 1991 |
High-dose cytosine arabinoside and etoposide in the treatment of relapsed or refractory adult leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate | 1991 |
Salvage chemotherapy containing moderate-dose cytosine arabinoside and mitoxantrone for relapsed and resistant acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction | 1991 |
High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Humans; Infant; Leukemia, Myeloid, Acute; Pilot Projects; Prognosis; Recurrence; Remission Induction; Survival Rate | 1991 |
Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Hydrocortisone; Infant; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Teniposide; Vincristine | 1990 |
Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Remission Induction | 1990 |
Low-dose cytosine arabinoside in relapsed acute lymphocytic leukemia.
Topics: Adolescent; Adult; Child; Cytarabine; Female; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1990 |
Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Evaluation; Etoposide; Humans; Lymphoma, Non-Hodgkin; Neoplasm Staging; Recurrence; Remission Induction | 1990 |
Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first l
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Rate; Thioguanine | 1990 |
Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.
Topics: Acute Disease; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Time Factors | 1990 |
Juvenile chronic myelocytic leukemia: experience with intensive combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Daunorubicin; Discriminant Analysis; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Recurrence; Survival Rate | 1990 |
Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Survival Rate | 1990 |
[The effects of 2, 2'-O-cyclocytidine (CC) and acyclovir (ACV) on latent herpes simplex virus in trigeminal ganglia of mice].
Topics: Acyclovir; Ancitabine; Animals; Cytarabine; Drug Synergism; Female; Ganglia; Herpes Simplex; Male; Mice; Recurrence; Simplexvirus; Trigeminal Nerve | 1985 |
Ascending myelopathy after chemotherapy for central nervous system acute lymphoblastic leukemia: correlation with cerebrospinal fluid myelin basic protein.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Combined Modality Therapy; Cytarabine; Humans; Hydrocortisone; Injections, Spinal; Leukemia, Lymphoid; Male; Methotrexate; Myelin Basic Protein; Prednisone; Radiotherapy Dosage; Recurrence; Spinal Cord Neoplasms; Testicular Neoplasms; Vincristine | 1985 |
[Relapse of gingival tumor during hematological remission in acute promyelocytic leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Gingival Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Recurrence; Remission Induction; Vinblastine; Vincristine | 1989 |
Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate | 1989 |
Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 1989 |
[The successful surgery of lung abscess formed from pulmonary aspergilloma in a patient with recurrence of acute promyelocytic leukemia during remission induction therapy].
Topics: Adult; Aspergillosis; Cytarabine; Female; Humans; Leukemia, Promyelocytic, Acute; Lung Abscess; Lung Diseases, Fungal; Pneumonectomy; Recurrence; Remission Induction | 1989 |
Intermediate-dose cytosine arabinoside in the treatment of recurrent or refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Cytarabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Platelet Count; Platelet Transfusion; Recurrence; Remission Induction | 1989 |
["AB-Triple V" therapy of relapsed or refractory acute myelogenous leukemia].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Vinblastine; Vincristine; Vindesine | 1989 |
Brachial plexus neuropathy following high-dose cytarabine in acute monoblastic leukemia.
Topics: Arm; Brachial Plexus; Cytarabine; Humans; Leukemia, Monocytic, Acute; Male; Middle Aged; Muscles; Nervous System Neoplasms; Neurologic Examination; Pain; Peripheral Nervous System Diseases; Recurrence; Time Factors | 1985 |
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematologic Diseases; Humans; Leukemia, Lymphoid; Lymphoma; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Thymoma; Thymus Neoplasms | 1988 |
Comparison of results of salvage therapy in adult acute myelogenous leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Prednisone; Prognosis; Prospective Studies; Recurrence; Regression Analysis; Retrospective Studies; Vincristine | 1987 |
Treatment of "poor risk" acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside.
Topics: Adult; Aged; Bone Marrow; Cell Count; Cytarabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid, Acute; Male; Prognosis; Recurrence; Remission Induction | 1988 |
[Cytosine arabinoside and VM-26 in induction treatment, failures and recurrences of childhood acute lymphoblastic leukemias].
Topics: Child; Child, Preschool; Cytarabine; Drug Combinations; Female; Humans; Male; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Risk Factors; Teniposide | 1988 |
High-dose cytosine arabinoside and fractionated total-body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission.
Topics: Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Lymphoid; Male; Quality of Life; Recurrence; Remission Induction; Whole-Body Irradiation | 1988 |
Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance; Female; Humans; Leukemia; Male; Middle Aged; Recurrence; Thioguanine | 1988 |
Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia; Male; Middle Aged; Pulmonary Edema; Radiography, Thoracic; Recurrence; Retrospective Studies | 1988 |
Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy.
Topics: Acute Disease; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Female; Humans; Leukemia; Lung Diseases, Fungal; Male; Pneumonia; Recurrence; Remission Induction; Risk Factors | 1988 |
[Low-dose cytosine arabinoside therapy in relapsed acute leukemia: correlation of clinical response and in vitro sensitivity tests].
Topics: Acute Disease; Adolescent; Adult; Age Factors; Child; Cytarabine; Drug Screening Assays, Antitumor; Female; Humans; Leukemia; Male; Recurrence; Tumor Cells, Cultured | 1987 |
[A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
Topics: Cytarabine; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence | 1986 |
Prediction of remission induction in childhood acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow; Child; Child, Preschool; Colony-Forming Units Assay; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Humans; Leukemia, Myeloid; Prognosis; Recurrence; Tumor Stem Cell Assay | 1986 |
[The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of relapsing or refractory cases of acute myelogenous leukemia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Vincristine | 1986 |
[Complete remission obtained in a child with relapse of erythroleukemia by low-dose cytosine arabinoside].
Topics: Child; Cytarabine; Female; Humans; Leukemia, Erythroblastic, Acute; Recurrence | 1986 |
[Complete remission achieved by high dose cytosine arabinoside therapy in the 4th relapse of AML].
Topics: Cytarabine; Female; Humans; Leukemia, Myeloid; Middle Aged; Recurrence | 1986 |
["A-triple-V" in refractory or relapsed acute myelocytic leukemia].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vinblastine; Vincristine | 1987 |
Paroxysmal nocturnal hemoglobinuria: termination in acute monocytic leukemia and reappearance after chemotherapy with N4-palmitoyl-1-beta-D-arabinofuranosylcytosine (PL-AC) and vincristine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Hemoglobinuria, Paroxysmal; Humans; Leukemia, Monocytic, Acute; Recurrence; Time Factors; Vincristine | 1987 |
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Topics: Adult; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; DNA Replication; Drug Evaluation; Female; Half-Life; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 1987 |
Modified chemotherapy with carmustine, cytarabine, cyclophosphamide, and 6-thioguanine (BACT) and autologous bone marrow transplantation in 24 poor-risk patients with acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Lymphoid; Male; Recurrence; Risk; Thioguanine; Transplantation, Autologous | 1986 |
High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Female; Humans; Leukemia; Liver; Male; Middle Aged; Podophyllotoxin; Recurrence; Time Factors | 1987 |
High-dose cytosine arabinoside, daunomycin and 6-thioguanine in relapsed or refractory acute nonlymphocytic leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Diseases; Cytarabine; Daunorubicin; Gastrointestinal Diseases; Humans; Leukemia; Recurrence; Remission Induction; Thioguanine | 1987 |
[Therapeutic effects of a combination of intermediate-dose cytosine arabinoside, adriamycin and vincristine in relapsed acute leukemia].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia; Male; Middle Aged; Recurrence; Vincristine | 1987 |
Low dose cytarabine in acute non-lymphoblastic leukemia or myelodysplastic syndrome: report of six cases and review of the literature.
Topics: Acute Disease; Aged; Anemia, Aplastic; Bone Marrow; Cytarabine; Female; Humans; Leukemia; Male; Middle Aged; Recurrence | 1985 |
Leukemia relapse in long-term survivors of acute leukemia.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Health Surveys; Humans; Infant; Japan; Leukemia; Leukemia, Lymphoid; Male; Mercaptopurine; Middle Aged; Nervous System Neoplasms; Prednisolone; Recurrence; Testicular Neoplasms | 1985 |
Intensive timed chemotherapy for 51 acute myeloid leukemia patients with poor prognosis.
Topics: Adult; Aged; Cytarabine; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Time Factors | 1985 |
High-dose cytosine arabinoside in the initial treatment of acute leukemia.
Topics: Adolescent; Adult; Bone Marrow; Cytarabine; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence | 1985 |
High-dose cytosine arabinoside in the treatment of resistant acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Child; Cytarabine; Drug Resistance; Female; Humans; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Time Factors | 1985 |
Sequential high-dose cytosine arabinoside and L-asparaginase in childhood leukemia in relapse.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Child; Child, Preschool; Cytarabine; Female; Humans; Infant; Leukemia; Leukemia, Lymphoid; Male; Neutropenia; Recurrence; Thrombocytopenia | 1985 |
High-dose cytosine arabinoside in the treatment of childhood malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Child; Child, Preschool; Cytarabine; Diterpenes; Doxorubicin; Female; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Male; Pancytopenia; Recurrence; Retinyl Esters; Vitamin A; Vomiting | 1985 |
Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Drug Evaluation; Female; Humans; Infant; Infusions, Parenteral; Injections, Intramuscular; Leukemia; Leukemia, Lymphoid; Male; Recurrence; Time Factors | 1985 |
Therapy of CNS leukemia with intraventricular chemotherapy and low-dose neuraxis radiotherapy.
Topics: Adolescent; Brain; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Drug Combinations; Female; Humans; Infant; Injections, Intraventricular; Injections, Spinal; Leukemia, Lymphoid; Male; Meningeal Neoplasms; Methotrexate; Prognosis; Radiotherapy Dosage; Recurrence | 1985 |
Continuous infusion of high-dose cytosine arabinoside for treatment of childhood acute leukemia and non-Hodgkin's lymphoma in relapse.
Topics: Acute Disease; Adolescent; Adult; B-Lymphocytes; Bacterial Infections; Burkitt Lymphoma; Cerebellar Ataxia; Child; Child, Preschool; Cytarabine; Female; Gastrointestinal Diseases; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Male; Neutropenia; Recurrence; Thrombocytopenia | 1985 |
High-dose cytarabine in consolidation chemotherapy or with bone marrow transplantation for patients with acute leukemia: preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Graft vs Host Disease; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Fibrosis; Recurrence; T-Lymphocytes; Thioguanine; Whole-Body Irradiation | 1985 |
Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients.
Topics: Acute Disease; Aged; Ambulatory Care; Bone Marrow; Cytarabine; Hematologic Diseases; Humans; Injections, Subcutaneous; Leukemia; Nausea; Recurrence | 1985 |
High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia; Life Expectancy; Male; Middle Aged; Recurrence | 1985 |
Treatment of diffuse aggressive non-Hodgkin's lymphomas with an intensive multi-drug regimen including high-dose cytosine arabinoside (F-MACHOP).
Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Fluorouracil; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Recurrence; Vincristine | 1985 |
The use of high-dose cytosine arabinoside for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Cytarabine; Doxorubicin; Humans; Lymphoma; Middle Aged; Neutropenia; Prednisolone; Recurrence; Skin Diseases; Thrombocytopenia; Vincristine | 1985 |
The treatment of patients with acute nonlymphocytic leukemia in remission.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Kinetics; Leukemia; Prognosis; Recurrence; Time Factors | 1985 |
Treatment of acute nonlymphocytic leukemia in young and elderly patients.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia; Male; Middle Aged; Prognosis; Recurrence; Sex Factors; Vincristine | 1985 |
[Herpetic disease].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Central Nervous System Diseases; Child; Child, Preschool; Cytarabine; Dermatitis Herpetiformis; Encephalitis; Female; Genital Diseases, Female; Genital Diseases, Male; Herpes Labialis; Herpes Simplex; Herpesviridae Infections; Humans; Idoxuridine; Immunoglobulins; Interferons; Keratitis, Dendritic; Male; Meningitis, Viral; Middle Aged; Recurrence; Respiratory Tract Infections; Stomatitis; Viral Vaccines | 1971 |
Cytomegalovirus myocarditis.
Topics: Antibodies; Cardiac Catheterization; Cardiomegaly; Complement Fixation Tests; Cytarabine; Cytomegalovirus; Female; Herpesviridae Infections; Humans; Lung Diseases; Middle Aged; Myocarditis; Radiography; Recurrence | 1972 |
Herpes zoster in children with cancer.
Topics: Adolescent; Bacterial Infections; Child; Child, Preschool; Cobalt Isotopes; Cytarabine; Herpes Zoster; Herpesvirus 3, Human; Hodgkin Disease; Humans; Idoxuridine; Immunoglobulins; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Neoplasms; Peptide Hydrolases; Recurrence; Remission, Spontaneous; Seasons; Splenectomy | 1973 |
Recurrent herpes simplex virus infections.
Topics: Antibodies, Viral; Cytarabine; Herpes Labialis; Herpes Simplex; Herpes Zoster Ophthalmicus; Herpesviridae Infections; Humans; Idoxuridine; Immune System Diseases; Recurrence; Stomatitis, Aphthous; Transplantation Immunology | 1974 |
[Cytosine arabinoside in the polychemotherapy of acute leukemia].
Topics: Adolescent; Adult; Asparaginase; Child; Child, Preschool; Cytarabine; Drug Synergism; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Prednisone; Recurrence; Thioguanine; Vincristine | 1972 |
[Should acute myeloblastic leukemias be treated in elderly patients?].
Topics: Age Factors; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Combinations; Drug Tolerance; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Remission, Spontaneous | 1972 |
Leukemia in arsenic poisoning.
Topics: Aged; Anemia, Aplastic; Arsenic; Arsenic Poisoning; Autopsy; Biopsy; Bone Marrow Cells; Cytarabine; Environmental Exposure; Humans; Klebsiella Infections; Leukemia, Myeloid, Acute; Male; Oxymetholone; Penicillamine; Pesticides; Poisoning; Prednisone; Recurrence; Sepsis; Thioguanine | 1972 |
Active immunotherapy used alone for maintenance of patients with acute myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Bone Marrow Examination; Cytarabine; Daunorubicin; Female; Humans; Immunization; Immunotherapy; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Radiation Effects; Recurrence; Remission, Spontaneous; Time Factors | 1973 |
[Meningeal leukaemia in chloroma with later generalized leukaemia (author's transl)].
Topics: Adult; Blood Cell Count; Bone Marrow Examination; Cytarabine; Female; Humans; Injections, Spinal; Leukemia, Myeloid; Lumbar Vertebrae; Methotrexate; Myelography; Recurrence; Remission, Spontaneous; Sciatica; Spinal Neoplasms | 1974 |
[Treatment of acute myeloblastic leukemia. 79 cases treated by cytosine-rubidomycin combination].
Topics: Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission, Spontaneous; Statistics as Topic; Time Factors | 1974 |
Fourteen relapses of acute lymphoblastic leukaemia in a child.
Topics: Agranulocytosis; Asparaginase; Blood Cell Count; Bone Marrow Examination; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Hemoglobins; Humans; Leukemia, Lymphoid; Male; Mercaptopurine; Methotrexate; Pneumonia; Prednisone; Recurrence; Vincristine | 1973 |
[Therapy of leukemic meningiosis. I].
Topics: Acute Disease; Adolescent; Child; Child, Preschool; Cytarabine; Electroencephalography; Humans; Infant; Injections, Spinal; Leukemia; Meninges; Methotrexate; Neoplasm Metastasis; Neurologic Manifestations; Recurrence | 1971 |
Cytogenetic studies and their clinical correlates in adults with acute leukemia.
Topics: Adolescent; Adult; Age Factors; Aneuploidy; Bone Marrow Cells; Chromosome Aberrations; Chromosome Disorders; Chromosomes, Human, 13-15; Chromosomes, Human, 16-18; Chromosomes, Human, 21-22 and Y; Chromosomes, Human, 6-12 and X; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisone; Recurrence; Remission, Spontaneous; Vincristine | 1971 |
Hyperleukocytosis before the beginning of treatment in acute leukaemia in children and its subsequent repetition at the onset of relapses.
Topics: Acute Disease; Antibiotics, Antineoplastic; Bone Marrow Examination; Child; Cytarabine; Humans; Leukemia; Leukemia, Lymphoid; Leukocytosis; Mercaptopurine; Methotrexate; Prednisone; Prognosis; Recurrence; Vincristine | 1970 |